



US011377500B2

(12) **United States Patent**
Panowski et al.(10) **Patent No.:** **US 11,377,500 B2**
(45) **Date of Patent:** ***Jul. 5, 2022**

- (54) **ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES**
- (71) Applicant: **Pfizer Inc.**, New York, NY (US)
- (72) Inventors: **Siler Panowski**, Berkeley, CA (US); **Tao Sai**, Foster City, CA (US); **Barbra Johnson Sasu**, San Francisco, CA (US); **Surabhi Srivatsa Srinivasan**, San Francisco, CA (US); **Thomas John Van Blarcom**, Oakland, CA (US)

- (73) Assignee: **Pfizer Inc.**, New York, NY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 303 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: **16/264,485**

- (22) Filed: **Jan. 31, 2019**

- (65) **Prior Publication Data**

US 2019/0233529 A1 Aug. 1, 2019

Related U.S. Application Data

- (60) Provisional application No. 62/641,873, filed on Mar. 12, 2018, provisional application No. 62/625,019, filed on Feb. 1, 2018.

- (51) **Int. Cl.**
C07K 16/28 (2006.01)
A61P 35/00 (2006.01)
A61K 39/00 (2006.01)

- (52) **U.S. Cl.**
CPC **C07K 16/2875** (2013.01); **A61P 35/00** (2018.01); **C07K 16/2809** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/526** (2013.01); **C07K 2317/53** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/734** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01)

- (58) **Field of Classification Search**
CPC **C07K 16/2875**; **C07K 16/2809**; **C07K 2317/565**; **C07K 2317/31**; **C07K 2317/76**; **C07K 2317/53**; **C07K 2317/92**; **C07K 2317/732**; **C07K 2317/734**; **C07K 2317/526**; **A61P 35/00**; **A61K 2039/505**
See application file for complete search history.

- (56) **References Cited**

U.S. PATENT DOCUMENTS

4,676,980 A 6/1987 Segal et al.
4,683,195 A 7/1987 Mullis et al.
4,683,202 A 7/1987 Mullis
4,754,065 A 6/1988 Levenson et al.
4,777,127 A 10/1988 Suni et al.
4,800,159 A 1/1989 Mullis et al.
4,816,567 A 3/1989 Cabilly et al.

4,975,278 A 12/1990 Senter et al.
5,037,743 A 8/1991 Welch et al.
5,047,335 A 9/1991 Paulson et al.
5,143,830 A 9/1992 Holland et al.
5,219,740 A 6/1993 Miller et al.
5,278,299 A 1/1994 Wong et al.
5,422,120 A 6/1995 Kim
5,500,362 A 3/1996 Robinson et al.
5,510,261 A 4/1996 Goochee et al.
5,530,101 A 6/1996 Queen et al.
5,545,806 A 8/1996 Lonberg et al.
5,545,807 A 8/1996 Surani et al.
5,565,332 A 10/1996 Hoogenboom et al.
5,569,825 A 10/1996 Lonberg et al.
5,580,717 A 12/1996 Dower et al.
5,580,859 A 12/1996 Felgner et al.
5,585,089 A 12/1996 Queen et al.
5,625,126 A 4/1997 Lonberg et al.
5,633,425 A 5/1997 Lonberg et al.
5,661,016 A 8/1997 Lonberg et al.
5,693,761 A 12/1997 Queen et al.
5,693,762 A 12/1997 Queen et al.
5,733,743 A 3/1998 Johnson et al.
5,750,373 A 5/1998 Garrard et al.
5,807,715 A 9/1998 Morrison et al.
5,814,482 A 9/1998 Dubensky, Jr. et al.
5,821,337 A 10/1998 Carter et al.
5,858,358 A 1/1999 June et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 345 242 A1 12/1989
EP 0 519 596 A1 12/1992

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 16/264,371, filed Feb. 2018, Chimeric Antigen Receptors Targeting CD70.*
Rudikoff S, Giusti AM, Cook WD, Scharff MD. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982; 79(6):1979-83. (Year: 1982).*
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295 (Year: 1993).*
Bendig M. M., Methods: A Companion to Methods in Enzymology, 1995; 8:83-93 (Year: 1995).*
Padlan, Advances in Protein Chemistry, 1996, 49:57-133 (Year: 1996).*
Berglund et al, 2008, Protein Science, 17:606-613 (Year: 2008).*

(Continued)

Primary Examiner — Julie Wu
Assistant Examiner — Sung Min Yoon

(57) **ABSTRACT**

The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

36 Claims, No Drawings**Specification includes a Sequence Listing.**

(56)

References Cited

U.S. PATENT DOCUMENTS

5,866,692	A	2/1999	Shitara et al.
5,883,223	A	3/1999	Gray
5,997,867	A	12/1999	Waldmann et al.
6,054,297	A	4/2000	Carter et al.
6,180,370	B1	1/2001	Queen et al.
6,180,377	B1	1/2001	Morgan et al.
6,210,671	B1	4/2001	Co
6,265,150	B1	7/2001	Terstappen et al.
6,331,415	B1	12/2001	Cabilly et al.
6,350,861	B1	2/2002	Co et al.
6,352,694	B1	3/2002	June et al.
6,376,471	B1	4/2002	Lawrence, III et al.
6,413,942	B1	7/2002	Felgner et al.
6,436,908	B1	8/2002	Koch et al.
6,534,055	B1	3/2003	June et al.
6,692,964	B1	2/2004	June et al.
6,737,056	B1	5/2004	Presta
6,797,514	B2	9/2004	Berenson et al.
6,867,041	B2	3/2005	Berenson et al.
6,887,466	B2	5/2005	June et al.
6,905,680	B2	6/2005	June et al.
6,905,681	B1	6/2005	June et al.
6,905,874	B2	6/2005	Berenson et al.
7,067,318	B2	6/2006	June et al.
7,144,575	B2	12/2006	June et al.
7,172,869	B2	2/2007	June et al.
7,175,843	B2	2/2007	June et al.
7,232,566	B2	6/2007	June et al.
7,314,622	B2	1/2008	Arlen et al.
2006/0121005	A1	6/2006	Berenson et al.
2009/0028872	A1	1/2009	Terret et al.
2016/0297884	A1	10/2016	Kuo et al.
2016/0297885	A1	10/2016	Kuo et al.
2017/0129961	A1	5/2017	Raum et al.
2017/0349668	A1*	12/2017	Rattel et al. C07K 16/468
2019/0233528	A1	8/2019	Srinivasan et al.

FOREIGN PATENT DOCUMENTS

EP	0 524 968	B1	6/1995
EP	2 335 744	A1	6/2011
GB	2200651	B	6/1991
WO	WO-87/04462	A1	7/1987
WO	WO-90/07936	A1	7/1990
WO	WO-90/11092	A1	10/1990
WO	WO-91/00360	A1	1/1991
WO	WO-91/02805	A2	3/1991
WO	WO-91/02805	A3	3/1991
WO	WO-91/14445	A1	10/1991
WO	WO-92/20373	A1	11/1992
WO	WO-93/03769	A1	3/1993
WO	WO-93/06213	A1	4/1993
WO	WO-93/10218	A1	5/1993
WO	WO-93/11230	A1	6/1993
WO	WO-93/19191	A1	9/1993
WO	WO-93/25234	A1	12/1993
WO	WO-93/25698	A1	12/1993
WO	WO-94/03622	A1	2/1994
WO	WO-94/04690	A1	3/1994
WO	WO-94/12649	A2	6/1994
WO	WO-94/12649	A3	6/1994
WO	WO-94/23697	A1	10/1994
WO	WO-94/28938	A1	12/1994
WO	WO-95/00655	A1	1/1995
WO	WO-95/07994	A2	3/1995
WO	WO-95/07994	A3	3/1995
WO	WO-95/11984	A2	5/1995
WO	WO-95/11984	A3	5/1995
WO	WO-95/13796	A1	5/1995
WO	WO-95/30763	A2	11/1995
WO	WO-95/30763	A3	11/1995
WO	WO-96/17072	A2	6/1996
WO	WO-96/17072	A3	6/1996
WO	WO-97/42338	A1	11/1997
WO	WO-99/58572	A1	11/1999

WO	WO-01/27160	A1	4/2001
WO	WO-2004/058184	A2	7/2004
WO	WO-2004/058184	A3	7/2004
WO	WO-2006/044643	A2	4/2006
WO	WO-2006/044643	A3	4/2006
WO	WO-2006/113909	A2	10/2006
WO	WO-2006/113909	A3	10/2006
WO	WO-2011/143545	A1	11/2011
WO	WO-2012/058458	A2	5/2012
WO	WO-2012/058458	A3	5/2012
WO	WO-2012/058460	A2	5/2012
WO	WO-2012/058460	A3	5/2012
WO	WO-2012/059882	A2	5/2012
WO	WO-2012/059882	A3	5/2012
WO	WO-2012/123586	A1	9/2012
WO	WO-2013/153391	A1	10/2013
WO	WO-2014/039523	A1	3/2014
WO	WO-2014/184143	A1	11/2014
WO	WO-2014/184741	A1	11/2014
WO	WO-2014/184744	A1	11/2014
WO	WO-2014/191128	A1	11/2014
WO	WO-2015/015448	A2	2/2015
WO	WO-2015/015448	A3	2/2015
WO	WO-2015/121454	A1	8/2015
WO	WO-2016/120126	A1	8/2016
WO	WO-2016/120216	A1	8/2016
WO	WO-2017/125831	A1	7/2017
WO	WO-2017/134140	A1	8/2017
WO	WO-2018/152181	A1	8/2018

OTHER PUBLICATIONS

- Colman P. M., *Research in Immunology*, 145:33-36, 1994 (Year: 2015).*
- Khantasup et al., *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*, 2015, 34(6): 404-417 (Year: 2015).*
- Murphy C, Stack E, Krivelo S, Breheny M, Ma H, O'Kennedy R. Enhancing recombinant antibody performance by optimally engineering its format. *J Immunol Methods*. Dec. 2018;463:127-133. (Year: 2018).*
- Chen, *Sci Adv*. Apr. 1, 2020;6(14):eaaz7825 (Year: 2020).*
- Aalberse, R.C. et al. (2002). "IgG4 breaking the rules," *Immunology* 105:9-19.
- Afimos, P. et al. (2017). "Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies," *Clinical Cancer Research* 23:6411-6420.
- Al-Lazikani, B. et al. (1997). "Standard conformations for the Canonical structures of immunoglobulins," *J. Molec. Biol.* 273:927-948.
- Armour, K.L. et al. (2003). "Differential binding to human FcγRIIIa and FcγRIIIb receptors by human IgG wildtype and mutant antibodies," *Molecular Immunology* 40:585-593.
- Armour, K.L. et al. (1999). "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities," *Eur. J. Immunol.* 29:2613-2624.
- Atkins, J.F. et al. (2007). "A case for "StopGo": Reprogramming translation to augment codon meaning of GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing continued translation (Go)," *RNA* 13:803-810.
- Balint, R.F. et al. (1993). "Antibody engineering by parsimonious mutagenesis," *Gene* 137:109-118.
- Barbas, C.F. et al. (1994). "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," *PNAS* 91:3809-3813.
- Berger, C. et al. (2015). "Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells," *Cancer Immunol. Res.* 3:206-216.
- Bierer, B.E. et al. (1993). "Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology," *Current Opin. Immunol.* 5:763-773.
- Bird, R.E. et al. (1988). "Single-chain antigen-binding proteins," *Science* 242:423-426.
- Bloom, J.W. et al. (1997). "Intrachain disulfide bond in the core hinge region of human IgG4," *Protein Science* 6:407-415.

(56)

References Cited

OTHER PUBLICATIONS

- Boerner, P. et al. (1991). "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes," *J. Immunol.* 147:86-95.
- Boursalian, T.E. et al. (2009). "Chapter 7: Targeting CD70 for human therapeutic use," *Adv. Exp. Med. Biol.* 647:108-119.
- Boyd, P.N. et al. (1996). "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," *Mol. Immunol.* 32:1311-1318.
- Brenner, M.K. et al. (2010). "Adoptive T cell therapy of cancer," *Curr. Opin. Immunol.* 22:251-257.
- Brown, B.A. et al. (1987). "Tumor-specific genetically engineered murine/human chimeric monoclonal antibody," *Cancer Res.* 47:3577-3583.
- Buck, D.W. et al. (1982). "Monoclonal Antibodies Specific for Cell Culture Mycoplasmas," *In Vitro* 18:377-381.
- Campana, D. et al. (2014). "4-1BB chimeric antigen receptors," *Cancer J.* 20:134-140.
- Capel, P.J.A. et al. (1994). "Heterogeneity of human IgG Fc receptors," *Immunomethods* 4:25-34.
- Chothia, C. et al. (1989). "Conformations of immunoglobulin hypervariable regions," *Nature* 342:877-883.
- Clackson, T. et al. (1991). "Making antibody fragments using phage display libraries," *Nature* 352:624-628.
- Clynes, R. et al. (1998). "Fc receptors are required in passive and active immunity to melanoma," *PNAS* 95:652-656.
- Cole, S.P.C. et al. (1985). "The EBV-hybridoma technique and its application to human lung cancer," in *Monoclonal Antibodies and Cancer Therapy, Proceedings of the Roche-UCLA Symposium Held in Park City, Utah*, pp. 77-96.
- Connelly, S. et al. (1995). "In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice," *Human Gene Therapy* 1:185-193.
- Courtois, A. et al. (2012). "Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling," *Electronic Journal of Biotechnology*, pp. 1-11.
- Curiel, D.T. et al. (1992). "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes," *Hum. Gene Ther.* 3:147-154.
- Daugherty, B.L. et al. (1991). "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19:2471-2476.
- Dayhoff, M.O. et al. (1978). "Chapter 22: A model of evolutionary change in proteins," in *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, A model of evolutionary change in proteins—Matrices for detecting distant relationships, Washington DC vol. 5, Suppl. 3, pp. 345-358.
- De Haas, M. et al. (1995). "Fcγ receptors of phagocytes," *J. Lab. Clin. Med.* 126:330-341.
- Donnelly, M. et al. (2001). "Fluorescent Tagging of Herpes Simplex Virus Tegument Protein VP13/14 in Virus Infection," *J. Virology* 75:2575-2583.
- Donnelly, M. et al. (2001). "Nuclear Localization and Shuttling of Herpes Simplex Virus Tegument Protein VP13/14," *J. Virology* 75:2566-2574.
- Doronina, V.A. et al. (2008). "Site-Specific Release of Nascent Chains from Ribosomes at a Sense Codon," *Mol. Cell. Biol.* 28:4227-4239.
- Eshhar, Z. et al. (1993). "Immunology Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors," *PNAS* 90:720-724.
- Fellouse, F.A. et al. (2007). "High-throughput Generation of Synthetic Antibodies from Highly Functional Minimalist Phage-displayed Libraries," *J. Mol. Biol.* 373:924-940.
- Findeis, M.A. et al. (1993). "Targeted delivery of DNA for gene therapy via receptor," *Trends Biotechnol.* 11:202-205.
- Gazzano-Santoro, H. et al. (1997). "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody," *J. Immunol. Methods* 202:163-171.
- Ge, H. et al. (2017). "Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM," *International Journal of Cancer* 141:1434-1444.
- GenBank accession No. P32970-1, CD70 antigen, 11 total pages.
- GenBank accession No. AAA53133, 4-1BB (*Homo sapiens*), 2 total pages.
- GenBank accession No. NP_006130.1, T-cell specific surface glycoprotein CD28 isoform 1 precursor (*Homo sapiens*), 4 total pages.
- GenBank accession No. NP_001139345.1, T-cell surface glycoprotein CD8 alpha chain isoform 1 precursor (*Homo sapiens*), 3 total pages.
- GenBank accession No. NM-005018.3, *Homo sapiens* programmed cell death 1 (PDCD1), mRNA, 5 total pages.
- GenBank accession No. AF414120.1, *Homo sapiens* CTLA4 (CTLA4) mRNA, complete cds, 2 total pages.
- GenBank accession No. NM-002286.5, *Homo sapiens* lymphocyte activating 3 (LAG3), mRNA, 4 total pages.
- GenBank accession No. JX049979.1, *Homo sapiens* T-cell immunoglobulin and mucin domain-containing protein 3 mRNA, complete cds, 2 total pages.
- GenBank accession No. NM-181780.3, *Homo sapiens* B and T lymphocyte associated (BTLA), transcript variant 1, mRNA, 5 total pages.
- GenBank accession No. CR541888.1, *Homo sapiens* full open reading frame cDNA clone RZPDo834D0633D for gene CD160, CD160 antigen; complete cds, without stopcodon, 2 total pages.
- GenBank accession No. NM-173799.4, *Homo sapiens* T cell immunoreceptor with Ig and ITIM domains (TIGIT), mRNA, 5 total pages.
- GenBank accession No. NM-022153.1, *Homo sapiens* V-set immunoregulatory receptor (VSIR), mRNA, 5 total pages.
- GenBank accession No. CR542051.1, *Homo sapiens* full open reading frame cDNA clone RZPDo834C0736D for gene LAIR1, leukocyte-associated Ig-like receptor 1; complete cds, without stopcodon, 2 total pages.
- GenBank accession No. AY358337.1, *Homo sapiens* clone DNA54002 SIGLEC10 (UNQ477) mRNA, complete cds, 2 total pages.
- GenBank accession No. NM-001166664.1, *Homo sapiens* CD244 molecule (CD244), transcript variant 3, mRNA, 4 total pages.
- Grewal, I.S. et al. (2008). "CD70 as a therapeutic target in human malignancies," *Expert Opinion on Therapeutic Targets* 12:341-351.
- Griffith, A.D. et al. (1993). "Human anti-self antibodies with high specificity from phage display libraries," *EMBO J.* 12:725-734.
- Guyer, R.L. et al. (1976). "Immunoglobulin binding by mouse intestinal epithelial cell receptors," *J. Immunol.* 117:587-593.
- Harlow, E. et al. (1999). Chapter 11: Epitope mapping in *Using Antibodies, a Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 379-405.
- Hawkins, R.E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation," *J. Mol. Biol.* 226:889-896.
- Hein, J. (1990). "Unified Approach to Alignment and Phylogenies," *Methods in Enzymology* 183: 626-645.
- Henderson, D.J. et al. (1991). "Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production," *Immunol.* 73:316-321.
- Higgins, D.G. et al. (1989). "Fast and sensitive multiple sequence alignments on a microcomputer," *CABIOS* 5:151-153.
- Hoogenboom, H.R. et al. (1991). "By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V_H Gene Segments Rearranged in Vitro," *J. Mol. Biol.* 227:381-388.
- Hsu, T.-A. et al. (1997). "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in *Trichoplusia ni* Cells," *J. Biol. Chem.* 272:9062-9070.
- Humphreys, D.P. et al. (1997). "Formation of dimeric Fabs in *Escherichia coli*: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions," *J. Immunol. Methods* 209:193-202.
- International Search Report dated May 28, 2019, for PCT Application No. PCT/US2019/016189, filed on Jan. 31, 2019, 9 pages.

(56)

References Cited

OTHER PUBLICATIONS

International Search Report dated May 13, 2019, for PCT Application No. PCT/US2019/016139, filed on Jan. 31, 2019, 14 pages.

Jackson, J.R. et al. (1995). "In vitro antibody maturation—Improvement of a high affinity, neutralizing antibody against IL-1 β ," *J. Immunol.* 154:3310-3319.

Jayasena, S.D. (1999). "Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics," *Clin. Chem.* 45:1628-1650.

Jefferis, R. et al. (1997). "Glycosylation of antibody molecules: Structural and functional significance," *Chem. Immunol. Basel. Karger* 65:111-128.

Jin, L. et al. (2017). "CD70, a novel target of CAR T-cell therapy for gliomas," *Neuro-Oncology* 20:55-65.

Johnson, K.S. et al. (1993). "Human antibody engineering," *Current Opinion in Structural Biol.* 3:564-571.

Jolly, D. (1994). "Viral vector systems for gene therapy," *Cancer Gene Therapy* 1:51-64.

Jones, P.T. et al. (1986). "Replacing the complementarity—Determining regions in a human antibody with those from a mouse," *Nature* 321:522-525.

Kaplitt, M.G. et al. (1994). "Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain," *Nature Genetics* 6:148-154.

Kim et al. "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor," *J. Immunol.* 24:2429-2434.

Kimura, O. et al. (1994). "Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas," *Human Gene Therapy* 5:845-852.

Kohler, C. et al. (1975). "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature* 256:495-497.

Liu, J. et al. (1992). "Inhibition of T Cell Signaling by Immunophilin-Ligand Complexes Correlates with Loss of Calcineurin Phosphatase Activity," *Biochem.* 31:3896-3901.

LoBuglio, A.F. et al. (1989). "Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response," *PNAS* 86:4220-4224.

Lonberg, N. et al. (1995). "Human antibodies from transgenic mice," *Intern. Rev. Immunol* 13:65-93.

Maccallum, R.M. et al. (1996). "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography," *J. Mol. Biol.* 262:732-745.

Makabe, K. et al. (2008). "Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth," *Journal of Biological Chemistry* 283:1156-1166.

Marks, J.D. et al. (1991). "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage," *J. Mol. Biol.* 222:581-597.

Marks, J.D. et al. (1992). "By-passing immunization: Building high affinity human antibodies by chain shuffling," *Bio/Technol.* 10:779-783.

Martyniszyn, A. et al. (2017). "CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies," *Human Gene Therapy* 28:1147-1157.

McCafferty, J. et al. (1990). "Phage antibodies: filamentous phage displaying antibody variable domains," *Nature* 348:552-554.

McEarchern J.A. et al. (2007). "Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities," *Blood* 109:1185-1192.

Millstein, C. et al. (1983). "Hybrid hybridomas and their use in immunohistochemistry," *Nature* 305:537-539.

Morrison, S.L. et al. (1984). "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," *PNAS* 81:6851-6855.

Myers, E.W. et al. (1988). "Optimal alignments in linear space," *CABIOS* 4:11-17.

Myszka, D.G. (1999). "Improving biosensor analysis," *J Mol. Recognit.* 12:279-284.

Niculescu-Duvaz, I. et al. (1997). "Antibody-directed enzyme prodrug therapy (ADEPT): a review," *Adv. Drug Del. Rev.* 26:151-172.

Payne, G. (2003). "Progress in immunoconjugate cancer therapeutics," *Cancer Cell* 3:207-212.

Peeters, K. et al. (2001). "Production of antibodies and antibody fragments in plants," *Vaccine* 19:2756-2761.

Philip, R. et al. (1994). "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adena-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," *Mol. Cell Biol.* 14:2411-2418.

Pollock, D.P. et al. (1999). "Transgenic milk as a method for the production of recombinant antibodies," *J Immunol Methods* 231:147-157.

Ravetch, J.V. et al. (1991). "Fc receptors," *Kinet, Ann. Rev. Immunol.* 9:457-492.

Riechmann, L. et al. (1988). "Reshaping human antibodies for therapy," *Nature* 332:323-327.

Robinson, D.F. (1971). "Comparison of Labeled Trees with Valency Three," *J. Comb. Theory* 11:105-119.

Rosenberg, S.A. et al. (2008). "Adoptive cell transfer: a clinical path to effective cancer Immunotherapy," *Nature Reviews Cancer* 8:299-308.

Sadelain, M. et al. (2009). "The promise and potential pitfalls of chimeric antigen receptors," *Curr. Opin. Immunol*, 21:215-223.

Sadelain, M. et al. (2013). "The Basic Principles of Chimeric Antigen Receptor Design," *Cancer Discovery* 3:388-398.

Saitou, N. et al. (1987). "The neighbor-joining method: A new method for reconstructing phylogenetic trees," *Mol. Biol. Evol.* 4:406-425.

Schier, R. et al. (1995). "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," *Gene* 169:147-155.

Shaffer, D.R. et al. (2011). "T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies," *Blood* 117:4304-4314.

Shaw, D.R. et al. (1987). "Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen," *J Immunol.* 138:4534-4538.

Sheets, M.D. et al. (1998). "Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens," *PNAS* 95:6157-6162.

Simmons, J.K. et al. (2015). "Animal Models of Bone Metastasis," *Veterinary Pathology* 52:827-841.

Suresh, M.R. et al. (1986). "Biospecific monoclonal antibodies from hybrid hybridomas," *Methods in Enzymology* 121:210-228.

Syrgos, K.N. et al. (1999). "Antibody Directed Enzyme Prodrug Therapy (ADEPT): A Review of the Experimental and Clinical Considerations," *Anticancer Research* 19:605-614.

Tiller, T. et al. (2008). "Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning," *J. Immunol. Methods* 329:112-124.

Trail, P.A. et al. (2003). "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer," *Cancer Immunol. Immunother.* 52:328-337.

Umana, P. et al. (1999). "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity," *Mature Biotech.* 17:176-180.

Vaughan, T.J. et al. (1996). "Human Antibodies with Subnanomolar Affinities Isolated from a Large Non-immunized Phage Display Library," *Nature Biotechnol.* 14:309-314.

Verhoeyen, M. et al. (1988). "Reshaping human antibodies: Grafting an antilysozyme activity," *Science* 239:1534-1536.

Wang, Q.J. et al. (2017). "Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers," *Clinical Cancer Research* 23:2267-2276.

Ward, E.S. et al. (1989). "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*," *Nature* 341:544-546.

Waterhouse, P. et al. (1993). "Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires," *Nucl. Acids Res.* 21:2265-2266.

Whitlow, M. et al. (1993). "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability," *Protein Eng.* 6:989-995.

(56)

References Cited

OTHER PUBLICATIONS

Wilbur, W.J. et al. (1983). "Rapid similarity searches of nucleic acid and protein data banks," PNAS 80:726-730.

Winter, G. et al. (1991). "Man-made antibodies," Nature 349:293-299.

Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," Annu. Rev. Immunol. 12:433-455.

Wittwer, A.J. et al. (1990). "Glycosylation at Asn-184 Inhibits the Conversion of Single-Chain to Two-Chain Tissue-Type Plasminogen Activator by Plasmin," Biochem. 29:4175-4180.

Woffendin, C. et al. (1994). "Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells," PNAS 91:11581-11585.

Wright, A. et al. (1997). "Effect of glycosylation on antibody function: implications for genetic engineering," Tibtech 15:26-32.

Written Opinion of the International Searching Authority dated May 28, 2019, for PCT Application No. PCT/US2019/016189, filed on Jan. 31, 2019, 11 pages.

Written Opinion of the International Searching Authority dated May 13, 2019, for PCT Application No. PCT/US2019/016139, filed on Jan. 31, 2019, 14 pages.

Wu, G.Y. et al. (1988). "Receptor-mediated Gene Delivery and Expression in Vivo," J. Biol. Chem. 263:14621-14624.

Wu, C.H. et al. (1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo," J. Biol. Chem. 264:16985-16987.

Wu, G.Y. et al. (1991). "Receptor-mediated gene delivery in Vivo," J. Biol. Chem. 266:14338-14342.

Wu, G.Y. et al. (1994). "Incorporation of Adenovirus into a Ligand-based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," J. Biol. Chem. 269:11542-11546.

Wyss, D.F. et al. (1996). "The structural role of sugars in glycoproteins," Current Opin. Biotech. 7:409-416.

Yelton, D.E. et al. (1995). "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," J. Immunol. 155:1994-2004.

Zarrabi, K. et al. (2017). "New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy," Journal of Hematology and Oncology 10:38, 12 total pages.

Zenke, M. et al. (1990). "Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells," PNAS 87:3655-3659.

* cited by examiner

ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Appl. No. 62/641,873, filed Mar. 12, 2018, and U.S. Provisional Patent Appl. No. 62/625,019, filed Feb. 1, 2018, each of which is incorporated herein by reference in its entirety.

REFERENCE TO SEQUENCE LISTING

This application is being filed electronically via EFS-Web and includes an electronically submitted sequence listing in .txt format. The .txt file contains a sequence listing entitled "ALGN-015_02 US_SL.txt" created on Jan. 30, 2019, and having a size of 223 kilobytes. The sequence listing contained in this .txt file is part of the specification and is incorporated herein by reference in its entirety.

FIELD

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to Cluster of Differentiation 70 (CD70). The invention further relates to heteromultimeric antibodies (e.g., bispecific antibodies) comprising CD70 antibody on one arm. Compositions comprising the CD70 antibodies, methods for producing and purifying such antibodies, and their use in diagnostics and therapeutics are also provided.

BACKGROUND

Renal Cell Carcinoma (RCC) is a cancer that originates in the renal cortex and accounts for about 90% of cancers in the kidney. Based on histology, RCC can be classified into several sub-types, of which Clear Cell Renal Cell Carcinoma (ccRCC) is the most common and leads to the most deaths. Each year, over 320,000 cases of RCC are reported worldwide leading to roughly 140,000 deaths. The incidence of RCC has risen steadily over the last 10 years and accounts for 2-3% of all adult malignancies. Patients with early stage localized tumors can opt for surgical resection; however, localized disease can undergo early hematogenous dissemination leading to metastasis. Sites of early metastases include lungs, lymph nodes, liver, bone, and brain; less commonly the adrenal glands, and the contralateral kidney. Patients with advanced disease face high morbidity rates with a 5-year median survival rate of 53% for stage III disease and only 8% for metastatic disease. Current first-line treatment options for advanced disease include small molecule Tyrosine Kinase Inhibitors (TKIs) such as sunitinib and pazopanib that target Vascular Endothelial Growth Factor (VEGF) receptor, monoclonal antibody targeting VEGF such as bevacizumab, mammalian target of Rapamycin (mTOR) inhibitor temsirolimus, as well as high dose IL-2. Although these VEGF-targeted therapies have improved over-all survival, long-term drug resistance leads to disease relapse and treatment for advanced disease still remains an unmet need (see, e.g., Zarrabi, K. et al., *Journal of Hematology and Oncology*, 10:38 (2017)).

Cluster of Differentiation 70 (CD70, CD27LG or TNFSF7) is a member of the tumor necrosis factor (TNF) superfamily and the ligand for CD27, a TNF superfamily provides T cell costimulation complementary to that pro-

vided by CD28. CD70 is expressed on hematological cancers such as Non-Hodgkin's Lymphoma and Hodgkin's disease as well as on solid tumors such as Glioblastoma and Renal Cell Carcinoma; with its expression on ccRCC being nearly uniform (see e.g., Grewal I., et al., *Expert Opinion on Therapeutic Targets*, 12(3): 341-351 (2008)).

CD70 bispecific antibody in the form of T-cell engaging bispecific approach has been developed recently. However, a limitation of many bispecific formats is that they are of small molecular weight, and of short half-life, thus requiring continuous infusion. Accordingly, there remains a need for antibodies (e.g., monospecific or bispecific) treating cancer where CD70 is expressed and in particular mRCC with improved efficacy and safety profile, and suitable for use with human patients.

SUMMARY

The invention disclosed herein is directed to antibodies (e.g., monospecific or bispecific antibodies) that specifically bind to Cluster of Differentiation 70 (CD70). In some embodiments, the CD70 antibodies as described herein in the full-length bispecific format have longer half-life, minimized Fc-interaction, and minimized non-specific cytokine release in vivo via interaction with immune cells.

Accordingly, in one aspect, the invention provides an isolated antibody which specifically binds to CD70, wherein the antibody comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 87, 91, 92, 93, 97, 98, 99, 103, 104, 105, 109, 110, 111, 115, 116, 117, 121, 122, 123, 127, 128, 129, 133, 134, 135, 139, 140, 141, 145, 146, 147, 151, 152, 153, 157, 158, 159, 163, 164, 165, 169, 170, 171, 175, 176, 177, 181, 182, 183, 187, 188, 189, 332, 333, 334, 338, 339, 340, 344, 345, 346, 350, 351, 352, 356, 357, 358, 362, 363, 364, 368, 369, 370, 374, 375, 376, 380, 381, 382, 386, 387, 388, 392, 393, 394, 398, 399, 400, 404, 405, 406, 410, 411, 412, 416, 437, 418, 422, 423, 424, 428, 429, 430, 434, 435, 436, 440, 441, 442, 446, 447, 448, 452, 453, 454, 458, 459 or 460; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 52, 53, 58, 59, 64, 65, 70, 71, 76, 77, 82, 83, 88, 89, 94, 95, 100, 101, 106, 107, 112, 113, 118, 119, 124, 125, 130, 131, 136, 137, 142, 143, 148, 149, 154, 155, 160, 161, 166, 167, 172, 173, 178, 179, 184, 185, 190, 191, 335, 336, 341, 342, 347, 348, 353, 354, 359, 360, 365, 366, 371, 372, 377, 378, 383, 384, 389, 390, 395, 396, 401, 402, 407, 408, 413, 414, 419, 420, 425, 426, 431, 432, 437, 438, 443, 444, 449, 450, 455, 456, 461 or 462; and (iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150, 156, 162, 168, 174, 180, 186, 192, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 or 463; or a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 464, 467, 470, 473, 476, 479, 482, 485, 488, 491, 494, 497, 500, 503, 506, 509, 512, 515, 518, 521, 524 or 527; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 194, 197, 200, 203, 206, 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 465, 468, 471, 474, 477, 480, 483, 486, 489, 492, 495, 498, 501, 504, 507, 510, 513, 516, 519, 522, 525 or 528; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 195, 198, 201, 204, 207,

210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 466, 469, 472, 475, 478, 481, 484, 487, 490, 493, 496, 499, 502, 505, 508, 511, 514, 517, 520, 523, 526 or 529.

In another aspect, provided is an isolated antibody which specifically binds to CD70, wherein the antibody comprises: a VH region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329 or 331; or a VL region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328 or 330. In some embodiments, the VH region as described herein comprises a variant with one or several conservative amino acid substitutions in residues that are not within a CDR or the VL region as described herein comprises a variant with one or several amino acid substitutions in amino acids that are not within a CDR. For example, in some embodiments, the VH or VL region can comprise an amino acid sequence described above or a variant thereof with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 conservative substitutions in residues that are not within a CDR.

In some embodiments, provided is an isolated antibody which specifically binds to CD70, wherein the antibody comprises: a VH region comprising the sequence shown in SEQ ID NO: 18; or a VL region comprising the sequence shown in SEQ ID NO: 17.

In some embodiments, provided is an antibody which specifically binds to CD70 and competes with an isolated antibody provided herein which specifically binds to CD70.

In another aspect, provided is a bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen (e.g., CD70), and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen (e.g., Cluster of differentiation 3 (CD3)) located on the human immune effector cell. In some embodiments, the first antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329 or 331; or a light chain variable (VL) region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328 or 330. In some embodiments, the first antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 87, 91, 92, 93, 97, 98, 99, 103, 104, 105, 109, 110, 111, 115, 116, 117, 121, 122, 123, 127, 128, 129, 133, 134, 135, 139, 140, 141, 145, 146, 147, 151, 152, 153, 157, 158, 159, 163, 164, 165, 169, 170, 171, 175, 176, 177, 181, 182, 183, 187, 188, 189, 332, 333, 334, 338, 339, 340, 344, 345, 346, 350, 351, 352, 356, 357, 358, 362, 363, 364, 368, 369, 370, 374, 375, 376, 380, 381, 382, 386, 387, 388, 392, 393, 394, 398, 399,

400, 404, 405, 406, 410, 411, 412, 416, 437, 418, 422, 423, 424, 428, 429, 430, 434, 435, 436, 440, 441, 442, 446, 447, 448, 452, 453, 454, 458, 459 or 460; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 52, 53, 58, 59, 64, 65, 70, 71, 76, 77, 82, 83, 88, 89, 94, 95, 100, 101, 106, 107, 112, 113, 118, 119, 124, 125, 130, 131, 136, 137, 142, 143, 148, 149, 154, 155, 160, 161, 166, 167, 172, 173, 178, 179, 184, 185, 190, 191, 335, 336, 341, 342, 347, 348, 353, 354, 359, 360, 365, 366, 371, 372, 377, 378, 383, 384, 389, 390, 395, 396, 401, 402, 407, 408, 413, 414, 419, 420, 425, 426, 431, 432, 437, 438, 443, 444, 449, 450, 455, 456, 461 or 462; and (iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150, 156, 162, 168, 174, 180, 186, 192, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 or 463; or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 464, 467, 470, 473, 476, 479, 482, 485, 488, 491, 494, 497, 500, 503, 506, 509, 512, 515, 518, 521, 524 or 527; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 194, 197, 200, 203, 206, 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 465, 468, 471, 474, 477, 480, 483, 486, 489, 492, 495, 498, 501, 504, 507, 510, 513, 516, 519, 522, 525 or 528; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 466, 469, 472, 475, 478, 481, 484, 487, 490, 493, 496, 499, 502, 505, 508, 511, 514, 517, 520, 523, 526 or 529.

In some embodiments, the second antibody variable domain comprises the VH or VL region specific against CD3. For example, the second antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 266; or a light chain variable (VL) region comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 265. In some embodiments, the second antibody variable domain comprises (a) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 267, 268, or 269; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 270 or 271; and (iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 272; or a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 273; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 274; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 275.

In some embodiments, the antibodies described herein comprise a constant region. In some embodiments, the antibodies described herein are of the human IgG1, IgG2 or IgG2Δa, IgG3, or IgG4 subclass. In some embodiments, the antibodies described herein comprise a glycosylated constant region. In some embodiments, the antibodies described herein comprise a constant region having decreased binding affinity to one or more human Fc gamma receptor(s).

In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at positions 223, 225, and 228 (e.g., (C223E or C223R), (E225R), and (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the CH3 region of human IgG2 (SEQ ID NO: 279).

In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at position 265 (e.g., D265A) of the human IgG2.

In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at one or more of positions 265 (e.g., D265A), 330 (e.g., A330S), and 331 (e.g., P331S) of the human IgG2. In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at each of positions 265 (e.g., D265A), 330 (e.g., A330S), and 331 (e.g., P331S) of the human IgG2.

In other embodiments, the invention provides pharmaceutical compositions comprising any of the antibodies described herein.

The invention also provides cell lines that recombinantly produce any of the antibodies described herein.

The invention also provides nucleic acids encoding any of the antibodies described herein. The invention also provides nucleic acids encoding a heavy chain variable region or a light chain variable region of any of the antibodies described herein.

The invention also provides a host cell comprising a nucleic acid or vector provided herein. Also provided is a method of producing an antibody (e.g. monospecific or bispecific) provided herein, comprising culturing a host cell provided herein under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture.

The invention also provides kits comprising an effective amount of any of the antibodies or antibody conjugates described herein.

Also provided is an antibody or bispecific antibody provided herein for use as a medicament.

The invention also provides methods of treating subjects in need thereof comprising providing the isolated antibodies or bispecific antibodies described herein, and administering said antibodies to said subject.

Also provided are methods of treating a condition associated with malignant cells expressing CD70 in a subject comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising the antibodies as described herein. In some embodiments, the condition is a cancer. In some embodiments, the cancer is an CD70 related cancer (e.g., any cancer with CD70 expression) selected from the group consisting of Renal Cell Carcinoma, Glioblastoma, glioma such as low grade glioma, Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD), Waldenstrom's macroglobulinemia, Acute Myeloid Leukemia, Multiple Myeloma, diffuse large-cell lymphoma, follicular lymphoma or Non-Small Cell Lung Cancer.

In another aspect, the invention provides a method of inhibiting tumor growth or progression in a subject who has malignant cells expressing CD70, comprising administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising the isolated antibodies or bispecific antibodies, as described herein.

In another aspect, the invention provides a method of inhibiting metastasis of malignant cells expressing CD70 in a subject, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition comprising the isolated antibodies or bispecific antibodies, as described herein.

In another aspect, the invention provides a method inducing tumor regression in a subject who has malignant cells

expressing CD70, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of a pharmaceutical composition comprising the isolated antibodies or bispecific antibodies, as described herein.

DETAILED DESCRIPTION

The invention disclosed herein provides antibodies (e.g., monospecific or bispecific) that specifically bind to CD70 (e.g., human CD70). The invention also provides polynucleotides encoding these antibodies, compositions comprising these antibodies, and methods of making and using these antibodies. The invention also provides methods for treating a condition associated with CD70-mediated pathologies in a subject, such as cancer. In particular, the inventors of the present invention have discovered that the CD70 antibodies as described herein in the full-length bispecific format have longer half-life, minimized Fc-interaction, and minimized non-specific cytokine release in vivo via interaction with the immune cells.

General Techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, immunology, virology, monoclonal antibody generation and engineering, which are within the skill of the art. Such techniques are explained fully in the literature, such as, *Molecular Cloning: A Laboratory Manual*, second edition (Sambrook et al., 1989) Cold Spring Harbor Press; *Oligonucleotide Synthesis* (M. J. Gait, ed., 1984); *Methods in Molecular Biology*, Humana Press; *Cell Biology: A Laboratory Notebook* (J. E. Cellis, ed., 1998) Academic Press; *Animal Cell Culture* (R. I. Freshney, ed., 1987); *Introduction to Cell and Tissue Culture* (J. P. Mather and P. E. Roberts, 1998) Plenum Press; *Cell and Tissue Culture: Laboratory Procedures* (A. Doyle, J. B. Griffiths, and D. G. Newell, eds., 1993-1998) J. Wiley and Sons; *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental Immunology* (D. M. Weir and C. C. Blackwell, eds.); *Gene Transfer Vectors for Mammalian Cells* (J. M. Miller and M. P. Calos, eds., 1987); *Current Protocols in Molecular Biology* (F. M. Ausubel et al., eds., 1987); *PCR: The Polymerase Chain Reaction*, (Mullis et al., eds., 1994); *Current Protocols in Immunology* (J. E. Coligan et al., eds., 1991); *Short Protocols in Molecular Biology* (Wiley and Sons, 1999); *Immunobiology* (C. A. Janeway and P. Travers, 1997); *Antibodies* (P. Finch, 1997); *Antibodies: a practical approach* (D. Catty, ed., IRL Press, 1988-1989); *Monoclonal antibodies: a practical approach* (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); *Using antibodies: a laboratory manual* (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); *The Antibodies* (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995).

Definitions

An "antibody" is an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact polyclonal or monoclonal antibodies, but also antigen binding fragments thereof (such as Fab, Fab', F(ab')₂, Fv), single chain (ScFv) and domain antibodies (including, for example, shark and camelid antibodies), and fusion proteins comprising an antibody, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site. An antibody includes

an antibody of any class, such as IgG, IgA, or IgM (or sub-class thereof), and the antibody need not be of any particular class. Depending on the antibody amino acid sequence of the constant region of its heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy-chain constant regions that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

The term “antigen binding fragment” or “antigen binding portion” of an antibody, as used herein, refers to one or more fragments of an intact antibody that retain the ability to specifically bind to a given antigen (e.g., CD70). Antigen binding functions of an antibody can be performed by fragments of an intact antibody. Examples of binding fragments encompassed within the term “antigen binding fragment” of an antibody include Fab; Fab'; F(ab')₂; an Fd fragment consisting of the VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a single domain antibody (dAb) fragment (Ward et al., *Nature* 341:544-546, 1989), and an isolated complementarity determining region (CDR).

An antibody or a polypeptide that “preferentially binds” or “specifically binds” (used interchangeably herein) to a target (e.g., CD70 protein) is a term well understood in the art, and methods to determine such specific or preferential binding are also well known in the art. A molecule is said to exhibit “specific binding” or “preferential binding” if it reacts or associates more frequently, more rapidly, with greater duration or with greater affinity with a particular cell or substance than it does with alternative cells or substances. An antibody “specifically binds” or “preferentially binds” to a target if it binds with greater affinity, avidity, more readily, or with greater duration than it binds to other substances. For example, an antibody that specifically or preferentially binds to an CD70 epitope is an antibody that binds this epitope with greater affinity, avidity, more readily, or with greater duration than it binds to other CD70 epitopes or non-CD70 epitopes. It is also understood that by reading this definition, for example, an antibody (or moiety or epitope) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding.

A “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. As known in the art, the variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs) also known as hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies. There are at least two techniques for determining CDRs: (1) an approach based on cross-species sequence variability (i.e., Kabat et al. *Sequences of Proteins of Immunological Interest*, (5th ed., 1991, National Institutes of Health, Bethesda Md.)); and (2) an approach based on crystallographic studies of antigen-antibody complexes (Al-lazikani et al., 1997, J.

Molec. Biol. 273:927-948). As used herein, a CDR may refer to CDRs defined by either approach or by a combination of both approaches.

A “CDR” of a variable domain are amino acid residues within the variable region that are identified in accordance with the definitions of the Kabat, Chothia, the accumulation of both Kabat and Chothia, AbM, contact, or conformational definitions or any method of CDR determination well known in the art. Antibody CDRs may be identified as the hypervariable regions originally defined by Kabat et al. See, e.g., Kabat et al., 1992, *Sequences of Proteins of Immunological Interest*, 5th ed., Public Health Service, NIH, Washington D.C. The positions of the CDRs may also be identified as the structural loop structures originally described by Chothia and others. See, e.g., Chothia et al., *Nature* 342:877-883, 1989. Other approaches to CDR identification include the “AbM definition,” which is a compromise between Kabat and Chothia and is derived using Oxford Molecular’s AbM antibody modeling software (now Accelrys®), or the “contact definition” of CDRs based on observed antigen contacts, set forth in MacCallum et al., *J. Mol. Biol.*, 262:732-745, 1996. In another approach, referred to herein as the “conformational definition” of CDRs, the positions of the CDRs may be identified as the residues that make enthalpic contributions to antigen binding. See, e.g., Makabe et al., *Journal of Biological Chemistry*, 283:1156-1166, 2008. Still other CDR boundary definitions may not strictly follow one of the above approaches, but will nonetheless overlap with at least a portion of the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. As used herein, a CDR may refer to CDRs defined by any approach known in the art, including combinations of approaches. The methods used herein may utilize CDRs defined according to any of these approaches. For any given embodiment containing more than one CDR, the CDRs may be defined in accordance with any of Kabat, Chothia, extended, AbM, contact, or conformational definitions.

As used herein, “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler and Milstein, *Nature* 256:495, 1975, or may be made by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty et al., *Nature* 348:552-554, 1990, for example.

As used herein, “humanized” antibody refers to forms of non-human (e.g. murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen binding

subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin.

Preferably, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Preferred are antibodies having Fc regions modified as described in WO 99/58572. Other forms of humanized antibodies have one or more CDRs (CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, or CDR H3) which are altered with respect to the original antibody, which are also termed one or more CDRs "derived from" one or more CDRs from the original antibody.

As used herein, "human antibody" means an antibody having an amino acid sequence corresponding to that of an antibody produced by a human or which has been made using any of the techniques for making human antibodies known to those skilled in the art or disclosed herein. This definition of a human antibody includes antibodies comprising at least one human heavy chain polypeptide or at least one human light chain polypeptide. One such example is an antibody comprising murine light chain and human heavy chain polypeptides. Human antibodies can be produced using various techniques known in the art. In one embodiment, the human antibody is selected from a phage library, where that phage library expresses human antibodies (Vaughan et al., *Nature Biotechnology*, 14:309-314, 1996; Sheets et al., *Proc. Natl. Acad. Sci. (USA)* 95:6157-6162, 1998; Hoogenboom and Winter, *J. Mol. Biol.*, 227:381, 1991; Marks et al., *J. Mol. Biol.*, 222:581, 1991). Human antibodies can also be made by immunization of animals into which human immunoglobulin loci have been transgenically introduced in place of the endogenous loci, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. This approach is described in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016. Alternatively, the human antibody may be prepared by immortalizing human B lymphocytes that produce an antibody directed against a target antigen (such B lymphocytes may be recovered from an individual or from single cell cloning of the cDNA, or may have been immunized in vitro). See, e.g., Cole et al. *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77, 1985; Boerner et al., *J. Immunol.*, 147 (1):86-95, 1991; and U.S. Pat. No. 5,750,373.

The term "chimeric antibody" is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a

mouse antibody and the constant region sequences are derived from a human antibody.

The terms "polypeptide", "oligopeptide", "peptide" and "protein" are used interchangeably herein to refer to chains of amino acids of any length. For example, the chain may be relatively short (e.g., 10-100 amino acids), or longer. The chain may be linear or branched, it may comprise modified amino acids, or may be interrupted by non-amino acids. The terms also encompass an amino acid chain that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that the polypeptides can occur as single chains or associated chains.

A "monovalent antibody" comprises one antigen binding site per molecule (e.g., IgG or Fab). In some instances, a monovalent antibody can have more than one antigen binding sites, but the binding sites are from different antigens.

A "monospecific antibody" comprises two identical antigen binding sites per molecule (e.g. IgG) such that the two binding sites bind identical epitope on the antigen.

Thus, they compete with each other on binding to one antigen molecule. Most antibodies found in nature are monospecific. In some instances, a monospecific antibody can also be a monovalent antibody (e.g. Fab)

A "bivalent antibody" comprises two antigen binding sites per molecule (e.g., IgG). In some instances, the two binding sites have the same antigen specificities. However, bivalent antibodies may be bispecific.

A "bispecific" or "dual-specific" is a hybrid antibody having two different antigen binding sites. The two antigen binding sites of a bispecific antibody bind to two different epitopes, which may reside on the same or different protein targets.

A "bifunctional" is antibody is an antibody having identical antigen binding sites (i.e., identical amino acid sequences) in the two arms but each binding site can recognize two different antigens.

A "heteromultimer", "heteromultimeric complex", or "heteromultimeric polypeptide" is a molecule comprising at least a first polypeptide and a second polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. The heteromultimer can comprise a "heterodimer" formed by the first and second polypeptide or can form higher order tertiary structures where polypeptides in addition to the first and second polypeptide are present.

A "heterodimer," "heterodimeric protein," "heterodimeric complex," or "heteromultimeric polypeptide" is a molecule comprising a first polypeptide and a second polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue.

The "hinge region," "hinge sequence", and variations thereof, as used herein, includes the meaning known in the art, which is illustrated in, for example, Janeway et al., *ImmunoBiology: the immune system in health and disease*, (Elsevier Science Ltd., NY) (4th ed., 1999); Bloom et al., *Protein Science* (1997), 6:407-415; Humphreys et al., *J. Immunol. Methods* (1997), 209:193-202.

The "immunoglobulin-like hinge region," "immunoglobulin-like hinge sequence," and variations thereof, as used herein, refer to the hinge region and hinge sequence of

an immunoglobulin-like or an antibody-like molecule (e.g., immunoadhesins). In some embodiments, the immunoglobulin-like hinge region can be from or derived from any IgG1, IgG2, IgG3, or IgG4 subtype, or from IgA, IgE, IgD or IgM, including chimeric forms thereof, e.g., a chimeric IgG1/2 hinge region.

The term “immune effector cell” or “effector cell as used herein refers to a cell within the natural repertoire of cells in the human immune system which can be activated to affect the viability of a target cell. The viability of a target cell can include cell survival, proliferation, or ability to interact with other cells.

Antibodies of the invention can be produced using techniques well known in the art, e.g., recombinant technologies, phage display technologies, synthetic technologies or combinations of such technologies or other technologies readily known in the art (see, for example, Jayasena, S. D., *Clin. Chem.*, 45: 1628-50, 1999 and Fellouse, F. A., et al., *J. Mol. Biol.*, 373(4):924-40, 2007).

As known in the art, “polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to chains of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, or their analogs, or any substrate that can be incorporated into a chain by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the chain. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports. The 5' and 3' terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl-, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs, alpha- or beta-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), (O)NR₂ (“amide”), P(O)R, P(O)OR', CO or

CH₂ (“formacetal”), in which each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (—O—) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

As known in the art, a “constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination.

As used herein, “substantially pure” refers to material which is at least 50% pure (i.e., free from contaminants), more preferably, at least 90% pure, more preferably, at least 95% pure, yet more preferably, at least 98% pure, and most preferably, at least 99% pure.

A “host cell” includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) of this invention.

As known in the art, the term “Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain. The “Fc region” may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The numbering of the residues in the Fc region is that of the EU index as in Kabat. Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. The Fc region of an immunoglobulin generally comprises two constant regions, CH₂ and CH₃.

As used in the art, “Fc receptor” and “FcR” describe a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an “activating receptor”) and FcγRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. FcRs are reviewed in Ravetch and Kinet, *Ann. Rev. Immunol.*, 9:457-92, 1991; Capel et al., *Immunomethods*, 4:25-34, 1994; and de Haas et al., *J. Lab. Clin. Med.*, 126:330-41, 1995. “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., *J. Immunol.*, 117:587, 1976; and Kim et al., *J. Immunol.*, 24:249, 1994).

The term “compete”, as used herein with regard to an antibody, means that a first antibody, or an antigen binding fragment (or portion) thereof, binds to an epitope in a manner sufficiently similar to the binding of a second antibody, or an antigen binding portion thereof, such that the result of binding of the first antibody with its cognate epitope is detectably decreased in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody. The alternative, where the binding of the second antibody to its epitope is also detectably decreased in the presence of the first antibody, can, but

need not be the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope. However, where each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to “cross-compete” with each other for binding of their respective epitope(s). Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof), the skilled artisan would appreciate, based upon the teachings provided herein, that such competing or cross-competing antibodies are encompassed and can be useful for the methods disclosed herein.

A “functional Fc region” possesses at least one effector function of a native sequence Fc region. Exemplary “effector functions” include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity; phagocytosis; down-regulation of cell surface receptors (e.g. B cell receptor), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector functions.

A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification, yet retains at least one effector function of the native sequence Fc region. In some embodiments, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g. from about one to about ten amino acid substitutions, and preferably, from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region or with an Fc region of a parent polypeptide, and most preferably, at least about 90% sequence identity therewith, more preferably, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity therewith.

The term “effector function” refers to the biological activities attributable to the Fc region of an antibody. Examples of antibody effector functions include, but are not limited to, antibody-dependent cell-mediated cytotoxicity (ADCC), Fc receptor binding, complement dependent cytotoxicity (CDC), phagocytosis, C1q binding, and down regulation of cell surface receptors (e.g., B cell receptor; BCR). See, e.g., U.S. Pat. No. 6,737,056. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector functions. An exemplary measurement of effector function is through Fcγ3 or C1q binding.

As used herein “antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g. natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC activity of

a molecule of interest can be assessed using an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or 5,821,337. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., 1998, PNAS (USA), 95:652-656.

“Complement dependent cytotoxicity” or “CDC” refers to the lysing of a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g. an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods, 202: 163 (1996), may be performed.

As used herein, “treatment” is an approach for obtaining beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: reducing the proliferation of (or destroying) neoplastic or cancerous cells, inhibiting metastasis of neoplastic cells, shrinking or decreasing the size of CD70 expressing tumor, remission of an CD70 associated disease (e.g., cancer), decreasing symptoms resulting from an CD70 associated disease (e.g., cancer), increasing the quality of life of those suffering from an CD70 associated disease (e.g., cancer), decreasing the dose of other medications required to treat an CD70 associated disease (e.g., cancer), delaying the progression of an CD70 associated disease (e.g., cancer), curing an CD70 associated disease (e.g., cancer), or prolong survival of patients having an CD70 associated disease (e.g., cancer).

“Ameliorating” means a lessening or improvement of one or more symptoms as compared to not administering an CD70 antibody (monospecific or bispecific). “Ameliorating” also includes shortening or reduction in duration of a symptom.

As used herein, an “effective dosage” or “effective amount” of drug, compound, or pharmaceutical composition is an amount sufficient to effect any one or more beneficial or desired results. For prophylactic use, beneficial or desired results include eliminating or reducing the risk, lessening the severity, or delaying the outset of the disease, including biochemical, histological or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include clinical results such as reducing incidence or amelioration of one or more symptoms of various CD70 associated diseases or conditions (such as for example multiple myeloma), decreasing the dose of other medications required to treat the disease, enhancing the effect of another medication, or delaying the progression of the CD70 associated disease of patients. An effective dosage can be administered in one or more administrations. For purposes of this invention, an effective dosage of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective dosage of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.

An "individual" or a "subject" is a mammal, more preferably, a human. Mammals also include, but are not limited to primates, horses, dogs, cats, mice and rats.

As used herein, "vector" means a construct, which is capable of delivering, and, preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.

As used herein, "expression control sequence" means a nucleic acid sequence that directs transcription of a nucleic acid. An expression control sequence can be a promoter, such as a constitutive or an inducible promoter, or an enhancer. The expression control sequence is operably linked to the nucleic acid sequence to be transcribed.

As used herein, "pharmaceutically acceptable carrier" or "pharmaceutical acceptable excipient" includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Preferred diluents for aerosol or parenteral administration are phosphate buffered saline (PBS) or normal (0.9%) saline. Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990; and Remington, The Science and Practice of Pharmacy 21st Ed. Mack Publishing, 2005).

The term "acyl donor glutamine-containing tag" or "glutamine tag" as used herein refers to a polypeptide or a protein containing one or more Gln residue(s) that acts as a transglutaminase amine acceptor. See, e.g., WO2012059882 and WO2015015448.

The term " k_{on} " or " k_a ", as used herein, refers to the rate constant for association of an antibody to an antigen. Specifically, the rate constants (k_{on}/k_a and k_{off}/k_d) and equilibrium dissociation constants are measured using whole antibody (i.e. bivalent) and monomeric CD70 proteins (e.g., Histidine-tagged CD70 fusion protein).

The term " k_{off} " or " k_d ", as used herein, refers to the rate constant for dissociation of an antibody from the antibody/antigen complex.

The term " K_D ", as used herein, refers to the equilibrium dissociation constant of an antibody-antigen interaction.

Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X." Numeric ranges are inclusive of the numbers defining the range. Generally speaking, the term "about" refers to the indicated value of the variable and to all values of the variable that are within the experimental error of the indicated value (e.g. within the 95% confidence interval for the mean) or within 10 percent of the indicated value, whichever is greater. Where the term "about" is used within the context of a time period (years, months, weeks, days etc.), the term "about" means that period of time plus or minus one amount of the next subordinate time period (e.g. about 1 year means 11-13 months; about 6 months means 6 months plus or minus 1 week; about 1 week means 6-8 days; etc.), or within 10 percent of the indicated value, whichever is greater.

It is understood that wherever embodiments are described herein with the language "comprising," otherwise analogous embodiments described in terms of "consisting of" or "consisting essentially of" are also provided.

Where aspects or embodiments of the invention are described in terms of a Markush group or other grouping of alternatives, the present invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, but also the main group absent one or more of the group members. The present invention also envisages the explicit exclusion of one or more of any of the group members in the claimed invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control. Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

Exemplary methods and materials are described herein, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. The materials, methods, and examples are illustrative only and not intended to be limiting.

CD70 Antibodies and Methods of Making Thereof

The present invention provides an antibody that binds to CD70 [e.g., human CD70 (e.g., accession number: NP_004110 or SEQ ID NO: 235)] and characterized by any one or more of the following characteristics: (a) treat, prevent, ameliorate one or more symptoms of a condition associated with malignant cells expressing CD70 in a subject (e.g., cancer such as AML); (b) inhibit tumor growth or progression in a subject (who has a malignant tumor expressing CD70); (c) inhibit metastasis of cancer (malignant) cells expressing CD70 in a subject (who has one or more malignant cells expressing CD70); (d) induce regression (e.g., long-term regression) of a tumor expressing CD70; (e) exert cytotoxic activity in malignant cells expressing CD70; (f) block CD70 interaction with other yet to be identified factors; or (g) induce bystander effect that kill or inhibit growth of non-CD70 expressing malignant cells in the vicinity.

In one aspect, provided is an isolated antibody which specifically binds to CD70, wherein the antibody comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 87, 91, 92, 93, 97, 98, 99, 103, 104, 105, 109, 110, 111, 115, 116, 117, 121, 122, 123, 127, 128, 129, 133, 134, 135, 139, 140, 141, 145, 146, 147, 151, 152, 153, 157, 158, 159, 163, 164, 165, 169, 170, 171, 175, 176, 177, 181, 182, 183, 187, 188, 189, 332, 333, 334, 338, 339, 340, 344, 345, 346, 350, 351, 352, 356, 357, 358, 362, 363, 364, 368, 369, 370, 374, 375, 376, 380, 381, 382, 386, 387, 388, 392, 393, 394, 398, 399, 400, 404, 405, 406, 410, 411, 412, 416, 437, 418, 422, 423, 424, 428, 429, 430, 434, 435, 436, 440, 441, 442, 446, 447, 448, 452, 453, 454, 458, 459 or 460; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 52, 53, 58, 59, 64, 65, 70, 71, 76, 77, 82, 83, 88, 89, 94, 95, 100, 101, 106, 107, 112,

113, 118, 119, 124, 125, 130, 131, 136, 137, 142, 143, 148, 149, 154, 155, 160, 161, 166, 167, 172, 173, 178, 179, 184, 185, 190, 191, 335, 336, 341, 342, 347, 348, 353, 354, 359, 360, 365, 366, 371, 372, 377, 378, 383, 384, 389, 390, 395, 396, 401, 402, 407, 408, 413, 414, 419, 420, 425, 426, 431, 432, 437, 438, 443, 444, 449, 450, 455, 456, 461 or 462; and
 iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150, 156, 162, 168, 174, 180, 186, 192, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 or 463; or a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 464, 467, 470, 473, 476, 479, 482, 485, 488, 491, 494, 497, 500, 503, 506, 509, 512, 515, 518, 521, 524 or 527; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 194, 197, 200, 203, 206, 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 465, 468, 471, 474, 477, 480, 483, 486, 489, 492, 495, 498, 501, 504, 507, 510, 513, 516, 519, 522, 525 or 528; and (iii) a VL

CDR3 comprising the sequence shown in SEQ ID NO: 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 466, 469, 472, 475, 478, 481, 484, 487, 490, 493, 496, 499, 502, 505, 508, 511, 514, 517, 520, 523, 526 or 529.

In another aspect, provided is an isolated antibody which specifically binds to CD70, wherein the antibody comprises: a VH region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329 or 331; or a VL region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328 or 330.

In some embodiments, provided is an antibody having any one of partial light chain sequence as listed in Table 1 or any one of partial heavy chain sequence as listed in Table 1. In Table 1, the underlined sequences are CDR sequences according to Kabat and in bold according to Chothia.

TABLE 1

mAb	Light Chain	Heavy Chain
31H1	DIVMTQNPLSSPVTLGQPASISCRS <u>SQSLVHSDGNTYLSWLQORPGQS</u> PRLLIYKISNRFSGVPDRFSGSGAG TDFTLKI SRVEAEDVGYYCMQAT <u>QFPLTIGGGSKVEIK</u> (SEQ ID NO: 1)	QVQLVQSGAEVKKPGSSVKVCSKA SGGTFSSYGF SWVRQAPGQGLEW MGGIIP IFGS ANYAQKFQGRVTITAD KSTSTVMEIISLRSEDTAVYYCAR GGSSSPFAY WGQGLTIVTVSS (SEQ ID NO: 2)
63B2	DIVMTQTPPLSSPVTLGQPASISCRS <u>SQSLVHSDGNTYLSWLQORPGQS</u> PRLLIYKISNRFSGVPDRFSGSGAG TDFTLKI SRVEAEDVGYYCMQAT <u>QFPLTIGGGSKVEIK</u> (SEQ ID NO: 3)	QVQLVQSGAEVKKPGSSVKVCSKA SGGTFSSYGF SWVRQAPGQGLEW MGGIIP IFGT ANYAQKFQGRVTITAD KSTSTVMEIISLRSEDTAVYYCAR GGSSSPFAY WGQGLTIVTVSS (SEQ ID NO: 4)
40E3	DIQMTQSPSSLSASVGDRTITCRA <u>SQGISNYLAWFQKPKKAPKSLIY</u> <u>AASSLQSGVPSKFSGSGSGTDFTL</u> TISSLQPEDFATYYCQYNSYPLTF GGGTKVEIK (SEQ ID NO: 5)	QVQLQESGPGLVKPKSETLSLTCTVS GGSISSYYWN WIRQPPGKGLEWIG <u>YIYYSGSTNYNPSL</u> KSRVTISVDTSK NQFSLKLRSVTAADTAVYYCARDIR <u>TWGQGLTIVTVSS</u> (SEQ ID NO: 6)
42C3	DVVMTQSPSLPVTLGQPASISCRS <u>SQSLVYSDENTYLNWFQORPGQS</u> LRRLIYQVSNRDSGVPDRFSGSGS GTDFTLKI SRVEAEDVGYYFCMQG <u>TYWPPTFGGGTKVEIK</u> (SEQ ID NO: 7)	EVQLVESGGGLVQPGGSLRLSCAA SGFTFRNS WMSWVRQAPGKGLEW VANIKR RDGSEK YYVDSVKGRFTISR DNAKNSLYLQMNLSRAEDTAVYYC <u>ARDQTGSFDY</u> WGQGLTIVTVSS (SEQ ID NO: 8)
45F11	EIVMTQSPATLSMSLGERATLSCRA <u>SQSVSSSLAWYQKPGQAPRLLIY</u> <u>GASTRATGI</u> PARFSGSGSGTEFTL TISSLQSEDFAVYYCQYINWPHFG GGTKVEIK (SEQ ID NO: 9)	QVQLRGSGLVQPKSETLSLTCTVS DDSISSVY WVIRQAPGKGLEWIGR <u>VYSSGNINYNPSLE</u> SRVTMSVDTSK SRFSLNLSVTAADTAVYYCARGLD <u>AFDI</u> WGQGMVTVSS (SEQ ID NO: 10)
64F9	DIQMTQSPSSLSASVGDRTITCQA <u>SQDISNYLNWYQKPKKILIIYG</u> <u>ASNLETG</u> VPSRFSGSGSGTDFTFAI SSLQPEDVATYYCQYDNFPITFG QGTRLEIK (SEQ ID NO: 11)	EVQLLESGGGLVQPGESLRLSCEVS GFTFTSYAM SWVRQVPGKLEWVS <u>IISGVAFTTY</u> YADSVKGRFTISR KNTLYLQMNGLRAEDTAVYYCVKY <u>DGEVY</u> WGQGLTIVTVSS (SEQ ID NO: 12)
72C2	EIVMTQSPDTLSVSPGERAILSCRA <u>SQSVSSNLAWYQKPGQAPRLLIY</u> <u>SASTRASGI</u> PARFSGSGSGTEFTLS ISSLQSEDFAVYYCQYDNWPPLT FGGTKVEIK (SEQ ID NO: 13)	QVQLVQSGAEVKKPGSSVKVSCFA SGGTFIT YAI SWVRQAPGQGLEW GGIIP FFGT ANYAQKFQGRVTITADK STSTASMELRSLRSED TAMYCAQ WELFFFDFE WGQGPVTVSS (SEQ ID NO: 14)

TABLE 1-continued

mAb	Light Chain	Heavy Chain
2F10	EIVLTQSPGTLSPGERATLSCRA <u>SQSVSSSYLAWYQQQPGQAPRLLI</u> YGASSRATGIPDRFSGSGSDTFT LTISRLEPEDFAIYYC <u>QQYGSSPLTF</u> GGGTKVEIK (SEQ ID NO: 15)	AVQLVESGGGLVQPGGSLRLSCAA <u>SGFTFTYYSMNWVRQAPGKGLEW</u> VSHISIRSTIYFADSAKGRFTISRDN AKNSLYLQMNLSRDEDTAVYYCAR <u>GSGWYGDYFDYWGQGLVTVSS</u> (SEQ ID NO: 16)
4F11	DIQMTQSPSAMSASVGDRTITCR <u>ASQDISNYLAWFQQKPKVPRLLI</u> YAASSLQSGVPSRFSGSGTEFT LTISLLPEDFATYYC <u>LQLNSFPFTF</u> GGGTKVEIN (SEQ ID NO: 17)	QVTLKESGPVLVKTETLTLTCTVS <u>GFSLSNARMGVTWIRQPPGKALEW</u> LAHIFSNDEKSYSTSLKSLRTISKDT SKTQVVLMTNMDPVDATYYCARI <u>RDYYDISSYYDWGQGLVSVSS</u> (SEQ ID NO: 18)
10H10	DIQMTQSPSSVSASVGDRTITCRA <u>SQGISSWLAWYQQKPKAPKVLII</u> <u>AASSLQSGVPSRFSGSGSDTFTL</u> TISSLQPEDFATYYC <u>QQAFSFPFTF</u> GPGTKVDIK (SEQ ID NO: 19)	EVQLVESGGGLVQPGGSLRLSCAV <u>SGFTFSNHNHWRQAPGKGLEWIS</u> <u>YISRSSSTIYADSVKGRFTISRDN</u> KNSLYLQMNLSRDEDTAVYYCARD <u>HAQWYGMVDYWGQGLVTVSS</u> (SEQ ID NO: 20)
17G6	DIVMTQSPDSLAVSLGERATINCKS <u>SQSVLYSYNNKNYVAWYQQKPGQ</u> PPNLLIFWASTRESGVPDRFSGSG SGTDFTLTISLQAEDEVAVYYC <u>QQY</u> <u>YSTLTFFGGGTKVEIK</u> (SEQ ID NO: 21)	EVQLVESGGGLVQPGGSLRLSCVA <u>SGFTFSSYWMWVRQAPGKGLEW</u> VASIKQDGEKEYVDSVKGRFTISR DNAKNSVYLQMNLSRAEDTGVYYC <u>AREGVNNGWRLYWHFDLWGRGTL</u> VTVSS (SEQ ID NO: 22)
65E11	EIVLTQSPGTLSPGERVTLSCRA <u>SQSVSSSYLAWYQQKPGQAPRLLI</u> YDASSRATGIPDRFSGSGSDTFT LTISRLEPEDFAVYYC <u>QQYGSSPLT</u> FGGGTKVEIK (SEQ ID NO: 23)	EVQVVESGGGLVQPGGSLRLSCAA <u>SGFTFSSYSMNWVRQAPGKGLEW</u> VSHSSISRGNIYFADSVKGRFTISR NAKNSLYLQMNLSRDEDTAVYYCA <u>RSGWYGDYFDYWGQGLVTVSS</u> (SEQ ID NO: 24)
P02B10	ELQSVLTQPPSASGTPGQRVTISCS <u>GSSSNIGSNVYVYQQLPGTAPKL</u> LIYRNNQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDEADYYC <u>AAWDDS</u> <u>LSGVVFGGTGKLTVL</u> (SEQ ID NO: 25)	EVQLLESGGGLVQPGGSLRLSCAA <u>SGFAFSNYAMWVRQAPGKGLEW</u> VSAIRGGGGSYYADSVKGRFTISR DNSKNTLYLQMNLSRAEDTAVYYCA <u>RDFISGTWYFDYWGQGLVTVSS</u> (SEQ ID NO: 26)
P07D03	ELQSVLTQPPSASGTPGQRVTISCS <u>GSRNIGSNVYVYQQLPGTAPKL</u> LIYRNNQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDEADYYC <u>ASWDGS</u> <u>LSAVVFGGTGKLTVL</u> (SEQ ID NO: 27)	EVQLVQSGAEVKKPGESLKI SCKGS <u>GFRFTSYWIGWVRQMPGKGLEWM</u> <u>GSIYPDSDTRYSPSFQGVVTSAD</u> KSISTAYLQWSSLKASDTAMYCAS <u>STVDYPGYSYFDYWGQGLVTVSS</u> (SEQ ID NO: 28)
P08A02	ELQSVLTQPPSASGTPGQRVTISCS <u>GSSSNIGSNVYVYQQLPGTAPKL</u> LIYRNNQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDEADYYC <u>ATWDDS</u> <u>LGSVPVFGGTGKLTVL</u> (SEQ ID NO: 29)	EVQLVQSGAEVKKPGESLKI SCKGS <u>GFTFTNYWIAWVRQMPGKGLEWM</u> <u>GIIYPDSDTRYSPSFQGVVTSADK</u> SISTAYLQWSSLKASDTAMYCARD <u>ITSWYGEPAFDIWGQGLVTVSS</u> (SEQ ID NO: 30)
P08E02	ELDIQMTQSPSSLSASVGDRTITC <u>RASQISRYLNWYQQKPKAPKLLI</u> YAASILQTVPSRFSGSGSDTFT LTISLQPEDFATYYC <u>QQSYSTTM</u> <u>WTFGQGTKVEIK</u> (SEQ ID NO: 31)	EVQLVQSGAEVKKPGESLKI SCKGS <u>GYSFTSSWIGWVRQMPGKGLEWM</u> <u>GIIYPDSDTRYSPSFQGVVTSADK</u> SISTAYLQWSSLKASDTAMYCAK <u>LSQAMTGFDFYWGQGLVTVSS</u> (SEQ ID NO: 32)
P08F08	ELQSVLTQPPSASGTPGQRVTISCS <u>GSSSNIGSNVYVYQQLPGTAPKL</u> LIYGDYQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDEADYYC <u>ATRDDSL</u> <u>SGSVVFGGTGKLTVL</u> (SEQ ID NO: 33)	EVQLVQSGAEVKKPGESLKI SCKGS <u>GYGFTSYWIGWVRQMPGKGLEWM</u> <u>GIIHPDSDTKYSPSFQGVVTSADK</u> SISTAYLQWSSLKASDTAMYCASS <u>YLRGLWGGYFDYWGQGLVTVSS</u> (SEQ ID NO: 34)
P08G02	ELDIQMTQSPSSLSASVGDRTITC <u>RASQSIYDYLHWYQQKPKAPKLLI</u> YDASNLSGVPDRFSGSGSDTFT LTISLQPEDFATYYC <u>QQSYTTLF</u> <u>TFGQGTKVEIK</u> (SEQ ID NO: 35)	EVQLVQSGAEVKKPGESLKI SCKGS <u>GFTFPSSWIGWVRQMPGKGLEWM</u> <u>GIIYPTSHTRYSPSFQGVVTSADK</u> SISTAYLQWSSLKASDTAMYCARA <u>SYFDRGTGYSWMDVWGQGLV</u> TVSS (SEQ ID NO: 36)

TABLE 1-continued

mAb	Light Chain	Heavy Chain
P12B09	ELDIQMTQSPSSLSASVGDRVITIC <u>RASQYIGRYLN</u> WYQQKRGKAPKLL IHGATSLASGVPSRFRSGSGTDF TLTISSLQPEDFATYYC <u>QQSYSTTS</u> PTFGQGTKEIK (SEQ ID NO: 37)	EVQLLESGGGLVQPGGSLRLSCAA SGFTFSQYSMSWVRQAPGKGLEW VSAISGGGVSTYYADSVKGRFTISR DNSKNTLYLQMNLSRAEDTAVYYCA SDISDSGGSHWYFDYWGQGLVTV SS (SEQ ID NO: 38)
P12F02	ELQSVLTQPPSASGTPGQRTVITCS <u>GSTSNIGRNYVY</u> WYQQLPGTAPKL LIY <u>RTNQRPS</u> GVPDFRSGSGTDF ASLAISGLRSEDEADYYCA <u>AAWDDS</u> <u>LSGRV</u> FGTGTCLTVL (SEQ ID NO: 39)	EVQLLESGGGLVQPGGSLRLSCAA SGFTFSSYAMSWVRQAPGKGLEW VSTISGTGGTTYADSVKGRFTISR NSKNTLYLQMNLSRAEDTAVYYCAK <u>VRAGIDPTASDV</u> WGQGLVTVSS (SEQ ID NO: 40)
P12G07	ELQSVLTQPPSASGTPGQRTVITCS <u>GSSSNIGSNVYVY</u> WYQQLPGTAPKP LIY <u>MNNQRPS</u> GVPDFRSGSGTDF ASLAISGLRSEDEADYYCA <u>AAWDDS</u> <u>LSAVV</u> FGTGTCLTVL (SEQ ID NO: 41)	EVQLLESGGGLVQPGGSLRLSCAA SGFTFNNFAMSWVRQAPGKGLEW VSGISGSGDNTYYADSVKGRFTISR DNSKNTLYLQMNLSRAEDTAVYYCA <u>KDRDIGLGWYSYLDV</u> WGQGLVTV VSS (SEQ ID NO: 42)
P13F04	ELQSVLTQPPSASGTPGQRTVITCS <u>GSNSNIGTNYVSWY</u> QQLPGTAPKL LIY <u>RSSRRPS</u> GVPDFRSGSGTDF ASLAISGLRSEDEADYYCA <u>AAWDGS</u> <u>LSGHV</u> FGTGTCLTVL (SEQ ID NO: 43)	QVQLVQSGAEVKKPGSSVKVSCA SGGTFSSYAIWVRQAPGQGLEWM GEIIPIFGTASYAQKFGQRTITADES TSTAYMELSSLRSEDATVYYCARAG <u>WDDSWFDY</u> WGQGLVTVSS (SEQ ID NO: 44)
P15D02	ELDIQMTQSPSSLSASVGDRVITIC <u>RASQSIDTYLN</u> WYQQKPGKAPKLLI YSASSLHSGVPSRFRSGSGTDF LTTISSLQPEDFATYYC <u>QQSYSTTAW</u> TFGQGTKEIK (SEQ ID NO: 45)	EVQLVQSGAEVKKPGESLKI SCKGS GYSFASYWIGWVRQMPGKGLEWM GVIYPGTSETRYSPSFQGVTVISAD KSI STAYLQWSSLKASDTAMYCAK <u>GLSASASGYSFY</u> WGQGLVTVSS (SEQ ID NO: 46)
P16C05	ELDIQMTQSPSSLSASVGDRVITIC <u>RASQSIGQSLN</u> WYQQKPGKAPKLL IY <u>GASSLQS</u> GVPSRFRSGSGTDF TLTISSLQPEDFATYYC <u>QQSYSTPIT</u> FGQGTKEIK (SEQ ID NO: 47)	EVQLVQSGAEVKKPGESLKI SCKGS GYSFTDYWIGWVRQMPGKGLEWM GMI SPGGSTTIYRPSFQGVTVISADK SISTAYLQWSSLKASDTAMYCARE <u>MYTGGYGGSWYFDY</u> WGQGLVTV SS (SEQ ID NO: 48)
10A1	DIQMTQSPSTLSASVGDRVITICRA <u>SQSISTWLA</u> WYQQKPGKAPKVLIIY <u>KASSLES</u> GVPSRFRSGSGTEFTL INSLQPDDEFASYC <u>QQYKSYSHTF</u> GQGTKEIK (SEQ ID NO: 288)	QVQLQESGPGLVKPSSETLSLTCTVS <u>GGISISYYYWT</u> WIRPPGKLEWIG <u>HIYYSGSTNYN</u> PSLKSRTISIDTSK NLFSLKLSSVTAADTAVYYCARAEG <u>SIDAFDF</u> WGQGMVTVSS (SEQ ID NO: 289)
10E2	DIQMTQSPSTLSASVGDRVITICRA <u>SQSISWLA</u> WYQQKPGKAPKVLIIY <u>KASSLES</u> GVPSRFRSGSGTEFTL TINSLQPDDEFATYYC <u>QQYKSFSLTF</u> GQGTKEIK (SEQ ID NO: 290)	EVQLVESGGGLIQPGGSLRLSCAAS <u>GFTVSSNYMT</u> WVRQAPGKLEWV <u>SVIYSGGSTY</u> ADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVYYCARN <u>WGDY</u> WGQGLVTVSS (SEQ ID NO: 291)
11A1	DIQMTQSPSTLSASVGDRVITICRA <u>SQSISWLA</u> WYQQKPGKAPKVLIIY <u>KASTLES</u> GVPSRFRSGSGTEFTL TISSLQPDDEFATYYC <u>QQYNSYSYTF</u> GHGKLEIK (SEQ ID NO: 292)	QVQLQESGPGLVKPSGTLSTCTVS <u>GGSIDYF</u> FWNFRQSPVKLEWIG <u>HVYDIGNTKYN</u> PSLKSRTISIDTSE NQFSLKLNSVTAADTAVYYCARGEG <u>AIDAFDI</u> WGQGMVTVSS (SEQ ID NO: 293)
11C1	DIQMTQSPSILSASVGDRVITICRA <u>SQSVSSWLA</u> WYQQKPGKAPKVLIIY <u>KASSLES</u> GVPSRFRSGTGSFTL TISSLQSDDEFATYYC <u>QQYNTYSHTF</u> GQGTKEIK (SEQ ID NO: 294)	QVQLQESGPGLVKPSSETLSLNCTVS <u>GGISISYYYWT</u> WIRPPGKLEWIG <u>HVIYSGT</u> TNYNPSLKSRTISVDTSK NQFSLKLNSVTAADTAVYYCVRAEG <u>SIDAFDL</u> WGQGMVTVSS (SEQ ID NO: 295)

TABLE 1-continued

mAb	Light Chain	Heavy Chain
11D1	AIQMTQSPSSLSASVGDRTITCRA <u>SQGIRNDLGWYQQKPKAPKLLIY</u> <u>AASSLQSGVPSRFRSGSGSDFTL</u> TISSLQPEDFATYYC <u>LQDYNYPFTF</u> GPGTKVDIK (SEQ ID NO: 296)	QVQLVESGGGVVQPGRSLRLSCVA <u>SGFTFSDYGIHWVRQAPGMGQEW</u> VAVIWYDGSiKKYSDSVKGRFII SRD NSENTVYLQMNLSLRGEDITAIYYCAR <u>DEVGtfgAFDFW</u> GGQGTKVTVSS (SEQ ID NO: 297)
11E1	DIQMTQSPSSLSASVGDSTITCRA <u>SQDIDNYLAWYQQKTGKVPKLLIY</u> <u>AASALQSGVPSRFRSGSGSDFTL</u> TISSLQPEDVATYYC <u>QNYNSGPRTF</u> GQGTKVEIK (SEQ ID NO: 298)	QVQLQESGPGLVKPLQTLSTCTVS <u>GGSISSdgYYWSWIRQNP</u> GKGLEWI <u>GYMYSGSTYYNPSL</u> KSRVTISVDT SKNQFSLKLSVTAADTAVYYCTR <u>D</u> <u>FGWYFDLWGRGTLVTVSS</u> (SEQ ID NO: 299)
12A2	DIQMTQSPSSLSASVGDRTITCRA <u>SQDISNYLTWYQQKGRVPEVLIY</u> <u>AASALQSGVPSRFRSGSGSDFTL</u> TISSLQPEDVATYYC <u>QNYNSAPRTF</u> GQGTKVEIK (SEQ ID NO: 300)	QVQLQESGPGLVKPSQSLSTCSVS <u>GGSVSSdgYYWSWIRQHP</u> GKGLEW IGYIYYRRTIDYNPSLKS RVNISLDT KNQFSLKLSVTAADTAVYYCARD <u>F</u> <u>GWYFDLWGRGTLVAVSS</u> (SEQ ID NO: 301)
12C4	DIVMTQSPSLPVTTPGEPASISCRS <u>SQSLLSHNGYNYLDWYLQKPGQS</u> PQVLILLGSRASGVPDRVSASGS GTDFTLKISRMAEDVGIYYC <u>MOTL</u> <u>QTPFTFGQGTKLEIK</u> (SEQ ID NO: 302)	QVQLVQSGAEVKKPGASVKVSCKA <u>SGYTFGTGYLHWVRQAPGQ</u> GLEW MGWINpNSGGTNYAQK <u>FQGRVTMT</u> RDTSIITAYMELSRIRIDDTAVYYCA <u>RDRGVTmi vDGMDDW</u> GQGTTVTVS S (SEQ ID NO: 303)
12C5	DIQLTQSPSFLSASVGDRTITCRA <u>QGINSHLAWYQQKPKAPKLLIYY</u> <u>ASTLPSGVPSRFRSGSGSTEFTLT</u> VTSLQPEDFATYYC <u>QQLNHYPITFG</u> QGTRLDIN (SEQ ID NO: 304)	EVELVESGGGMVQPGRSLRLSCAA <u>SGFTFSDYGMHWVRQAPGM</u> GLEW VTVIWYDGSnKYADSVKGRFTI SR DNSKNTVFLQMNLSRAEDTAVYYC ARDEVGfvGA <u>FDIW</u> GQGMVTVSS (SEQ ID NO: 305)
12D3	DIQMTQSPSSLSASVGDRTITCRA <u>SQGISNYLAWYQQKPKVPKLLIY</u> <u>AASTLHSGVPSRFRSGSGSDFTL</u> TISSLQPEDVATYYC <u>QKYNAPRTF</u> GQGTKVEIK (SEQ ID NO: 306)	QVQLQESGPGLVKPSQTLSTCTVS <u>GGSISSdgYYWSWIRQHP</u> GKGLEWI GYMYSGITYHNP <u>SLKSRVTISVDT</u> S KNQFSLRLSSVTAADTAVYYCARD <u>F</u> <u>GWYFDLWGRGTLVTVSS</u> (SEQ ID NO: 307)
12D6	DIQMTQSPSSLSASVGDRTITCRA <u>SQDISNYLAWYQQKPKVPKLLIYA</u> <u>ASTLHSGVPSRFRSGSGSDFTLTI</u> SSLQPDFAAYYC <u>QKYNAPRTFG</u> GQGTKVEIK (SEQ ID NO: 308)	QVQLQESGPGLVKPSQTLSTCTVS <u>GGSISSdaYYWSWIRQHP</u> GKGLEWI GYMYSGITYYNP <u>SLKSRVTISVDT</u> S KNQFSLKLSVTAADTAVYYCARD <u>F</u> <u>GWYFDLWGRGTLVTVSS</u> (SEQ ID NO: 309)
12D7	DIQLTQSPSFLSASVGDRTITCRA <u>SQDISSFLAWYQQKPKAPVLLIYV</u> <u>ASTLQSGVPSRFRSGSGSTEFTLT</u> VSSLQPEDFATYYC <u>QQLHVYPITFG</u> QGTRLEIR (SEQ ID NO: 310)	QVQLVESGGGVVQPGRSLRLSCVA <u>SGFTFSDYGIHWVRQAPGM</u> GQEW VAVIWYDGSiKKYSDSVKGRFII SRD NSENTVYLQMNLSLRGEDITAIYYCAR <u>DEVGtfgAFDFW</u> GGQGTKVIVSS (SEQ ID NO: 311)
12F5	DIVMTQTPSLPVTTPGEPASISCRS <u>SQSLLDSDDGNTYLDWYLQKPGQS</u> PQLLIYTL <u>SYRASGVPDRFRSGSGS</u> GTDFTLKISRVEAEDVGVYYC <u>MORI</u> <u>EFPTFGPGTKVDIK</u> (SEQ ID NO: 312)	EVQLVESGGGLVKPGGSLRLSCAA <u>SGFTFSNAWMSWVRQAPG</u> KGLEW VGRIKsktGGTTDYAAPVKGRFTIS RDDSKNTLYLQMNLSKTEDTAVYYC TSLIVGaiSL <u>FDYWGQ</u> GLTVTVSS (SEQ ID NO: 313)
12H4	DIQMTQSPSALSASVGDRTITCRA <u>SQTISTWLAWYQQKPKAPKLLIY</u> <u>KASNLESGVPSRFRSGSGSTEFTL</u> TINSLQPDFAAYYC <u>QQYQTFSTF</u> GQGTKLEIK (SEQ ID NO: 314)	QVQLRESGPGLVKPSSETLSLTCTIS <u>GGSISSYFWTWIRQPPGR</u> GLEWIG <u>QIYYSGNTNSNP</u> SLKSRVTISIDTSK NQFSLKLSVTVADTAVYYCVRA <u>EG</u> <u>SIDAFDIW</u> GQGMVAVSS (SEQ ID NO: 315)
8C8	DMQMTQSPSSLSASVGDRTITCR <u>ASQGISNYLAWFQKPKVPKLLIY</u> <u>AASTLQSGVPSRFRSGSGSDFTL</u> TISSLQPEDVATYYC <u>QKYNAPLTF</u> GGGTKVEIK (SEQ ID NO: 316)	EVQLVESGGGLVKPGGSLRLSCVA <u>SGFTFSYSMNWVRQFP</u> GKGLEW VSSISstSSNYIHADSLQGRFTISRDN AKNSLYLQMSLSRVEDTAVYYCV <u>RD</u> <u>KGTtlt nWYFDLWGRGTLVTVSS</u> (SEQ ID NO: 317)

TABLE 1-continued

mAb	Light Chain	Heavy Chain
8F7	DIVMTQSP ^{LS} LPVTPGEPASISCRS <u>SQTLVHSNGYNYLN</u> WYLQKPGQS PQLLIY <u>LGSNRAS</u> GVDRFSGSGS GSDFTLKISRMEAEDVGVYVY <u>CMQA</u> <u>IQTPYTF</u> FGGTNVEIK (SEQ ID NO: 318)	QVQLVESGGGVVQPGRSLRLSCGA <u>SGFTFSSY</u> GMHWVRQAPGKGLEW VAVIWYDGS <u>nKY</u> YADSLKGRFTISR DNSKNTLYLQMNLSRAEDTAVYYCA <u>RDGYSgsDAFDI</u> WGQGMVTVSS (SEQ ID NO: 319)
8F8	DIQMTQSPSTLSASVGDRTITCR <u>A</u> <u>SQSISSWLA</u> WYQKPKAPKLLIY <u>KASNLES</u> GVPSRFSGSGSGTEFTL TISSLQPD ^{DF} FATYYC <u>QQYNSYSCTF</u> GQGTKLEIK (SEQ ID NO: 320)	QVQLQESGPGLVQPSETLSLTCTVS <u>GGSISSYY</u> WSWIRQPPGKLEWIG <u>NINYMNTI</u> YNPSLRSRVTISVDTSK DQFSLKLT ^{SV} SAADTAVYYCV <u>RAEG</u> <u>SIDAFDF</u> WGQGLVAVSL (SEQ ID NO: 321)
9D8	DIQMTQSPSSLSASVGDRIIFT <u>CQA</u> <u>SQDINNYL</u> H ^{WY} QKPKAPKLLIY <u>DASDWET</u> GVPSRFSGSGSGTDFT FTISLQPED ^{IA} TYYC <u>QQYDHLPI</u> TF GQGRVEIK (SEQ ID NO: 322)	QVQLVQSGAEVTKPGASVKVSCA <u>SGYIFTGYI</u> YWVRQAPGQGLEWM GWIN <u>PSSGGT</u> NYAQKFQGRVTMAR DTSISTAYMELSLRSDDTAVYYCA <u>RDRKReyyynFGMDV</u> WGQGT ^{TV} TV ST (SEQ ID NO: 323)
9E10	DIQMTQSPSSLSASVGDRIILT <u>CQA</u> <u>SQDISNYL</u> H ^{WY} QKPKAPKLLIYD <u>ASDLET</u> GVPSRFSGSGSGADFTFTI SNLQPED ^{FA} TYYC <u>QQYDHLPI</u> TFG QGRLEIK (SEQ ID NO: 324)	QVQLVQSGAEVTKPGASVKVSCA <u>SGYFTFSHYI</u> YWVRQAPGQGLEWM GWIN <u>PNSGGT</u> NYAQKFQDRVTMAR DTSISTAYMELSLRSDDTAVYYCA <u>KDRKReyyynFGMDV</u> WGQGT ^{TV} TV SA (SEQ ID NO: 325)
9E5	DIQMTQSPSSLSASVGDRIILT <u>CQA</u> <u>SQDISNYL</u> H ^{WY} QKPKAPKLLIYD <u>ASDLET</u> GVPSRFSGSGSGADFTFTI SNLQPED ^{FA} TYYC <u>QQYDHLPI</u> TFG QGRLEIK (SEQ ID NO: 326)	QVQLVQFGVEVRKPGASVKVSCV <u>SGFTFTSHYI</u> YWVRQAPGQGLEWM GWIN <u>PNSGGT</u> KYAQKFQDRVTMAR DTSISTAYMELSLRSDDTSVYYCV <u>KDRKReyyynFGMDV</u> WGQGT ^{TV} TV SS (SEQ ID NO: 327)
9F4	DIQMTQSPSSLSASVGDRTIT <u>CQA</u> <u>SQDISNYLN</u> WYQKPKAPKLLIYD <u>ASNLET</u> GVPSRFSGSGSGTDFTFTI SSLQPED ^{IA} TYYC <u>QQYDNLPI</u> TFG GQTKLEIK (SEQ ID NO: 328)	EVQMLESGGLIQPGLSLRLSCKTS <u>GFTLSIYAI</u> H ^{WVR} QAPGRGLEWVSS <u>FGgRGSSTY</u> FADSVKGRFTISR DAS ENSLYLHMNSLRAEDTAVYYCA <u>KAKEK</u> <u>DWgRGFDY</u> WGQGLVTVSS (SEQ ID NO: 329)
9F8	DIVMTQSP ^{LS} LPVTPGEPASISCRS <u>SQSLLYSNGYNYLD</u> WYLQKPGQS PQLLI <u>FLNSNRAS</u> GVDRFSGSGS GTDFTLKISRVEAEDVGVYVY <u>CMQA</u> <u>LQTPLTF</u> GGGKVEIK (SEQ ID NO: 330)	EVQLVESGGGLVKPGGSLRLSCAA <u>SGFTFSNY</u> SMNWRQAPGKGLEW VSSIS <u>sSTIYI</u> YADSVKGRFTISRDN AKKSLYLQMNLSRAEDTAVYYCARD <u>IGWevftLGF</u> DYWGQGTQVTVSS (SEQ ID NO: 331)

Also provided herein are CDR portions of antigen binding domains of antibodies to CD70 (including Chothia, Kabat CDRs, and CDR contact regions). Determination of CDR regions is well within the skill of the art. It is understood that in some embodiments, CDRs can be a combination of the Kabat and Chothia CDR (also termed “combined CRs” or

“extended CDRs”). In some embodiments, the CDRs are the Kabat CDRs. In other embodiments, the CDRs are the Chothia CDRs. In other words, in embodiments with more than one CDR, the CDRs may be any of Kabat, Chothia, combination CDRs, or combinations thereof. Table 2 provides examples of CDR sequences provided herein.

TABLE 2

Heavy Chain			
mAb	CDRH1	CDRH2	CDRH3
31H1	SYGFS (SEQ ID NO: 49) (Kabat); GGTFSSY (SEQ ID NO: 50) (Chothia); GGTFSSYGFS (SEQ ID NO: 51) (Extended)	GIPIFIGSANYAQK FQG (SEQ ID NO: 52) (Kabat); IPIFGS (SEQ ID NO: 53) (Chothia)	GGSSSPFAY (SEQ ID NO: 54)

TABLE 2-continued

63B2	SYGFS (SEQ ID NO: 55) (Kabat); GGTFSSY (SEQ ID NO: 56) (Chothia) GGTFSSYGFS (Extended) (SEQ ID NO: 57)	GIIPIFGTANYAQK FQG (SEQ ID NO: 58) (Kabat); IPIFGT (SEQ ID NO: 59) (Chothia)	GGSSSPFAY (SEQ ID NO: 60)
40E3	SYIWN (SEQ ID NO: 61) (Kabat); GGSISSY (SEQ ID NO: 62) (Chothia); GGSISSYWN (SEQ ID NO: 63) (Extended)	YIYSGSTNYNPS LKS (SEQ ID NO: 64) (Kabat); YYSGS (SEQ ID NO: 65) (Chothia)	DIRTW (SEQ ID NO: 66)
42C3	NSVVMS (SEQ ID NO: 67) (Kabat); GFTFRNS (SEQ ID NO: 68) (Chothia); GFTFRNSWMS (SEQ ID NO: 69) (Extended)	NIKRDGSEKYYV DSVKG (SEQ ID NO: 70) (Kabat); KRDGSE (SEQ ID NO: 71) (Chothia)	DQTGSEFDY (SEQ ID NO: 72)
45F11	VYYWS (SEQ ID NO: 73) (Kabat); DDISVY (SEQ ID NO: 74) (Chothia); DDISVYYWS (SEQ ID NO: 75) (Extended)	VYSSGNINYNPSL ES (SEQ ID NO: 76) (Kabat); YSSGN (SEQ ID NO: 77) (Chothia)	GLDAFDI (SEQ ID NO: 78)
64F9	SYAMS (SEQ ID NO: 79) (Kabat); GFTFTSY (SEQ ID NO: 80) (Chothia); GFTFTSYAMS (SEQ ID NO: 81) (Extended)	RVYSSGNINYNP SLES (SEQ ID NO: 82) (Kabat); YSSGN (SEQ ID NO: 83) (Chothia)	GLDAFDI (SEQ ID NO: 84)
72C2	TYAIS (SEQ ID NO: 85) (Kabat); GGTFITY (SEQ ID NO: 86) (Chothia); GGTFITYAIS (SEQ ID NO: 87) (Extended)	GIIPFFGTANYAQ KFQG (SEQ ID NO: 88) (Kabat); IPFFGT (SEQ NO: 89) (Chothia)	WELFFDF (SEQ ID NO: 90) ID
2F10	YYSMN (SEQ ID NO: 91) (Kabat); GFTFTYY (SEQ ID NO: 92) (Chothia); GFTFTYYSMN (SEQ ID NO: 93) (Extended)	HISIRSSSTIYFADS AKG (SEQ ID NO: 94) (Kabat); SIRSSST (SEQ ID NO: 95) (Chothia)	GSGWYGDYFDY (SEQ ID NO: 96)
4F11	NARMGVT (SEQ ID NO: 97) (Kabat); GFSLSNARM (SEQ ID NO: 98) (Chothia); GFSLSNARMGVT (SEQ ID NO: 99) (Extended)	HIFSNDEKSYSTS LKS (SEQ ID NO: 100) (Kabat); FSNDE (SEQ ID NO: 101) (Chothia)	IRDYDIDISSYDY (SEQ ID NO: 102)
10H10	NHNIH (SEQ ID NO: 103) (Kabat); GFTFSNH (SEQ ID NO: 104) (Chothia); GFTFSNHNIH (SEQ ID NO: 105) (Extended)	YISRSSSTIYYAD SVKG (SEQ ID NO: 106) (Kabat); SRSSST (SEQ ID NO: 107) (Chothia)	DHAQWYGMVDV (SEQ ID NO: 108)
17G6	SYWMS (SEQ ID NO: 109) (Kabat); GFTFSSY (SEQ ID NO: 110) (Chothia); GFTFSSYWMS (SEQ ID NO: 111) (Extended)	SIKQDGSEKYYV DSVKG (SEQ ID NO: 112) (Kabat); KQDGSE (SEQ ID NO: 113) (Chothia)	EGVNWGWRLYW HFDL (SEQ ID NO: 114)
65E11	YSMN (SEQ ID NO: 115) (Kabat); GFTFSSY (SEQ ID NO: 116) (Chothia); GFTFSSYSMN (SEQ ID NO: 117) (Extended)	HSSISRGNIYFAD SVKG (SEQ ID NO: 118) (Kabat); SISRGN (SEQ ID NO: 119) (Chothia)	GSGWYGDYFDY (SEQ ID NO: 120)

TABLE 2-continued

P02B10	NYAMS (SEQ ID NO: 121) (Kabat); GFAPSNY (SEQ ID NO: 122) (Chothia); GFAPSNYAMS (SEQ ID NO: 123) (Extended)	AIRGGGGSTYYA DSVKG (SEQ ID NO: 124) (Kabat); RGGGGS (SEQ ID NO: 125) (Chothia)	DFISGTWYPDY (SEQ ID NO: 126)
P07D03	SYWIG (SEQ ID NO: 127) (Kabat); GYRFTSY (SEQ ID NO: 128) (Chothia); GYRFTSYWIG (SEQ ID NO: 129) (Extended)	SIYPDDSDTRYSP SFQG (SEQ ID NO: 130) (Kabat); YPDDSD (SEQ ID NO: 131) (Chothia)	STVDYPGYSYFD Y (SEQ ID NO: 132)
P08A02	NYWIA (SEQ ID NO: 133) (Kabat); GYTFTNY (SEQ ID NO: 134) (Chothia); GYTFTNYWIA (SEQ ID NO: 135) (Extended)	IIYPDGS DTRYSP SFQG (SEQ ID NO: 136) (Kabat); YPDGS D (SEQ ID NO: 137) (Chothia)	DITSWYYGEPAF DI (SEQ ID NO: 138)
P08E02	SSWIG (SEQ ID NO: 139) (Kabat); GYSFTSS (SEQ ID NO: 140) (Chothia); GYSFTSSWIG (SEQ ID NO: 141) (Extended)	IIYPGDS DTRYSP SFQG (SEQ ID NO: 142) (Kabat); YPGDS D (SEQ ID NO: 143) (Chothia)	GLSQAMTGFGFD Y (SEQ ID NO: 144)
P08F08	SYWIG (SEQ ID NO: 145) (Kabat); GYGFTSY (SEQ ID NO: 146) (Chothia); GYGFTSYWIG (SEQ ID NO: 147) (Extended)	IIHPDSDTKYSP SFQG (SEQ ID NO: 148) (Kabat); HPDSD (SEQ ID NO: 149) (Chothia)	SYLRGLWGGYF DY (SEQ ID NO: 150)
P08G02	SSWIG (SEQ ID NO: 151) (Kabat); GYTFPSS (SEQ ID NO: 152) (Chothia); GYTFPSSWIG (SEQ ID NO: 153) (Extended)	IIYPTSHTRYSP SFQ (SEQ ID NO: 154) (Kabat); YPTSH (SEQ ID NO: 155) (Chothia)	ASYFDRGTGYSS WMDV (SEQ ID NO: 156)
P12809	QYSMS (SEQ ID NO: 157) (Kabat); GFTFSQY (SEQ ID NO: 158) (Chothia); GFTFSQYSMS (SEQ ID NO: 159) (Extended)	AISGGGVSTYYA DSVKG (SEQ ID NO: 160) (Kabat); SGGGVS (SEQ ID NO: 161) (Chothia)	DISDSGGSHWYF DY (SEQ ID NO: 162)
P12F02	SYAMS (SEQ ID NO: 163) (Kabat); GFTFSSY (SEQ ID NO: 164) (Chothia); GFTFSSYAMS (SEQ ID NO: 165) (Extended)	TISGTGGTTYAD SVKG (SEQ ID NO: 166) (Kabat); SGTGGT (SEQ ID NO: 167) (Chothia)	VRAGIDPTASDV (SEQ ID NO: 168)
P12G07	NFAMS (SEQ ID NO: 169) (Kabat); GFTFNNF (SEQ ID NO: 170) (Chothia); GFTFNNFAMS (SEQ ID NO: 171) (Extended)	GISGSGDNTYYA DSVKG (SEQ ID NO: 172) (Kabat); SGSGDN (SEQ ID NO: 173) (Chothia)	DRDIGLGWYSYY LDV (SEQ ID NO: 174)
P13F04	SYAIS (SEQ ID NO: 175) (Kabat); GGTFSSY (SEQ ID NO: 176) (Chothia); GGTFSSYAIS (SEQ ID NO: 177) (Extended)	EIIPFGTASYAQK FQG (SEQ ID NO: 178) (Kabat); IPIFGT (SEQ ID NO: 179) (Chothia)	AGWDDSWFDY (SEQ ID NO: 180)
P15D02	SYWIG (SEQ ID NO: 181) (Kabat); GYSFASY (SEQ ID NO: 182) (Chothia); GYSFASYWIG (SEQ ID NO: 183) (Extended)	VIYPGTSETRYSP SFQG (SEQ ID NO: 184) (Kabat); YPGTSE (SEQ ID NO: 185) (Chothia)	GLSASASGYSFQ Y (SEQ ID NO: 186)

TABLE 2-continued

P16C05	DYWIG (SEQ ID NO: 187) (Kabat); GYSFTDY (SEQ ID NO: 188) (Chothia); GYSFTDYWIG (SEQ ID NO: 189) (Extended)	MISPPGGSTTIYRP SFQG (SEQ ID NO: 190) (Kabat); SPGGST (SEQ ID NO: 191) (Chothia)	MYTGGYGGSWY FDY (SEQ ID NO: 192)
10A1	YYYWT (SEQ ID NO: 332) (Kabat); GGISISYY (SEQ ID NO: 333) (Chothia); GGISISYYWT (SEQ ID NO: 334) (Extended)	HIYYSGSTNYNPS LKS (SEQ ID NO: 335) (Kabat); YYSGS (SEQ ID NO: 336) (Chothia)	AEGSIDAFDF (SEQ ID NO: 337)
10E2	SNYMT (SEQ ID NO: 338) (Kabat); GFTVSSN (SEQ ID NO: 339) (Chothia); GFTVSSNYMT (SEQ ID NO: 340) (Extended)	VIYSGGSTYYADS VKG (SEQ ID NO: 341) (Kabat); YSGGS (SEQ ID NO: 342) (Chothia)	NWGDYW (SEQ ID NO: 343)
11A1	YYFVN (SEQ ID NO: 344) (Kabat); GGSIDYY (SEQ ID NO: 345) (Chothia); GGSIDYYFVN (SEQ ID NO: 346) (Extended)	HVYDIGNTKYNP SLKS (SEQ ID NO: 347) (Kabat); YDIGN (SEQ ID NO: 348) (Chothia)	GEGAIDAFDI (SEQ ID NO: 349)
11C1	YYYWT (SEQ ID NO: 350) (Kabat); GGISISYY (SEQ ID NO: 351) (Chothia); GGISISYYWT (SEQ ID NO: 352) (Extended)	HVIYSGTTNYNPS LKS (SEQ ID NO: 353) (Kabat); IYSGT (SEQ ID NO: 354) (Chothia)	AEGSIDAFDL (SEQ ID NO: 355)
11D1	DYGIH (SEQ ID NO: 356) (Kabat); GFTFSDY (SEQ ID NO: 357) (Chothia); GFTFSDYGIH (SEQ ID NO: 358) (Extended)	VIWYDGSiKKYSD SVKG (SEQ ID NO: 359) (Kabat); WYDGSi (SEQ ID NO: 360) (Chothia)	DEVGtfgAFDF (SEQ ID NO: 361)
11E1	SdgYYWS (SEQ ID NO: 362) (Kabat); GGSISSdgY (SEQ ID NO: 363) (Chothia); GGSISSdgYYWS (SEQ ID NO: 364) (Extended)	YMYYSGSTYYNP SLKS (SEQ ID NO: 365) (Kabat); YYSGS (SEQ ID NO: 366) (Chothia)	DFGWYFDL (SEQ ID NO: 367)
12A2	SdgYYWS (SEQ ID NO: 368) (Kabat); GGSVSSdgY (SEQ ID NO: 369) (Chothia); GGSVSSdgYYWS (SEQ ID NO: 370) (Extended)	YIYRRITDYNPS LKS (SEQ ID NO: 371) (Kabat); YRRI (SEQ ID NO: 372) (Chothia)	DFGWYFDL (SEQ ID NO: 373)
12C4	GYYLH (SEQ ID NO: 374) (Kabat); GYTFTGY (SEQ ID NO: 375) (Chothia); GYTFTGYLH (SEQ ID NO: 376) (Extended)	WINpNSGGTNYA QKFQG (SEQ ID NO: 377) (Kabat); NpNSGG (SEQ ID NO: 378) (Chothia)	DRGVtmivDGMD D (SEQ ID NO: 379)
12C5	DYGMH (SEQ ID NO: 380) (Kabat); GFTFSDY (SEQ ID NO: 381) (Chothia); GFTFSDYGMH (SEQ ID NO: 382) (Extended)	VIWYDGSnKYYA DSVKG (SEQ ID NO: 383) (Kabat); WYDGSn (SEQ ID NO: 384) (Chothia)	DEVGfvGAFDI (SEQ ID NO: 385)
12D3	SdgYYWS (SEQ ID NO: 386) (Kabat); GGSISSdgY (SEQ ID NO: 387) (Chothia); GGSISSdgYYWS (SEQ ID NO: 388) (Extended)	YMYYSGITYHNP SLKS (SEQ ID NO: 389) (Kabat); YYSGI (SEQ ID NO: 390) (Chothia)	DFGWYFDL (SEQ ID NO: 391)

TABLE 2-continued

12D6	SdaYYWS (SEQ ID NO: 392) (Kabat); GGSISSdaY (SEQ ID NO: 393) (Chothia); GGSISSdaYYWS (SEQ ID NO: 394) (Extended)	YMYYSGITYYNP SLKS (SEQ ID NO: 395) (Kabat); YYSGI (SEQ ID NO: 396) (Chothia)	DFGWYFDL (SEQ ID NO: 397)
12D7	DYGIH (SEQ ID NO: 398) (Kabat); GFTFSDY (SEQ ID NO: 399) (Chothia); GFTFSDYGIH (SEQ ID NO: 400) (Extended)	VIWYDGSIKKYS SVKG (SEQ ID NO: 401) (Kabat); WYDGSi (SEQ ID NO: 402) (Chothia)	DEVGtfgAFDF (SEQ ID NO: 403)
12F5	NAWMS (SEQ ID NO: 404) (Kabat); GFTFSNA (SEQ ID NO: 405) (Chothia); GFTFSNAWMS (SEQ ID NO: 406) (Extended)	RIKsktGGGTTDY AAPVKG (SEQ ID NO: 407) (Kabat); KsktGGGT (SEQ ID NO: 408) (Chothia)	LIVGaisLFDY (SEQ ID NO: 409)
12H4	YYFWT (SEQ ID NO: 410) (Kabat); GGSISYY (SEQ ID NO: 411) (Chothia); GGSISYYFWT (SEQ ID NO: 412) (Extended)	QIYYSGNTNSNP SLKS (SEQ ID NO: 413) (Kabat); YYSGN (SEQ ID NO: 414) (Chothia)	AEGSIDAFDI (SEQ ID NO: 415)
8C8	SYSMN (SEQ ID NO: 416) (Kabat); GFTFSSY (SEQ ID NO: 417) (Chothia); GFTFSSYSMN (SEQ ID NO: 418) (Extended)	SISTSSNYIHYADS LQG (SEQ ID NO: 419) (Kabat); StSSNY (SEQ ID NO: 420) (Chothia)	DKGTtltNwYFDL (SEQ ID NO: 421)
8F7	SYGMH (SEQ ID NO: 422) (Kabat); GFTFSSY (SEQ ID NO: 423) (Chothia); GFTFSSYGMH (SEQ ID NO: 424) (Extended)	VIWYDGSnKYA DSLKG (SEQ ID NO: 425) (Kabat); WYDGSn (SEQ ID NO: 426) (Chothia)	DGYSgssDAFDI (SEQ ID NO: 427)
8F8	YYYWS (SEQ ID NO: 428) (Kabat); GGSISYY (SEQ ID NO: 429) (Chothia); GGSISYYYWS (SEQ ID NO: 430) (Extended)	NINYMGNTIYNPS LKS (SEQ ID NO: 431) (Kabat); NYMGN (SEQ ID NO: 432) (Chothia)	AEGSIDAFDF (SEQ ID NO: 433)
9D8	GYIYI (SEQ ID NO: 434) (Kabat); GYIFTGY (SEQ ID NO: 435) (Chothia); GYIFTGYIYI (SEQ ID NO: 436) (Extended)	WINpSSGGTNYA QKFQ (SEQ ID NO: 437) (Kabat); NpSSGG (SEQ ID NO: 438) (Chothia)	DRKReyyynFGMD V (SEQ ID NO: 439)
9E10	SHYIY (SEQ ID NO: 440) (Kabat); GYTFTSH (SEQ ID NO: 441) (Chothia); GYTFTSHYIY (SEQ ID NO: 442) (Extended)	WINpNSGGTNYA QKFQD (SEQ ID NO: 443) (Kabat); NpNSGG (SEQ ID NO: 444) (Chothia)	DRKReyyynFGMD V (SEQ ID NO: 4454)
9E5	SHYIY (SEQ ID NO: 446) (Kabat); GFTFTSH (SEQ ID NO: 447) (Chothia); GFTFTSHYIY (SEQ ID NO: 448) (Extended)	WINpNSGGTKYA QKFQD (SEQ ID NO: 449) (Kabat); NpNSGG (SEQ ID NO: 450) (Chothia)	DRKReyyynFGMD V (SEQ ID NO: 451)
9F4	IYAIH (SEQ ID NO: 452) (Kabat); GFTLSIY (SEQ ID NO: 453) (Chothia); GFTLSIYAIH (SEQ ID NO: 454) (Extended)	SFGgRGSSTYFA DSVKG (SEQ ID NO: 455) (Kabat); GgRGSS (SEQ ID NO: 456) (Chothia)	EKDWgRGFDY (SEQ ID NO: 457)

TABLE 2-continued

mAb	CDRL1	CDRL2	CDRL3
9F8	NYSMN (SEQ ID NO: 458) (Kabat); GFTFSNY (SEQ ID NO: 459) (Chothia); GFTFSNYSMN (SEQ ID NO: 460) (Extended)	SISsSTIYIYADS VKG (SEQ ID NO: 461) (Kabat); SsSTIY (SEQ ID NO: 462) (Chothia)	DIGWvftLGFDY (SEQ ID NO: 463)
Light Chain			
31H1	RSSQSLVHSDGNTYLS (SEQ ID NO: 193);	KISNRFS (SEQ ID NO: 194)	MQATQFPLT (SEQ ID NO: 195)
63B2	RSSQSLVHSDGNTYLS (SEQ ID NO: 196);	KISNRFS (SEQ ID NO: 197)	MQATQFPLT (SEQ ID NO: 198)
40E3	RASQGISNYLA (SEQ ID NO: 199);	AASSLQS (SEQ ID NO: 200)	QQYNSYPLT (SEQ ID NO: 201)
42C3	RSSQSLVYSDENTYLN (SEQ ID NO: 202);	QVSNRDS (SEQ ID NO: 203)	MQGTYWPPT (SEQ ID NO: 204)
45F11	RASQSVSSSLA (SEQ ID NO: 205);	GASTRAT (SEQ ID NO: 206)	QQYINWPH (SEQ ID NO: 207)
64F9	QASQDISNYLN (SEQ ID NO: 208);	GASNLET (SEQ ID NO: 209)	QQYDNFPIT (SEQ ID NO: 210)
72C2	RASQSVSSNLA (SEQ ID NO: 211);	SASTRAS (SEQ ID NO: 212)	QQYDNWPPLT (SEQ ID NO: 213)
2F10	RASQSVSSSYLA (SEQ ID NO: 214);	GASSRAT (SEQ ID NO: 215)	QQYGSSPLT (SEQ ID NO: 216)
4F11	RASQDISNYLA (SEQ ID NO: 217);	AASSLQS (SEQ ID NO: 218)	LQLNSFPFT (SEQ ID NO: 219)
10H10	RASQGISSWLA (SEQ ID NO: 220);	AASSLQS (SEQ ID NO: 221)	QQAFSFPFT (SEQ ID NO: 222)
17G6	KSSQSVLYSYNNKNYV A (SEQ ID NO: 223);	WASTRES (SEQ ID NO: 224)	QQYYSTLT (SEQ ID NO: 225)
65E11	RASQSVSSSYLA (SEQ ID NO: 226);	DASSRAT (SEQ ID NO: 227)	QQYGSSPLT (SEQ ID NO: 228)
P02B10	SGSSSNIGSNYVY (SEQ ID NO: 229);	RNNQRPS (SEQ ID NO: 230)	AAWDDSLSGVV (SEQ ID NO: 231)
P07D03	SGSRSNIGSNYVY (SEQ ID NO: 232);	RNNQRPS (SEQ ID NO: 233)	ASWDGSLSAVV (SEQ ID NO: 234)
P08A02	SGSSSNIGSNYVY (SEQ ID NO: 235);	RNNQRPS (SEQ ID NO: 236)	ATWDDSLGSPV (SEQ ID NO: 237)
P08E02	RASQISRYLN (SEQ ID NO: 238);	AASILQT (SEQ ID NO: 239)	QQSYSTMWT (SEQ ID NO: 240)
P08F08	SGSSSNIGSNYVN (SEQ ID NO: 241);	GDYQRPS (SEQ ID NO: 242)	ATRDDSLSGSVV (SEQ ID NO: 243)
P08G02	RASQSIYDYLH (SEQ ID NO: 244);	DASNLQS (SEQ ID NO: 245)	QQSYTTPPLT (SEQ ID NO: 246)
P12809	RASQYIGRYLN (SEQ ID NO: 247);	GATSLAS (SEQ ID NO: 248)	QQSYTTSPT (SEQ ID NO: 249)
P12F02	SGSTSNIGRNYVY (SEQ ID NO: 250);	RTNQRPS (SEQ ID NO: 251)	AAWDDSLSGRV (SEQ ID NO: 252)
P12G07	SGSSSNIGSNYVY (SEQ ID NO: 253);	MNNQRPS (SEQ ID NO: 254)	AAWDDSLSAVV (SEQ ID NO: 255)
P13F04	SGSNSNIGTNYVS (SEQ ID NO: 256);	RSSRRPS (SEQ ID NO: 257)	AAWDGSLSGHW V (SEQ ID NO: 258)

TABLE 2-continued

P15D02	RASQSIDTYLN (SEQ ID NO: 259);	SASSLHS (SEQ ID NO: 260)	QQSYSTTAWT (SEQ ID NO: 261)
P16C05	RASQSIGQSLN (SEQ ID NO: 262);	GASSLQS (SEQ ID NO: 263)	QQSYSTPIT (SEQ ID NO: 264)
10A1	RASQSISTWLA (SEQ ID NO: 464);	KASSLES (SEQ ID NO: 465)	QQYKSYSHT (SEQ ID NO: 466)
10E2	RASQISSWLA (SEQ ID NO: 467);	KASSLES (SEQ ID NO: 468)	QQYKSFSLT (SEQ ID NO: 469)
11A1	RASQISSWLA (SEQ ID NO: 470);	KASTLES (SEQ ID NO: 471)	QQYNSYSYT (SEQ ID NO: 472)
11C1	RASQSVSSWLA (SEQ ID NO: 473);	KASSLES (SEQ ID NO: 474)	QQYNTYSHT (SEQ ID NO: 475)
11D1	RASQGIRNDLG (SEQ ID NO: 476);	AASSLQS (SEQ ID NO: 477)	LQDYNYPFT (SEQ ID NO: 478)
11E1	RASQDIDNYLA (SEQ ID NO: 479);	AASALQS (SEQ ID NO: 480)	QNYNSGPRT (SEQ ID NO: 481)
12A2	RASQDISNYLT (SEQ ID NO: 482);	AASALQS (SEQ ID NO: 483)	QNYNSAPRT (SEQ ID NO: 484)
12C4	RSSQSLLSNGYNYLD (SEQ ID NO: 485);	LGSNRAS (SEQ ID NO: 486)	MQTLQTPFT (SEQ ID NO: 487)
12C5	RASQGINSHLA (SEQ ID NO: 488);	YASTLPS (SEQ ID NO: 489)	QQLNHYPIT (SEQ ID NO: 490)
12D3	RASQGISNYLA (SEQ ID NO: 491);	AASTLHS (SEQ ID NO: 492)	QKYNAPRT (SEQ ID NO: 493)
12D6	RASQDISNYLA (SEQ ID NO: 494);	AASTLHS (SEQ ID NO: 495)	QKYNAPRT (SEQ ID NO: 496)
12D7	RASQDISSFLA (SEQ ID NO: 497);	VASTLQS (SEQ ID NO: 498)	QQLHVYPIT (SEQ ID NO: 499)
12F5	RSSQSLLDSDDGNTYLD (SEQ ID NO: 500);	TLSYRAS (SEQ ID NO: 501)	MQRIEFPFT (SEQ ID NO: 502)
12H4	RASQTISTWLA (SEQ ID NO: 503);	KASNLES (SEQ ID NO: 504)	QQYQTFSHS (SEQ ID NO: 505)
8C8	RASQGISNYLA (SEQ ID NO: 506);	AASTLQS (SEQ ID NO: 507)	QKYNAPLPT (SEQ ID NO: 508)
8F7	RSSQTLVHSNGYNYLN (SEQ ID NO: 509);	LGSNRAS (SEQ ID NO: 510)	MQAIQTPYT (SEQ ID NO: 511)
8F8	RASQISSWLA (SEQ ID NO: 512);	KASNLES (SEQ ID NO: 513)	QQYNSYSCT (SEQ ID NO: 514)
9D8	QASQDINNYLH (SEQ ID NO: 515);	DASDWET (SEQ ID NO: 516)	QQYDHLPT (SEQ ID NO: 517)
9E10	QASQDISNYLH (SEQ ID NO: 518);	DASDLET (SEQ ID NO: 519)	QQYDHLPT (SEQ ID NO: 520)
9E5	QASQDISNYLH (SEQ ID NO: 521);	DASDLET (SEQ ID NO: 522)	QQYDHLPT (SEQ ID NO: 523)
9F4	QASQDISNYLN (SEQ ID NO: 524);	DASNLET (SEQ ID NO: 525)	QQYDNLPT (SEQ ID NO: 526)
9F8	RSSQSLLYSNGYNYLD (SEQ ID NO: 527);	LNSNRAS (SEQ ID NO: 528)	MQALQTPLT (SEQ ID NO: 529)

In some embodiments, the present invention provides an antibody that binds to CD70 and competes with the antibody as described herein, including 31H1, 6362, 40E3, 42C3, 45F11, 64F9, 72C2, 2F10, 4F11, 10H10, 17G6, 65E11, P02B10, P07D03, P08A02, P08E02, P08F08, P08G02, P12B09, P12F02, P12G07, P13F04, P15D02, P16C05, 10A1, 10E2, 11A1, 11C1, 11D1, 11E1, 12A2, 12C4, 12C5, 12D3, 12D6, 12D7, 12F5, 12H4, 8C8, 8F7, 8F8, 9D8, 9E10, 9E5, 9F4 or 9F8.

In some embodiments, the invention also provides CDR portions of antibodies to CD70 antibodies based on CDR contact regions. CDR contact regions are regions of an antibody that imbue specificity to the antibody for an antigen. In general, CDR contact regions include the residue positions in the CDRs and Vernier zones which are constrained in order to maintain proper loop structure for the antibody to bind a specific antigen. See, e.g., Makabe et al., J. Biol. Chem., 283:1156-1166, 2007. Determination of CDR contact regions is well within the skill of the art.

The binding affinity (K_D) of the CD70 antibody as described herein to CD70 (such as human CD70 (e.g., (SEQ ID NO: 278)) can be about 0.001 to about 5000 nM. In some embodiments, the binding affinity is about any of 5000 nM, 4500 nM, 4000 nM, 3500 nM, 3000 nM, 2500 nM, 2000 nM, 1789 nM, 1583 nM, 1540 nM, 1500 nM, 1490 nM, 1064 nM, 1000 nM, 933 nM, 894 nM, 750 nM, 705 nM, 678 nM, 532 nM, 500 nM, 494 nM, 400 nM, 349 nM, 340 nM, 353 nM, 300 nM, 250 nM, 244 nM, 231 nM, 225 nM, 207 nM, 200 nM, 186 nM, 172 nM, 136 nM, 113 nM, 104 nM, 101 nM, 100 nM, 90 nM, 83 nM, 79 nM, 74 nM, 54 nM, 50 nM, 45 nM, 42 nM, 40 nM, 35 nM, 32 nM, 30 nM, 25 nM, 24 nM, 22 nM, 20 nM, 19 nM, 18 nM, 17 nM, 16 nM, 15 nM, 12 nM, 10 nM, 9 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5.5 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.3 nM, 0.1 nM, 0.01 nM, or 0.001 nM. In some embodiments, the binding affinity is less than about any of 5000 nM, 4000 nM, 3000 nM, 2000 nM, 1000 nM, 900 nM, 800 nM, 250 nM, 200 nM, 100 nM, 50 nM, 30 nM, 20 nM, 10 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5 nM, 4.5 nM, 4 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.5 nM, 1 nM, or 0.5 nM.

Bispecific antibodies, monoclonal antibodies that have binding specificities for at least two different antigens, can be prepared using the antibodies disclosed herein. Methods for making bispecific antibodies are known in the art (see, e.g., Suresh et al., Methods in Enzymology 121:210, 1986). Traditionally, the recombinant production of bispecific antibodies was based on the coexpression of two immunoglobulin heavy chain-light chain pairs, with the two heavy chains having different specificities (Millstein and Cuello, Nature 305, 537-539, 1983). Accordingly, in one aspect, provided is a bispecific antibody wherein the bispecific antibody is a full-length human antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen (e.g., CD70), and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell.

The human immune effector cell can be any of a variety of immune effector cells known in the art. For example, the immune effector cell can be a member of the human lymphoid cell lineage, including, but not limited to, a T cell (e.g., a cytotoxic T cell), a B cell, and a natural killer (NK) cell. The immune effector cell can also be, for example without limitation, a member of the human myeloid lineage, including, but not limited to, a monocyte, a neutrophilic granulocyte, and a dendritic cell. Such immune effector cells may

have either a cytotoxic or an apoptotic effect on a target cell or other desired effect upon activation by binding of an effector antigen.

The effector antigen is an antigen (e.g., a protein or a polypeptide) that is expressed on the human immune effector cell. Examples of effector antigens that can be bound by the heterodimeric protein (e.g., a heterodimeric antibody or a bispecific antibody) include, but are not limited to, human CD3 (or CD3 (Cluster of Differentiation) complex), CD16, NKG2D, NKp46, CD2, CD28, CD25, CD64, and CD89.

The target cell can be a cell that is native or foreign to humans. In a native target cell, the cell may have been transformed to be a malignant cell or pathologically modified (e.g., a native target cell infected with a virus, a *plasmodium*, or a bacterium). In a foreign target cell, the cell is an invading pathogen, such as a bacterium, a *plasmodium*, or a virus.

The target antigen is expressed on a target cell in a diseased condition (e.g., an inflammatory disease, a proliferative disease (e.g., cancer), an immunological disorder, a neurological disease, a neurodegenerative disease, an autoimmune disease, an infectious disease (e.g., a viral infection or a parasitic infection), an allergic reaction, a graft-versus-host disease or a host-versus-graft disease). A target antigen is not effector antigen. In some embodiments, the target antigen is CD70.

In some embodiments, provided is a bispecific antibody, wherein the bispecific antibody is a full-length antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen, and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329 or 331; or a light chain variable (VL) region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328 or 330.

In some embodiments, provided is a bispecific antibody, wherein the bispecific antibody is a full-length antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen, and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 87, 91, 92, 93, 97, 98, 99, 103, 104, 105, 109, 110, 111, 115, 116, 117, 121, 122, 123, 127, 128, 129, 133, 134, 135, 139, 140, 141, 145, 146, 147, 151, 152, 153, 157, 158, 159, 163, 164, 165, 169, 170, 171, 175, 176, 177, 181, 182, 183, 187, 188, 189, 332, 333, 334, 338, 339, 340, 344, 345, 346, 350, 351, 352, 356, 357, 358, 362, 363, 364, 368, 369, 370, 374, 375, 376, 380, 381, 382, 386, 387, 388, 392, 393, 394, 398, 399, 400, 404, 405, 406, 410, 411, 412, 416, 437, 418, 422, 423, 424,

41

428, 429, 430, 434, 435, 436, 440, 441, 442, 446, 447, 448, 452, 453, 454, 458, 459 or 460; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 52, 53, 58, 59, 64, 65, 70, 71, 76, 77, 82, 83, 88, 89, 94, 95, 100, 101, 106, 107, 112, 113, 118, 119, 124, 125, 130, 131, 136, 137, 142, 143, 148, 149, 154, 155, 160, 161, 166, 167, 172, 173, 178, 179, 184, 185, 190, 191, 335, 336, 341, 342, 347, 348, 353, 354, 359, 360, 365, 366, 371, 372, 377, 378, 383, 384, 389, 390, 395, 396, 401, 402, 407, 408, 413, 414, 419, 420, 425, 426, 431, 432, 437, 438, 443, 444, 449, 450, 455, 456, 461 or 462; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150, 156, 162, 168, 174, 180, 186, 192, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 or 463; or a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 464, 467, 470, 473, 476, 479, 482, 485, 488, 491, 494, 497, 500, 503, 506, 509, 512, 515, 518, 521, 524 or 527; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 194, 197, 200, 203, 206, 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 465, 468, 471, 474, 477, 480, 483, 486, 489, 492, 495, 498, 501, 504, 507, 510, 513, 516, 519, 522, 525 or 528; and (iii) a VL

42

CDR3 comprising the sequence shown in SEQ ID NO: 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 466, 469, 472, 475, 478, 481, 484, 487, 490, 493, 496, 499, 502, 505, 508, 511, 514, 517, 520, 523, 526 or 529.

In some embodiments, the second antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 266; or a light chain variable (VL) region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 265.

In some embodiments, the second antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementary determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 267, 268, or 269; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 270 or 271; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 272; or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 273; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 274; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 275.

Table 3 shows the specific amino acid and nucleic acid sequences of the second antibody variable domain, which is specific to CD3. In Table 3, the underlined sequences are CDR sequences according to Kabat and in bold according to Chothia.

TABLE 3

mAb	Light Chain	Heavy Chain
h2B4_	DIVMTQSPD SLAVSLGERATINC	EVQLVESGGGLVQPGGSLRLSCA
HNPS_	KSSQSLFNVR SRKNYLAWYQQK	ASGFTFSDY YMTWVRQAPGKGLE
VL_TK	PGQPPKLLIS WASTRES GVPDRF	WVA FIRNRARGYT SDHNPSVKGR
	SGSGSGTDFLTITISLQAE DAVAV	FTISRDNAKNSLYLQMN SLRAEDT
	YY KQSYDLFT FGSGTKLEIK	AVYYCARD DRPSYYVLDY WGQGT
	(SEQ ID NO: 265)	VTVSS (SEQ ID NO: 266)
h2B4_	GACATTGTGATGACTCAATCCC	GAAGTCCAACCTGTGCAATCGGG
HNPS_	CCGACTCCCTGGCTGTGTCCCT	AGGAGGCCTGTGCAACCCGGT
VL_TK	CGGCGAACCGCAACTATCAAC	GGATCCCTGAGGCTGTATGCG
	TGTA AAAAGCAGCCAGTCCCTGT	CGGCCTCGGGCTTACCTTTTCC
	TCAACGTCCGGTCGAGGAAGAA	GATTACTACATGACCTGGGTGAG
	CTACCTGGCCTGGTATCAGCAG	ACAGGCCCTGGAAAGGGGTTG
	AAACCTGGGCAGCCGCCGAAG	GAATGGGTGGCATTATCCGGA
	CTTCTGATCTCATGGGCTCAA	ATAGAGCCCGCGGATACACTTCC
	CTCGGAAAGCGGAGTGCCAG	GACCACAACCCAGCGTGAAGG
	ATAGATTCTCCGGATCTGGCTC	GGCGGTTACCATTAGCCGCGA
	CGGAACCGACTTACCCTGACG	CAACGCCAAGAACTCCCTCTACC
	ATTCGAGCTTGCAAGCGGAGG	TCCAAATGAACAGCCTGCGGGC
	ATGTGGCCGTGTACTACTGCAA	GGAGGATACCGCTGTGTACTACT
	GCAGTCCTACGACCTCTTCACC	GCGCCCGCGACCGGCGCTCTA
	TTTGGTTCGGGCACCAAGCTGG	CTATGTGCTGGACTACTGGGGC
	AGATCAAA (SEQ ID NO: 276)	CAGGGTACTACGGTACCCGTCT
		CCTCA (SEQ ID NO: 277)

Table 4 shows the examples of CDR sequences of the second antibody variable domain, which is specific to CD3.

TABLE 4

Heavy Chain			
mAb	CDRH1	CDRH2	CDRH3
h2B4_	SDYYMT (SEQ ID	RNRARGYT (SEQ ID NO:	DRPSYYVLDY
HNPS_VL_	NO: 267) (Kabat);	270) (Kabat)	(SEQ ID NO: 272)
TK	GFTFSDY (SEQ ID	FIRNRARGYTS DHNPSVKG	
	NO: 268) (Chothia);	(SEQ ID NO: 271)	
	GFTFSDYYMT (SEQ	(Extended)	
	ID NO: 269)		
	(Extended)		
Light Chain			
mAb	CDRH1	CDRH2	CDRH3
h2B4_	KSSQSLFNVRSRKN	WASTRES	KQSYDLFT
HNPS_VL_	YLA	(SEQ ID NO: 274)	(SEQ ID NO: 275)
TK	(SEQ ID NO: 273)		

In some embodiments, a bispecific antibody provided herein which contains a CD3-specific variable domain having an anti-CD3 sequence as provided in U.S. Publication No. 20160297885, which is hereby incorporated by reference for all purposes.

According to one approach to making bispecific antibodies, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant region sequences. The fusion preferably is with an immunoglobulin heavy chain constant region, comprising at least part of the hinge, CH2 and CH3 regions. It is preferred to have the first heavy chain constant region (CH1), containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are cotransfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In another approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. This asymmetric structure, with an immunoglobulin light chain in only one half of the bispecific molecule, facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations. This approach is described in PCT Publication No. WO 94/04690.

In another approach, the bispecific antibodies are composed of amino acid modification in the first hinge region in one arm, and the substituted/replaced amino acid in the first hinge region has an opposite charge to the corresponding amino acid in the second hinge region in another arm. This approach is described in International Patent Application No. PCT/US2011/036419 (WO2011/143545).

In another approach, the formation of a desired heteromultimeric or heterodimeric protein (e.g., bispecific anti-

body) is enhanced by altering or engineering an interface between a first and a second immunoglobulin-like Fc region

(e.g., a hinge region or a CH3 region). In this approach, the bispecific antibodies may be composed of a CH3 region, wherein the CH3 region comprises a first CH3 polypeptide and a second CH3 polypeptide which interact together to form a CH3 interface, wherein one or more amino acids within the CH3 interface destabilize homodimer formation and are not electrostatically unfavorable to homodimer formation. This approach is described in International Patent Application No. PCT/US2011/036419 (WO2011/143545).

In another approach, the bispecific antibodies can be generated using a glutamine-containing peptide tag engineered to the antibody directed to an epitope (e.g., CD70) in one arm and another peptide tag (e.g., a Lys-containing peptide tag or a reactive endogenous Lys) engineered to a second antibody directed to a second epitope in another arm in the presence of transglutaminase. This approach is described in International Patent Application No. PCT/IB2011/054899 (WO2012/059882).

In some embodiments, the heterodimeric protein (e.g., bispecific antibody) as described herein comprises a full-length human antibody, wherein a first antibody variable domain of the bispecific antibody specifically binding to a target antigen (e.g., CD70), and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen (e.g., CD3) located on the human immune effector cell, wherein the first and second antibody variable domain of the heterodimeric protein comprise amino acid modifications at positions 223, 225, and 228 (e.g., (C223E or C223R), (E225E or E225R), and (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the CH3 region of human IgG2 (SEQ ID NO: 279).

In some embodiments, the first and second antibody variable domains of the heterodimeric protein comprise amino acid modifications at positions 221 and 228 (e.g., (D221R or D221E) and (P228R or P228E)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the CH3 region of human IgG1 (SEQ ID NO: 280).

In some embodiments, the first and second antibody variable domains of the heterodimeric protein comprise amino acid modifications at positions 228 (e.g., (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g.,

R409 or L368E (EU numbering scheme)) in the CH3 region of human IgG4 (SEQ ID NO: 281).

The antibodies useful in the present invention can encompass monoclonal antibodies, polyclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')₂, Fv, Fc, etc.), chimeric antibodies, bispecific antibodies, heteroconjugate antibodies, single chain (ScFv), mutants thereof, fusion proteins comprising an antibody portion (e.g., a domain antibody), humanized antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. The antibodies may be murine, rat, human, or any other origin (including chimeric or humanized antibodies).

In some embodiments, the CD70 monospecific antibody or the CD70 bispecific antibody (e.g., CD70-CD3) as described herein is a monoclonal antibody. For example, the CD70 monospecific antibody is a human monoclonal antibody. In another example, the CD70 arm of the CD70-CD3 bispecific antibody is a human monoclonal antibody, and the CD3 arm of the CD70-CD3 bispecific antibody is a humanized monoclonal antibody.

In some embodiments, the antibody comprises a modified constant region, such as, for example without limitation, a constant region that has increased potential for provoking an immune response. For example, the constant region may be modified to have increased affinity to an Fc gamma receptor such as, e.g., FcγRI, FcγRIIA, or FcγIII.

In some embodiments, the antibody comprises a modified constant region, such as a constant region that is immunologically inert, that is, having a reduced potential for provoking an immune response. In some embodiments, the constant region is modified as described in Eur. J. Immunol., 29:2613-2624, 1999; PCT Application No. PCT/GB99/01441; or UK Patent Application No. 98099518. The Fc can be human IgG1, human IgG2, human IgG3, or human IgG4. The Fc can be human IgG2 containing the mutation A330P331 to S330S331 (IgG2Δa), in which the amino acid residues are numbered with reference to the wild type IgG2 sequence. Eur. J. Immunol., 29:2613-2624, 1999. In some embodiments, the antibody comprises a constant region of IgG4 comprising the following mutations (Armour et al., Molecular Immunology 40 585-593, 2003): E233F234L235 to P233V234A235 (IgG4Δc), in which the numbering is with reference to wild type IgG4. In yet another embodiment, the Fc is human IgG4 E233F234L235 to P233V234A235 with deletion G236 (IgG4Δb). In another embodiment, the Fc is any human IgG4 Fc (IgG4, IgG4Δb or IgG4Δc) containing hinge stabilizing mutation S228 to P228 (Aalberse et al., Immunology 105, 9-19, 2002). In another embodiment, the Fc can be aglycosylated Fc.

In some embodiments, the constant region is aglycosylated by mutating the oligosaccharide attachment residue (such as Asn297) or flanking residues that are part of the glycosylation recognition sequence in the constant region. In some embodiments, the constant region is aglycosylated for N-linked glycosylation enzymatically. The constant region may be aglycosylated for N-linked glycosylation enzymatically or by expression in a glycosylation deficient host cell.

In some embodiments, the constant region has a modified constant region that removes or reduces Fc gamma receptor binding. For example, the Fc can be human IgG2 containing the mutation D265, in which the amino acid residues are numbered with reference to the wild type IgG2 sequence (SEQ ID NO: 279). Accordingly, in some embodiments, the constant region has a modified constant region having the

sequence shown in SEQ ID NO: 282: ASTKGPSVF-
PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS-
GALTSVHTFPAVLQSS GLYSLSSVVTVPSSNFGTQ-
TYTCNVDHKPSNTKVDKTVKRCRVCPRCPAPPV-
AGPSV FLFPPKPKDTLMISRTPEVTCVAVSHEDPE-
VQFNVVYVDGVEVHNAKTKPREEQFNSTF RWSVLT-
WHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQP-
REPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIA-
VEWESNGQPENNYKTTTPMLDSDGSFFLYSRLTV-
DKSRWQQ GNVFSCSVMHEALHNHYTQKSLSL-
SPGK. And the nucleic acid encoding the sequence shown
in SEQ ID NO: 282 is shown in SEQ ID NO: 283.

In some embodiments, the constant region has a modified constant region having the sequence shown in SEQ ID NO: 284: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF-
PEPVTVSWNSGALTSVHTFPAVLQSS GLYSLSSVVT-
VPSSNFGTQTYTCNVDHKPSNTKVDKTVKRC-
VECPECPAPPVAGPSV FLFPPKPKDTLMISRTPE-
VTCVAVSHEDPEVQFNVVYVDGVEVHNAKTK-
PREEQFNSTF RWSVLTWHQDWLNGKEYKCKVS-
NKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTK
NQVSLTCEVKGFPYPSDIAVEWESNGQPENNYKTT-
PPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMH-
EALHNHYTQKSLSLSPGK. And the nucleic acid encod-
ing the sequence shown in SEQ ID NO: 284 is shown in
SEQ ID NO: 285.

The amino acid of the human Kappa constant region is shown in SEQ ID NO: 286: GTVAAPSVFIFPPSD-
EQLKSGTASVIVCLLNNFYPREAKVQWKVD-
NALQSGNSQESVTEQ DSKDSTYLSLSTLTL-
SKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC.
And the nucleic acid encoding the sequence of SEQ ID NO:
286 is shown in SEQ ID NO: 287.

One way of determining binding affinity of antibodies to CD70 is by measuring binding affinity of the bivalent antibody to monomeric CD70 protein. The affinity of an CD70 antibody can be determined by surface plasmon resonance (Biacore™3000™ surface plasmon resonance (SPR) system, Biacore™, INC, Piscataway N.J.) equipped with pre-immobilized anti-mouse Fc or anti-human Fc using HBS-EP running buffer (0.01M HEPES, pH 7.4, 0.15 NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20). Monomeric 8-histidine tagged human CD70 extracellular domain (SEQ ID NO: 530) can be diluted into HBS-EP buffer to a concentration of less than 0.5 μg/mL and injected across the individual chip channels using variable contact times, to achieve two ranges of antigen density, either 50-200 response units (RU) for detailed kinetic studies or 800-1,000 RU for screening assays. Regeneration studies have shown that 25 mM NaOH in 25% v/v ethanol effectively removes the bound CD70 protein while keeping the activity of CD70 antibodies on the chip for over 200 injections. Typically, serial dilutions (spanning concentrations of 0.1-10× estimated K_o) of purified 8-histidine tagged CD70 samples (SEQ ID NO: 530) are injected for 1 min at 100 μL/minute and dissociation times of up to 2 hours are allowed. The concentrations of the CD70 proteins are determined by absorbance at 280 nm based on sequence specific extinction coefficient of the 8-histidine tagged CD70 protein (SEQ ID NO: 530). Kinetic association rates (k_{on} or k_a) and dissociation rates (k_{off} or k_d) are obtained simultaneously by fitting the data globally to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B. (1994). Methods Enzymology 6. 99-110) using the BIAevaluation program. Equilibrium dissociation constant (K_o) values are

calculated as k_{off}/k_{on} . This protocol is suitable for use in determining binding affinity of an antibody to any monomeric CD70, including human CD70, CD70 of another mammal (such as mouse CD70, rat CD70, or primate CD70), as well as different forms of CD70 (e.g., glycosylated CD70). Binding affinity of an antibody is generally measured at 25° C., but can also be measured at 37° C.

The antibodies as described herein may be made by any method known in the art. For the production of hybridoma cell lines, the route and schedule of immunization of the host animal are generally in keeping with established and conventional techniques for antibody stimulation and production, as further described herein. General techniques for production of human and mouse antibodies are known in the art or are described herein.

It is contemplated that any mammalian subject including humans or antibody producing cells therefrom can be manipulated to serve as the basis for production of mammalian, including human and hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantar, or intradermally with an amount of immunogen, including as described herein.

Hybridomas can be prepared from the lymphocytes and immortalized myeloma cells using the general somatic cell hybridization technique of Kohler, B. and Milstein, C., *Nature* 256:495-497, 1975 or as modified by Buck, D. W., et al., *In Vitro*, 18:377-381, 1982. Available myeloma lines, including but not limited to X63-Ag8.653 and those from the Salk Institute, Cell Distribution Center, San Diego, Calif., USA, may be used in the hybridization. Generally, the technique involves fusing myeloma cells and lymphoid cells using a fusogen such as polyethylene glycol, or by electrical means well known to those skilled in the art. After the fusion, the cells are separated from the fusion medium and grown in a selective growth medium, such as hypoxanthine-aminopterin-thymidine (HAT) medium, to eliminate unhybridized parent cells. Any of the media described herein, supplemented with or without serum, can be used for culturing hybridomas that secrete monoclonal antibodies. As another alternative to the cell fusion technique, EBV immortalized B cells may be used to produce the monoclonal antibodies of the subject invention. The hybridomas are expanded and subcloned, if desired, and supernatants are assayed for anti-immunogen activity by conventional immunoassay procedures (e.g., radioimmunoassay, enzyme immunoassay, or fluorescence immunoassay).

Hybridomas that may be used as source of antibodies encompass all derivatives, progeny cells of the parent hybridomas that produce monoclonal antibodies specific for CD70, or portions thereof.

Hybridomas that produce such antibodies may be grown in vitro or in vivo using known procedures. The monoclonal antibodies may be isolated from the culture media or body fluids, by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis, chromatography, and ultrafiltration, if desired. Undesired activity, if present, can be removed, for example, by running the preparation over adsorbents made of the immunogen attached to a solid phase and eluting or releasing the desired antibodies off the immunogen. Immunization of a host animal with cells expressing human CD70, a human CD70 protein, or a fragment containing the target amino acid sequence conjugated to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing

agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R^1 are different alkyl groups, can yield a population of antibodies (e.g., monoclonal antibodies).

If desired, the antibody (monoclonal or polyclonal) of interest may be sequenced and the polynucleotide sequence may then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for future use. Production of recombinant monoclonal antibodies in cell culture can be carried out through cloning of antibody genes from B cells by means known in the art. See, e.g. Tiller et al., *J. Immunol. Methods* 329, 112, 2008; U.S. Pat. No. 7,314,622.

In an alternative, the polynucleotide sequence may be used for genetic manipulation to “humanize” the antibody or to improve the affinity, or other characteristics of the antibody. For example, the constant region may be engineered to more nearly resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. It may be desirable to genetically manipulate the antibody sequence to obtain greater affinity to CD70 and greater efficacy in inhibiting CD70.

There are four general steps to humanize a monoclonal antibody. These are: (1) determining the nucleotide and predicted amino acid sequence of the starting antibody light and heavy variable domains (2) designing the humanized antibody, i.e., deciding which antibody framework region to use during the humanizing process (3) the actual humanizing methodologies/techniques and (4) the transfection and expression of the humanized antibody. See, for example, U.S. Pat. Nos. 4,816,567; 5,807,715; 5,866,692; 6,331,415; 5,530,101; 5,693,761; 5,693,762; 5,585,089; and 6,180,370.

A number of “humanized” antibody molecules comprising an antigen binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent or modified rodent V regions and their associated CDRs fused to human constant regions. See, for example, Winter et al. *Nature* 349:293-299, 1991, Lobuglio et al. *Proc. Nat. Acad. Sci. USA* 86:4220-4224, 1989, Shaw et al. *J Immunol.* 138:4534-4538, 1987, and Brown et al. *Cancer Res.* 47:3577-3583, 1987. Other references describe rodent CDRs grafted into a human supporting framework region (FR) prior to fusion with an appropriate human antibody constant region. See, for example, Riechmann et al. *Nature* 332:323-327, 1988, Verhoeyen et al. *Science* 239:1534-1536, 1988, and Jones et al. *Nature* 321:522-525, 1986. Another reference describes rodent CDRs supported by recombinantly engineered rodent framework regions. See, for example, European Patent Publication No. 0519596. These “humanized” molecules are designed to minimize unwanted immunological response toward rodent anti-human antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients. For example, the antibody constant region can be engineered such that it is immunologically inert (e.g., does not trigger complement lysis). See, e.g. PCT Publication No. PCT/GB99/01441; UK Patent Application No. 9809951.8. Other methods of humanizing antibodies that may also be utilized are disclosed by Daugherty et al., *Nucl. Acids Res.* 19:2471-2476, 1991, and in U.S. Pat. Nos. 6,180,377; 6,054,297; 5,997,867; 5,866,692; 6,210,671; and 6,350,861; and in PCT Publication No. WO 01/27160.

The general principles related to humanized antibodies discussed above are also applicable to customizing antibodies for use, for example, in dogs, cats, primate, equines and bovines. Further, one or more aspects of humanizing an antibody described herein may be combined, e.g., CDR grafting, framework mutation and CDR mutation.

In one variation, fully human antibodies may be obtained by using commercially available mice that have been engineered to express specific human immunoglobulin proteins. Transgenic animals that are designed to produce a more desirable (e.g., fully human antibodies) or more robust immune response may also be used for generation of humanized or human antibodies. Examples of such technology are Xenomouse™ from Abgenix, Inc. (Fremont, Calif.) and HuMAb-Mouse® and TC Mouse™ from Medarex, Inc. (Princeton, N.J.).

In an alternative, antibodies may be made recombinantly and expressed using any method known in the art. In another alternative, antibodies may be made recombinantly by phage display technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and Winter et al., *Annu. Rev. Immunol.* 12:433-455, 1994. Alternatively, the phage display technology (McCafferty et al., *Nature* 348:552-553, 1990) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B cell. Phage display can be performed in a variety of formats; for review see, e.g., Johnson, Kevin S. and Chiswell, David J., *Current Opinion in Structural Biology* 3:564-571, 1993. Several sources of V-gene segments can be used for phage display. Clackson et al., *Nature* 352:624-628, 1991, isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Mark et al., *J. Mol. Biol.* 222:581-597, 1991, or Griffith et al., *EMBO J.* 12:725-734, 1993. In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by employing the technique known as "chain shuffling." (Marks et al., *Bio/Technol.* 10:779-783, 1992). In this method, the affinity of "primary" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from unimmunized donors. This technique allows the production of antibodies and antibody fragments with affinities in the pM-nM range. A strategy for making very large phage antibody repertoires (also known as "the mother-of-all libraries") has been described by Waterhouse et al., *Nucl. Acids Res.* 21:2265-2266, 1993. Gene shuffling can also be

used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as "epitope imprinting", the heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable regions capable of restoring a functional antigen binding site, i.e., the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see PCT Publication No. WO 93/06213). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.

Antibodies may be made recombinantly by first isolating the antibodies and antibody producing cells from host animals, obtaining the gene sequence, and using the gene sequence to express the antibody recombinantly in host cells (e.g., CHO cells). Another method which may be employed is to express the antibody sequence in plants (e.g., tobacco) or transgenic milk. Methods for expressing antibodies recombinantly in plants or milk have been disclosed. See, for example, Peeters, et al. *Vaccine* 19:2756, 2001; Lonberg, N. and D. Huszar *Int. Rev. Immunol* 13:65, 1995; and Pollock, et al., *J Immunol Methods* 231:147, 1999. Methods for making derivatives of antibodies, e.g., humanized, single chain, etc. are known in the art.

Immunoassays and flow cytometry sorting techniques such as fluorescence activated cell sorting (FACS) can also be employed to isolate antibodies that are specific for CD70, or tumor antigens of interest.

The antibodies as described herein can be bound to many different carriers. Carriers can be active or inert. Examples of well-known carriers include polypropylene, polystyrene, polyethylene, dextran, nylon, amylases, glass, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation. In some embodiments, the carrier comprises a moiety that targets the myocardium.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors (such as expression vectors disclosed in PCT Publication No. WO 87/04462), which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. See, e.g., PCT Publication No. WO87/04462. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant regions in place of the homologous murine sequences, Morrison et al., *Proc. Nat. Acad. Sci.* 81:6851, 1984, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, "chimeric" or "hybrid" antibodies are prepared that have the binding specificity of a monoclonal antibody herein.

The CD70 antibodies as described herein can be identified or characterized using methods known in the art, whereby reduction of CD70 expression levels are detected or measured. In some embodiments, an CD70 antibody is identified by incubating a candidate agent with CD70 and monitoring binding or attendant reduction of CD70 expression levels. The binding assay may be performed with purified CD70 polypeptide(s), or with cells naturally expressing, or transfected to express, CD70 polypeptide(s). In one embodiment, the binding assay is a competitive binding assay, where the ability of a candidate antibody to compete with a known CD70 antibody for CD70 binding is evaluated. The assay may be performed in various formats, including the ELISA format.

Following initial identification, the activity of a candidate CD70 antibody can be further confirmed and refined by bioassays, known to test the targeted biological activities. Alternatively, bioassays can be used to screen candidates directly. Some of the methods for identifying and characterizing antibodies are described in detail in the Examples.

CD70 antibodies may be characterized using methods well known in the art. For example, one method is to identify the epitope to which it binds, or "epitope mapping." There are many methods known in the art for mapping and characterizing the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in Chapter 11 of Harlow and Lane, *Using Antibodies, a Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999. In an additional example, epitope mapping can be used to determine the sequence to which an antibody binds. Epitope mapping is commercially available from various sources, for example, Pepscan Systems (Edelhertweg 15, 8219 PH Lelystad, The Netherlands). The epitope can be a linear epitope, i.e., contained in a single stretch of amino acids, or a conformational epitope formed by a three-dimensional interaction of amino acids that may not necessarily be contained in a single stretch. Peptides of varying lengths (e.g., at least 4-6 amino acids long) can be isolated or synthesized (e.g., recombinantly) and used for binding assays with an CD70 or other tumor antigen antibody. In another example, the epitope to which the CD70 antibody binds can be determined in a systematic screening by using overlapping peptides derived from the CD70 sequence and determining binding by the CD70 antibody. According to the gene fragment expression assays, the open reading frame encoding CD70 is fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of CD70 with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then transcribed and translated into protein *in vitro*, in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled CD70 is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed on the surface of phage particles (phage libraries). Alternatively, a defined library of overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. In an additional example, mutagenesis of an antigen binding domain, domain swapping experiments and alanine scanning mutagenesis can be performed to identify residues required, sufficient, or necessary for epitope binding. For example, domain swapping experiments can be performed using a mutant CD70 in which various fragments of the CD70 protein have been replaced (swapped) with

sequences from CD70 from another species (e.g., mouse), or a closely related, but antigenically distinct protein. By assessing binding of the antibody to the mutant CD70, the importance of the particular CD70 fragment to antibody binding can be assessed. In the case of CD70 specific antibody (i.e. antibody that does not bind CD70 wt (wild type) or any other proteins), epitope can be deduced from the sequence alignment of CD70 to CD70 wt.

Yet another method which can be used to characterize an CD70 antibody is to use competition assays with other antibodies known to bind to the same antigen, i.e., various fragments on CD70, to determine if the CD70 antibody binds to the same epitope as other antibodies. Competition assays are well known to those of skill in the art.

An expression vector can be used to direct expression of an CD70 antibody. One skilled in the art is familiar with administration of expression vectors to obtain expression of an exogenous protein *in vivo*. See, e.g., U.S. Pat. Nos. 6,436,908; 6,413,942; and 6,376,471. Administration of expression vectors includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. In another embodiment, the expression vector is administered directly to the sympathetic trunk or ganglion, or into a coronary artery, atrium, ventricle, or pericardium.

Targeted delivery of therapeutic compositions containing an expression vector, or subgenomic polynucleotides can also be used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., *Trends Biotechnol.*, 1993, 11:202; Chiou et al., *Gene Therapeutics: Methods And Applications Of Direct Gene Transfer*, J. A. Wolff, ed., 1994; Wu et al., *J. Biol. Chem.*, 263:621, 1988; Wu et al., *J. Biol. Chem.*, 269:542, 1994; Zenke et al., *Proc. Natl. Acad. Sci. USA*, 87:3655, 1990; and Wu et al., *J. Biol. Chem.*, 266:338, 1991. Therapeutic compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 to about 2 mg, about 5 μ g to about 500 μ g, and about 20 μ g to about 100 μ g of DNA can also be used during a gene therapy protocol. The therapeutic polynucleotides and polypeptides can be delivered using gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, *Cancer Gene Therapy*, 1:51, 1994; Kimura, *Human Gene Therapy*, 5:845, 1994; Connelly, *Human Gene Therapy*, 1995, 1:185; and Kaplitt, *Nature Genetics*, 6:148, 1994). Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., PCT Publication Nos. WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; WO 93/11230; WO 93/10218; WO 91/02805; U.S. Pat. Nos. 5,219,740 and 4,777,127; GB Pat. No. 2,200,651; and EP Pat. No. 0 345 242), alphavirus-based vectors (e.g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532)), and adeno-associated virus (AAV) vectors (see, e.g., PCT Publication Nos. WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and

WO 95/00655). Administration of DNA linked to killed adenovirus as described in Curiel, *Hum. Gene Ther.*, 1992, 3:147 can also be employed.

Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, *Hum. Gene Ther.*, 3:147, 1992); ligand-linked DNA (see, e.g., Wu, *J. Biol. Chem.*, 264:16985, 1989); eukaryotic cell delivery vehicles cells (see, e.g., U.S. Pat. No. 5,814,482; PCT Publication Nos. WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with cell membranes. Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in PCT Publication No. WO 90/11092 and U.S. Pat. No. 5,580,859. Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120; PCT Publication Nos. WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968. Additional approaches are described in Philip, *Mol. Cell Biol.*, 14:2411, 1994 and in Woffendin, *Proc. Natl. Acad. Sci.*, 91:1581, 1994.

In some embodiments, the invention encompasses compositions, including pharmaceutical compositions, comprising antibodies described herein or made by the methods and having the characteristics described herein. As used herein, compositions comprise one or more antibodies that bind to CD70, or one or more polynucleotides comprising sequences encoding one or more these antibodies. These compositions may further comprise suitable excipients, such as pharmaceutically acceptable excipients including buffers, which are well known in the art.

The invention also provides methods of making any of these antibodies. The antibodies of this invention can be made by procedures known in the art. The polypeptides can be produced by proteolytic or other degradation of the antibodies, by recombinant methods (i.e., single or fusion polypeptides) as described above or by chemical synthesis. Polypeptides of the antibodies, especially shorter polypeptides up to about 50 amino acids, are conveniently made by chemical synthesis. Methods of chemical synthesis are known in the art and are commercially available. For example, an antibody could be produced by an automated polypeptide synthesizer employing the solid phase method. See also, U.S. Pat. Nos. 5,807,715; 4,816,567; and 6,331,415.

In another alternative, the antibodies can be made recombinantly using procedures that are well known in the art. In one embodiment, a polynucleotide comprises a sequence encoding the heavy chain or the light chain variable regions of antibody 31H1, 6362, 40E3, 42C3, 45F11, 64F9, 72C2, 2F10, 4F11, 10H10, 17G6, 65E11, P02B10, P07D03, P08A02, P08E02, P08F08, P08G02, P12B09, P12F02, P12G07, P13F04, P15D02 or P16C05. The sequence encoding the antibody of interest may be maintained in a vector in a host cell and the host cell can then be expanded and frozen for future use. Vectors (including expression vectors) and host cells are further described herein.

Heteroconjugate antibodies, comprising two covalently joined antibodies, are also within the scope of the invention. Such antibodies have been used to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (PCT Publication Nos. WO 91/00360 and WO 92/200373; EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents and techniques are well known in the art, and are described in U.S. Pat. No. 4,676,980.

Chimeric or hybrid antibodies also may be prepared in vitro using known methods of synthetic protein chemistry, including those involving cross-linking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrim idate.

In the recombinant humanized antibodies, the Fc γ portion can be modified to avoid interaction with Fc γ receptor and the complement and immune systems. The techniques for preparation of such antibodies are described in WO 99/58572. For example, the constant region may be engineered to more resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. See, for example, U.S. Pat. Nos. 5,997,867 and 5,866,692.

The invention encompasses modifications to the antibodies and polypeptides of the invention including variants shown in Table 5, including functionally equivalent antibodies which do not significantly affect their properties and variants which have enhanced or decreased activity or affinity. For example, the amino acid sequence may be mutated to obtain an antibody with the desired binding affinity to CD70. Modification of polypeptides is routine practice in the art and need not be described in detail herein. Examples of modified polypeptides include polypeptides with conservative substitutions of amino acid residues, one or more deletions or additions of amino acids which do not significantly deleteriously change the functional activity, or which mature (enhance) the affinity of the polypeptide for its ligand, or use of chemical analogs.

Amino acid sequence insertions include amino- or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme or a polypeptide which increases the half-life of the antibody in the blood circulation.

Substitution variants have at least one amino acid residue in the antibody molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 5 under the heading of "conservative substitutions." If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table 5, or as further described below in reference to amino acid classes, may be introduced and the products screened. In some embodiments, substitution variants of antibodies provided herein have no more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 conservative substitution in the VH or VL region as compared to the reference parent antibody. In some embodiments, the substitutions are not within a CDR of the VH or VL region.

TABLE 5

Amino Acid Substitutions		
Original Residue (naturally occurring amino acid)	Conservative Substitutions	Exemplary Substitutions
Ala (A)	Val	Val; Leu; Ile
Arg (R)	Lys	Lys; Gln; Asn
Asn (N)	Gln	Gln; His; Asp; Lys; Arg
Asp (D)	Glu	Glu; Asn
Cys (C)	Ser	Ser; Ala
Gln (Q)	Asn	Asn; Glu
Glu (E)	Asp	Asp; Gln
Gly (G)	Ala	Ala
His (H)	Arg	Asn; Gln; Lys; Arg
Ile (I)	Leu	Leu; Val; Met; Ala; Phe; Norleucine
Leu (L)	Ile	Norleucine; Ile; Val; Met; Ala; Phe
Lys (K)	Arg	Arg; Gln; Asn
Met (M)	Leu	Leu; Phe; Ile
Phe (F)	Tyr	Leu; Val; Ile; Ala; Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Ser	Ser
Trp (W)	Tyr	Tyr; Phe
Tyr (Y)	Phe	Trp; Phe; Thr; Ser
Val (V)	Leu	Ile; Leu; Met; Phe; Ala; Norleucine

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring amino acid residues are divided into groups based on common side-chain properties:

- (1) Non-polar: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) Polar without charge: Cys, Ser, Thr, Asn, Gln;
- (3) Acidic (negatively charged): Asp, Glu;
- (4) Basic (positively charged): Lys, Arg;
- (5) Residues that influence chain orientation: Gly, Pro; and
- (6) Aromatic: Trp, Tyr, Phe, His.

Non-conservative substitutions are made by exchanging a member of one of these classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross-linking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability, particularly where the antibody is an antibody fragment such as an Fv fragment.

Amino acid modifications can range from changing or modifying one or more amino acids to complete redesign of a region, such as the variable region. Changes in the variable region can alter binding affinity or specificity. In some embodiments, no more than one to five conservative amino acid substitutions are made within a CDR domain. In other embodiments, no more than one to three conservative amino acid substitutions are made within a CDR domain. In still other embodiments, the CDR domain is CDR H3 or CDR L3.

Modifications also include glycosylated and nonglycosylated polypeptides, as well as polypeptides with other post-translational modifications, such as, for example, glycosylation with different sugars, acetylation, and

phosphorylation. Antibodies are glycosylated at conserved positions in their constant regions (Jefferis and Lund, *Chem. Immunol.* 65:111-128, 1997; Wright and Morrison, *TibTECH* 15:26-32, 1997). The oligosaccharide side chains of the immunoglobulins affect the protein's function (Boyd et al., *Mol. Immunol.* 32:1311-1318, 1996; Wittwe and Howard, *Biochem.* 29:4175-4180, 1990) and the intramolecular interaction between portions of the glycoprotein, which can affect the conformation and presented three-dimensional surface of the glycoprotein (Jefferis and Lund, supra; Wyss and Wagner, *Current Opin. Biotech.* 7:409-416, 1996). Oligosaccharides may also serve to target a given glycoprotein to certain molecules based upon specific recognition structures. Glycosylation of antibodies has also been reported to affect antibody-dependent cellular cytotoxicity (ADCC). In particular, CHO cells with tetracycline-regulated expression of $\beta(1,4)$ -N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisecting GlcNAc, was reported to have improved ADCC activity (Umana et al., *Mature Biotech.* 17:176-180, 1999).

Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine, asparagine-X-threonine, and asparagine-X-cysteine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

The glycosylation pattern of antibodies may also be altered without altering the underlying nucleotide sequence. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for expression of recombinant glycoproteins, e.g. antibodies, as potential therapeutics is rarely the native cell, variations in the glycosylation pattern of the antibodies can be expected (see, e.g. Hse et al., *J. Biol. Chem.* 272:9062-9070, 1997).

In addition to the choice of host cells, factors that affect glycosylation during recombinant production of antibodies include growth mode, media formulation, culture density, oxygenation, pH, purification schemes and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host organism including introducing or overexpressing certain enzymes involved in oligosaccharide production (U.S. Pat. Nos. 5,047,335; 5,510,261 and 5,278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example, using endoglycosidase H (Endo H), N-glycosidase F, endoglycosidase F1, endoglycosidase F2, endoglycosidase F3. In addition, the recombinant host cell can be genetically engineered to be defective in processing certain types of polysaccharides. These and similar techniques are well known in the art.

Other methods of modification include using coupling techniques known in the art, including, but not limited to, enzymatic means, oxidative substitution and chelation.

Modifications can be used, for example, for attachment of labels for immunoassay. Modified polypeptides are made using established procedures in the art and can be screened using standard assays known in the art, some of which are described below and in the Examples.

Other antibody modifications include antibodies that have been modified as described in PCT Publication No. WO 99/58572. These antibodies comprise, in addition to a binding domain directed at the target molecule, an effector domain having an amino acid sequence substantially homologous to all or part of a constant region of a human immunoglobulin heavy chain. These antibodies are capable of binding the target molecule without triggering significant complement dependent lysis, or cell-mediated destruction of the target. In some embodiments, the effector domain is capable of specifically binding FcRn or FcγRIIb. These are typically based on chimeric domains derived from two or more human immunoglobulin heavy chain CH2 domains. Antibodies modified in this manner are particularly suitable for use in chronic antibody therapy, to avoid inflammatory and other adverse reactions to conventional antibody therapy.

The invention includes affinity matured embodiments. For example, affinity matured antibodies can be produced by procedures known in the art (Marks et al., *Bio/Technology*, 10:779-783, 1992; Barbas et al., *Proc Nat. Acad. Sci. USA* 91:3809-3813, 1994; Schier et al., *Gene*, 169:147-155, 1995; Yelton et al., *J. Immunol.*, 155:1994-2004, 1995; Jackson et al., *J. Immunol.*, 154(7):3310-9, 1995; Hawkins et al., *J. Mol. Biol.*, 226:889-896, 1992; and PCT Publication No. WO2004/058184).

The following methods may be used for adjusting the affinity of an antibody and for characterizing a CDR. One way of characterizing a CDR of an antibody or altering (such as improving) the binding affinity of a polypeptide, such as an antibody, termed "library scanning mutagenesis". Generally, library scanning mutagenesis works as follows. One or more amino acid positions in the CDR are replaced with two or more (such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) amino acids using art recognized methods. This generates small libraries of clones (in some embodiments, one for every amino acid position that is analyzed), each with a complexity of two or more members (if two or more amino acids are substituted at every position). Generally, the library also includes a clone comprising the native (unsubstituted) amino acid. A small number of clones, e.g., about 20-80 clones (depending on the complexity of the library), from each library are screened for binding affinity to the target polypeptide (or other binding target), and candidates with increased, the same, decreased, or no binding are identified. Methods for determining binding affinity are well-known in the art. Binding affinity may be determined using Biacore™ surface plasmon resonance analysis, which detects differences in binding affinity of about 2-fold or greater. Biacore™ is particularly useful when the starting antibody already binds with a relatively high affinity, for example a K_D of about 10 nM or lower. Screening using Biacore™ surface plasmon resonance is described in the Examples, herein.

Binding affinity may be determined using Kinexa Biosensor, scintillation proximity assays, ELISA, ORIGEN immunoassay (IGEN), fluorescence quenching, fluorescence transfer, or yeast display. Binding affinity may also be screened using a suitable bioassay.

In some embodiments, every amino acid position in a CDR is replaced (in some embodiments, one at a time) with all 20 natural amino acids using art recognized mutagenesis methods (some of which are described herein). This generates small libraries of clones (in some embodiments, one for every amino acid position that is analyzed), each with a complexity of 20 members (if all 20 amino acids are substituted at every position).

In some embodiments, the library to be screened comprises substitutions in two or more positions, which may be in the same CDR or in two or more CDRs. Thus, the library may comprise substitutions in two or more positions in one CDR. The library may comprise substitution in two or more positions in two or more CDRs. The library may comprise substitution in 3, 4, 5, or more positions, said positions found in two, three, four, five or six CDRs. The substitution may be prepared using low redundancy codons. See, e.g., Table 2 of Balint et al., *Gene* 137(1):109-18, 1993.

The CDR may be CDRH3 or CDRL3. The CDR may be one or more of CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3. The CDR may be a Kabat CDR, a Chothia CDR, or an extended CDR.

Candidates with improved binding may be sequenced, thereby identifying a CDR substitution mutant which results in improved affinity (also termed an "improved" substitution). Candidates that bind may also be sequenced, thereby identifying a CDR substitution which retains binding.

Multiple rounds of screening may be conducted. For example, candidates (each comprising an amino acid substitution at one or more position of one or more CDR) with improved binding are also useful for the design of a second library containing at least the original and substituted amino acid at each improved CDR position (i.e., amino acid position in the CDR at which a substitution mutant showed improved binding). Preparation, and screening or selection of this library is discussed further below.

Library scanning mutagenesis also provides a means for characterizing a CDR, in so far as the frequency of clones with improved binding, the same binding, decreased binding or no binding also provide information relating to the importance of each amino acid position for the stability of the antibody-antigen complex. For example, if a position of the CDR retains binding when changed to all 20 amino acids, that position is identified as a position that is unlikely to be required for antigen binding. Conversely, if a position of CDR retains binding in only a small percentage of substitutions, that position is identified as a position that is important to CDR function. Thus, the library scanning mutagenesis methods generate information regarding positions in the CDRs that can be changed to many different amino acids (including all 20 amino acids), and positions in the CDRs which cannot be changed or which can only be changed to a few amino acids.

Candidates with improved affinity may be combined in a second library, which includes the improved amino acid, the original amino acid at that position, and may further include additional substitutions at that position, depending on the complexity of the library that is desired, or permitted using the desired screening or selection method. In addition, if desired, adjacent amino acid position can be randomized to at least two or more amino acids. Randomization of adjacent amino acids may permit additional conformational flexibility in the mutant CDR, which may in turn, permit or facilitate the introduction of a larger number of improving mutations. The library may also comprise substitution at positions that did not show improved affinity in the first round of screening.

The second library is screened or selected for library members with improved or altered binding affinity using any method known in the art, including screening using Biacore™ surface plasmon resonance analysis, and selection using any method known in the art for selection, including phage display, yeast display, and ribosome display.

The invention also encompasses fusion proteins comprising one or more fragments or regions from the antibodies of this invention. In one embodiment, a fusion polypeptide is provided that comprises at least 10 contiguous amino acids of the variable light chain region shown in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 or 47, or at least 10 amino acids of the variable heavy chain region shown in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 or 48. In other embodiments, a fusion polypeptide is provided that comprises at least about 10, at least about 15, at least about 20, at least about 25, or at least about 30 contiguous amino acids of the variable light chain region or at least about 10, at least about 15, at least about 20, at least about 25, or at least about 30 contiguous amino acids of the variable heavy chain region. In another embodiment, the fusion polypeptide comprises one or more CDR(s). In still other embodiments, the fusion polypeptide comprises CDR H3 (VH CDR3) or CDR L3 (VL CDR3). For purposes of this invention, a fusion protein contains one or more antibodies and another amino acid sequence to which it is not attached in the native molecule, for example, a heterologous sequence or a homologous sequence from another region. Exemplary heterologous sequences include, but are not limited to a “tag” such as a FLAG tag or a 6His tag (SEQ ID NO: 531). Tags are well known in the art.

A fusion polypeptide can be created by methods known in the art, for example, synthetically or recombinantly. Typically, the fusion proteins of this invention are made by preparing an expressing a polynucleotide encoding them using recombinant methods described herein, although they may also be prepared by other means known in the art, including, for example, chemical synthesis.

This invention also provides compositions comprising antibodies conjugated (for example, linked) to an agent that facilitate coupling to a solid support (such as biotin or avidin). For simplicity, reference will be made generally to antibodies with the understanding that these methods apply to any of the CD70 antibody embodiments described herein. Conjugation generally refers to linking these components as described herein. The linking (which is generally fixing these components in proximate association at least for administration) can be achieved in any number of ways. For example, a direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

The invention also provides isolated polynucleotides encoding the antibodies of the invention, and vectors and host cells comprising the polynucleotide.

Accordingly, the invention provides polynucleotides (or compositions, including pharmaceutical compositions), comprising polynucleotides encoding any of the following: 31H1, 6362, 40E3, 42C3, 45F11, 64F9, 72C2, 2F10, 4F11, 10H10, 17G6, 65E11, P02B10, P07D03, P08A02, P08E02, P08F08, P08G02, P12B09, P12F02, P12G07, P13F04, P15D02 or P16C05, or any fragment or part thereof having the ability to bind CD70.

In another aspect, the invention provides polynucleotides encoding any of the antibodies (including antibody fragments) and polypeptides described herein, such as antibodies and polypeptides having impaired effector function. Polynucleotides can be made and expressed by procedures known in the art.

In another aspect, the invention provides compositions (such as a pharmaceutical compositions) comprising any of the polynucleotides of the invention. In some embodiments, the composition comprises an expression vector comprising a polynucleotide encoding any of the antibodies described herein.

Expression vectors, and administration of polynucleotide compositions are further described herein.

In another aspect, the invention provides a method of making any of the polynucleotides described herein.

Polynucleotides complementary to any such sequences are also encompassed by the present invention. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules or support materials.

Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes an antibody or a portion thereof) or may comprise a variant of such a sequence. Polynucleotide variants contain one or more substitutions, additions, deletions or insertions such that the immunoreactivity of the encoded polypeptide is not diminished, relative to a native immunoreactive molecule. The effect on the immunoreactivity of the encoded polypeptide may generally be assessed as described herein. Variants preferably exhibit at least about 70% identity, more preferably, at least about 80% identity, yet more preferably, at least about 90% identity, and most preferably, at least about 95% identity to a polynucleotide sequence that encodes a native antibody or a portion thereof.

Two polynucleotide or polypeptide sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, or 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O., 1978, A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; Hein J., 1990, Unified Approach to Alignment and Phylogenesis pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.; Higgins, D. G. and Sharp, P. M., 1989,

CABIOS 5:151-153; Myers, E. W. and Muller W., 1988, CABIOS 4:11-17; Robinson, E. D., 1971, Comb. Theor. 11:105; Santou, N., Nes, M., 1987, Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R., 1973, Numerical Taxonomy the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W. J. and Lipman, D. J., 1983, Proc. Natl. Acad. Sci. USA 80:726-730.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e. the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Variants may also, or alternatively, be substantially homologous to a native gene, or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding a native antibody (or a complementary sequence).

Suitable "moderately stringent conditions" include pre-washing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.–65° C., 5×SSC, overnight; followed by washing twice at 65° C. for 20 minutes with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS.

As used herein, "highly stringent conditions" or "high stringency conditions" are those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions or substitutions of nucleotides. The

resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification or database sequence comparison).

The polynucleotides of this invention can be obtained using chemical synthesis, recombinant methods, or PCR. Methods of chemical polynucleotide synthesis are well known in the art and need not be described in detail herein. One of skill in the art can use the sequences provided herein and a commercial DNA synthesizer to produce a desired DNA sequence.

For preparing polynucleotides using recombinant methods, a polynucleotide comprising a desired sequence can be inserted into a suitable vector, and the vector in turn can be introduced into a suitable host cell for replication and amplification, as further discussed herein. Polynucleotides may be inserted into host cells by any means known in the art. Cells are transformed by introducing an exogenous polynucleotide by direct uptake, endocytosis, transfection, F-mating or electroporation. Once introduced, the exogenous polynucleotide can be maintained within the cell as a non-integrated vector (such as a plasmid) or integrated into the host cell genome. The polynucleotide so amplified can be isolated from the host cell by methods well known within the art. See, e.g., Sambrook et al., 1989.

Alternatively, PCR allows reproduction of DNA sequences. PCR technology is well known in the art and is described in U.S. Pat. Nos. 4,683,195, 4,800,159, 4,754,065 and 4,683,202, as well as PCR: The Polymerase Chain Reaction, Mullis et al. eds., Birkauser Press, Boston, 1994.

RNA can be obtained by using the isolated DNA in an appropriate vector and inserting it into a suitable host cell. When the cell replicates and the DNA is transcribed into RNA, the RNA can then be isolated using methods well known to those of skill in the art, as set forth in Sambrook et al., 1989, *supra*, for example.

Suitable cloning vectors may be constructed according to standard techniques, or may be selected from a large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, or may carry genes for a marker that can be used in selecting clones containing the vector. Suitable examples include plasmids and bacterial viruses, e.g., pUC18, pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28. These and many other cloning vectors are available from commercial vendors such as BioRad, Stratagene, and Invitrogen.

Expression vectors generally are replicable polynucleotide constructs that contain a polynucleotide according to the invention. It is implied that an expression vector must be replicable in the host cells either as episomes or as an integral part of the chromosomal DNA. Suitable expression vectors include but are not limited to plasmids, viral vectors, including adenoviruses, adeno-associated viruses, retroviruses, cosmids, and expression vector(s) disclosed in PCT Publication No. WO 87/04462. Vector components may generally include, but are not limited to, one or more of the following: a signal sequence; an origin of replication; one or more marker genes; suitable transcriptional controlling elements (such as promoters, enhancers and terminator). For expression (i.e., translation), one or more translational controlling elements are also usually required, such as ribosome binding sites, translation initiation sites, and stop codons.

The vectors containing the polynucleotides of interest can be introduced into the host cell by any of a number of appropriate means, including electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (e.g., where the vector is an infectious agent such as vaccinia virus). The choice of introducing vectors or polynucleotides will often depend on features of the host cell.

The invention also provides host cells comprising any of the polynucleotides described herein. Any host cells capable of over-expressing heterologous DNAs can be used for the purpose of isolating the genes encoding the antibody, polypeptide or protein of interest. Non-limiting examples of mammalian host cells include but not limited to COS, HeLa, and CHO cells. See also PCT Publication No. WO 87/04462. Suitable non-mammalian host cells include prokaryotes (such as *E. coli* or *B. subtilis*) and yeast (such as *S. cerevisiae*, *S. pombe*; or *K. lactis*). Preferably, the host cells express the cDNAs at a level of about 5 fold higher, more preferably, 10 fold higher, even more preferably, 20 fold higher than that of the corresponding endogenous antibody or protein of interest, if present, in the host cells. Screening the host cells for a specific binding to CD70 is effected by an immunoassay or FACS. A cell overexpressing the antibody or protein of interest can be identified.

Methods of Using the CD70 Antibodies

The antibodies of the present invention are useful in various applications including, but are not limited to, therapeutic treatment methods and diagnostic treatment methods.

The antibodies (e.g., monospecific and bispecific) obtained by the methods described above can be used as a medicament. In some embodiments, such a medicament can be used for treating cancer. In some embodiments, the cancer is a cancer of hematopoietic origin, such as a lymphoma or leukemia. In some embodiments, the cancer is Renal Cell Carcinoma, Glioblastoma, glioma such as low grade glioma, Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD), Waldenstrom's macroglobulinemia, Acute Myeloid Leukemia, Multiple Myeloma, diffuse large-cell lymphoma, follicular lymphoma or Non-Small Cell Lung Cancer

In some embodiments, provided is a method of inhibiting tumor growth or progression in a subject who has malignant cells expressing CD70, comprising administering to the subject in need thereof an effective amount of a composition comprising the CD70 antibodies (e.g., CD70-CD3 bispecific antibodies) as described herein. In other embodiments, provided is a method of inhibiting metastasis of cells expressing CD70 in a subject, comprising administering to the subject in need thereof an effective amount of a composition comprising the CD70 antibodies (e.g., CD70-CD3 bispecific antibodies) as described herein. In other embodiments, provided is a method of inducing tumor regression in malignant cells in a subject, comprising administering to the subject in need thereof an effective amount of a composition comprising the CD70 antibodies (e.g., CD70-CD3 bispecific antibodies) as described herein.

In some embodiments, the antibody (e.g., CD70-CD3 bispecific antibody) according to the invention can be used in the manufacture of a medicament for treatment of a cancer in a patient in need thereof.

In some embodiments, the treatment can be in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, targeted therapy, vaccine therapy, dendritic cell

therapy, gene therapy, hormone therapy, surgical resection, laser light therapy and radiation therapy.

For example, in some embodiments, the CD70 antibodies (e.g., CD70-CD3 bispecific antibodies) of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) treatment with small molecule Tyrosine Kinase Inhibitors (TKIs) such as sunitinib and pazopanib that target Vascular Endothelial Growth Factor (VEGF) receptor, monoclonal antibody targeting VEGF such as bevacizumab, mammalian target of Rapamycin (mTOR) inhibitor temsirolimus, as well as high dose IL-2. In some embodiments, the CD70 antibodies (e.g., CD70-CD3 bispecific antibodies) of the present invention are administered to a patient in conjunction with one or more of the following: an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab, or PF-06801591), an anti-PD-L1 antibody (e.g., avelumab, atezolizumab, or durvalumab) an anti-OX40 antibody (e.g., PF-04518600), an anti-4-1 BB antibody (e.g., PF-05082566), an anti-MCSF antibody (e.g., PD-0360324), an anti-GITR antibody, or an anti-TIGIT antibody.

The administration of the antibodies (e.g., monospecific or bispecific) according to the invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intracranially, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the antibody compositions of the invention are preferably administered by intravenous injection.

In some embodiments, the administration of the antibodies (e.g., monospecific or bispecific) can comprise administration of, for example, about 0.01 to about 20 mg per kg body weight including all integer values of mg per kg within those ranges. In some embodiments, the administration of the antibodies can comprise administration of about 0.1 to 10 mg per kg body weight including all integer values of mg per kg within those ranges. The antibody can be administered in one or more doses. In some embodiments, said effective amount of the antibody can be administered as a single dose. In some embodiments, said effective amount of antibodies can be administered as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. While individual needs vary, determination of optimal ranges of effective amounts of a given antibody (e.g., monospecific or bispecific) for a particular disease or conditions within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. In some embodiments, an effective amount of heteromultimeric antibody or composition comprising those antibodies are administered parenterally. In some embodiments, administration can be an intravenous administration. In some embodiments, administration can be directly done by injection within a tumor.

In some embodiments, anti-CD70 antibodies provided herein may be used for diagnostic purposes, such in assays to identify CD70 protein in samples (e.g. in immunohistochemistry assays) or in patients.

65 Compositions

In one aspect, the present invention provides a pharmaceutical composition comprising an antibody (e.g., mono-

specific or bispecific) of the invention or portion thereof as described above in a pharmaceutically acceptable carrier. In certain embodiments, the polypeptides of the invention may be present in a neutral form (including zwitter ionic forms) or as a positively or negatively-charged species. In some 5 embodiments, the polypeptides may be complexed with a counterion to form a “pharmaceutically acceptable salt,” which refers to a complex comprising one or more polypeptides and one or more counterions, where the counterions are derived from pharmaceutically acceptable inorganic and organic acids and bases.

The antibody (e.g., monospecific or bispecific) or portions thereof, may be administered alone or in combination with one or more other polypeptides of the invention or in combination with one or more other drugs (or as any 10 combination thereof). The pharmaceutical compositions, methods and uses of the invention thus also encompass embodiments of combinations (co-administration) with other active agents, as detailed below.

As used herein, the terms “co-administration,” “co-administered” and “in combination with,” referring to the antibodies of the invention and one or more other therapeutic agents, is intended to mean, and does refer to and include the following: (i) simultaneous administration of such combination of an antibody disclosed herein and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components at substantially the same time to said patient; (ii) substantially simultaneous administration of such combination of an antibody disclosed herein and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at substantially the same time by said patient, whereupon said components are released at substantially the same time to said patient; (iii) sequential administration of such combination of an antibody disclosed herein and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at consecutive times by said patient with a significant time interval between each administration, whereupon said components are released at substantially different times to said patient; and (iv) sequential administration of such combination of an antibody disclosed herein and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner whereupon they are concurrently, consecutively, or overlappingly released at the same or different times to said patient, where each part may be administered by either the same or a different route.

Generally, the antibody (e.g., monospecific or bispecific) disclosed herein or portions thereof are suitable to be administered as a formulation in association with one or more pharmaceutically acceptable excipient(s). The term ‘excipient’ is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient(s) will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. As used herein, “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Some examples of pharmaceutically acceptable excipients are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as

combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Additional examples of pharmaceutically acceptable substances are wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody.

Pharmaceutical compositions of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington’s Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995). Pharmaceutical compositions are preferably manufactured under GMP conditions.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. Any method for administering peptides, proteins or antibodies accepted in the art may suitably be employed for the heterodimeric proteins and portions thereof disclosed herein.

The pharmaceutical compositions of the invention are typically suitable for parenteral administration. As used herein, “parenteral administration” of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue, thus generally resulting in the direct administration into the blood stream, into muscle, or into an internal organ. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intraperitoneal, intramuscular, intrasternal, intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intracranial, intrasynovial injection or infusions; and kidney dialytic infusion techniques. Preferred embodiments include the intravenous and the subcutaneous routes.

Formulations of a pharmaceutical composition suitable for parenteral administration typically generally comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and the like. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e. powder or granular) form for reconstitution with a suitable vehicle (e.g. sterile pyrogen free water) prior to parenteral administration of the reconstituted composition. Parenteral formulations also include aqueous solutions

which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water. Exemplary parenteral administration forms include solutions or suspensions in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, or in a liposomal preparation. Formulations for parenteral administration may be formulated to be immediate or modified release. Modified release formulations include controlled, delayed, sustained, pulsed, targeted and programmed release formulations. For example, in one aspect, sterile injectable solutions can be prepared by incorporating the heterodimeric protein, e.g., bispecific antibody, in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages for the patients/subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are generally dictated by and directly dependent on (a) the unique characteristics of the chemotherapeutic agent and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

Thus, the skilled artisan would appreciate, based upon the disclosure provided herein, that the dose and dosing regimen is adjusted in accordance with methods well-known in the therapeutic arts. That is, the maximum tolerable dose can be readily established, and the effective amount providing a detectable therapeutic benefit to a patient may also be determined, as can the temporal requirements for administering each agent to provide a detectable therapeutic benefit to the patient. Accordingly, while certain dose and administration regimens are exemplified herein, these examples in

no way limit the dose and administration regimen that may be provided to a patient in practicing the present invention.

It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. Further, the dosage regimen with the compositions of this invention may be based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular antibody employed. Thus, the dosage regimen can vary widely, but can be determined routinely using standard methods. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical effects such as toxic effects or laboratory values. Thus, the present invention encompasses intrapatient dose-escalation as determined by the skilled artisan. Determining appropriate dosages and regimens are well-known in the relevant art and would be understood to be encompassed by the skilled artisan once provided the teachings disclosed herein.

Generally, for administration of the antibodies described herein (monospecific or bispecific), the candidate dosage can be administered daily, every week, every other week, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every ten weeks, every twelve weeks, or more than every twelve weeks. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of symptoms occurs or until sufficient therapeutic levels are achieved, for example, to reduce symptoms associated with cancer. The progress of this therapy is easily monitored by conventional techniques and assays. The dosing regimen (including the anti-FLT monospecific or bispecific antibody used) can vary over time.

In some embodiments, the candidate dosage is administered daily with the dosage ranging from about any of 1 $\mu\text{g}/\text{kg}$ to 30 $\mu\text{g}/\text{kg}$ to 300 $\mu\text{g}/\text{kg}$ to 3 mg/kg, to 30 mg/kg, to 100 mg/kg or more, depending on the factors mentioned above. For example, daily dosage of about 0.01 mg/kg, about 0.03 mg/kg, about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, and about 25 mg/kg may be used.

In some embodiments, the candidate dosage is administered every week with the dosage ranging from about any of 1 $\mu\text{g}/\text{kg}$ to 30 $\mu\text{g}/\text{kg}$ to 300 $\mu\text{g}/\text{kg}$ to 3 mg/kg, to 30 mg/kg, to 100 mg/kg or more, depending on the factors mentioned above. For example, a weekly dosage of about 0.01 mg/kg, about 0.03 mg/kg, about 0.1 mg/kg, about 0.3 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 25 mg/kg, and about 30 mg/kg may be used.

In some embodiments, the candidate dosage is administered every two weeks with the dosage ranging from about any of 1 $\mu\text{g}/\text{kg}$ to 30 $\mu\text{g}/\text{kg}$ to 300 $\mu\text{g}/\text{kg}$ to 3 mg/kg, to 30 mg/kg, to 100 mg/kg or more, depending on the factors mentioned above. For example, a bi-weekly dosage of about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 2.5

mg/kg, about 3 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 25 mg/kg, and about 30 mg/kg may be used.

In some embodiments, the candidate dosage is administered every three weeks with the dosage ranging from about any of 1 $\mu\text{g}/\text{kg}$ to 30 $\mu\text{g}/\text{kg}$ to 300 $\mu\text{g}/\text{kg}$ to 3 mg/kg, to 30 mg/kg, to 100 mg/kg or more, depending on the factors mentioned above. For example, a tri-weekly dosage of about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, and about 50 mg/kg may be used.

In some embodiments, the candidate dosage is administered every month or every four weeks with the dosage ranging from about any of 1 $\mu\text{g}/\text{kg}$ to 30 $\mu\text{g}/\text{kg}$ to 300 $\mu\text{g}/\text{kg}$ to 3 mg/kg, to 30 mg/kg, to 100 mg/kg or more, depending on the factors mentioned above. For example, a monthly dosage of about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, and about 50 mg/kg may be used.

In other embodiments, the candidate dosage is administered daily with the dosage ranging from about 0.01 mg to about 1200 mg or more, depending on the factors mentioned above. For example, daily dosage of about 0.01 mg, about 0.1 mg, about 1 mg, about 10 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, or about 1200 mg may be used.

In other embodiments, the candidate dosage is administered every week with the dosage ranging from about 0.01 mg to about 2000 mg or more, depending on the factors mentioned above. For example, weekly dosage of about 0.01 mg, about 0.1 mg, about 1 mg, about 10 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, or about 2000 mg may be used.

In other embodiments, the candidate dosage is administered every two weeks with the dosage ranging from about 0.01 mg to about 2000 mg or more, depending on the factors mentioned above. For example, bi-weekly dosage of about 0.01 mg, about 0.1 mg, about 1 mg, about 10 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, or about 2000 mg may be used.

In other embodiments, the candidate dosage is administered every three weeks with the dosage ranging from about 0.01 mg to about 2500 mg or more, depending on the factors mentioned above. For example, tri-weekly dosage of about 0.01 mg, about 0.1 mg, about 1 mg, about 10 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg may be used.

In other embodiments, the candidate dosage is administered every four weeks or month with the dosage ranging from about 0.01 mg to about 3000 mg or more, depending on the factors mentioned above. For example, monthly dosage of about 0.01 mg, about 0.1 mg, about 1 mg, about 10 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, about 2500, about 2600 mg, about 2700 mg, about 2800 mg, about 2900 mg, or about 3000 mg may be used.

Kits

The invention also provides kits for use in the instant methods. Kits of the invention include one or more containers comprising the antibody (e.g., monospecific or bispecific) as described herein and instructions for use in accordance with any of the methods of the invention described herein. Generally, these instructions comprise a description of administration of the antibody protein for the above described therapeutic treatments.

The instructions relating to the use of the antibody (e.g., monospecific or bispecific) as described herein generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.

The kits of this invention are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Also contemplated are packages for use in combination with a specific device, such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump. A kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a bispecific antibody. The container may further comprise a second pharmaceutically active agent.

Kits may optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

-continued

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Thr Gln Phe Pro Leu Thr Ile Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 2
 <211> LENGTH: 118
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 2

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
 20 25 30
 Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
 65 70 75 80
 Met Glu Leu Ile Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Gly Ser Ser Ser Pro Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 3
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 3

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

-continued

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95

Thr Gln Phe Pro Leu Thr Ile Gly Gly Gly Ser Lys Val Glu Ile Lys
100 105 110

<210> SEQ ID NO 4
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Val Phe
65 70 75 80

Met Glu Leu Ile Ser Leu Arg Ser Glu Tyr Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Ser Ser Ser Pro Phe Ala Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> SEQ ID NO 5
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 5

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20 25 30

Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 6
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 6

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 20 25 30
 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60
 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80
 Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg Asp Ile Arg Thr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 100 105 110

<210> SEQ ID NO 7

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 7

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
 20 25 30
 Asp Glu Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
 35 40 45
 Leu Arg Arg Leu Ile Tyr Gln Val Ser Asn Arg Asp Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Met Gln Gly
 85 90 95
 Thr Tyr Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 8

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 8

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Ser
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Asn Ile Lys Arg Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val

-continued

115

<210> SEQ ID NO 11
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 11

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
          20           25           30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ile Leu Ile
          35           40           45
Tyr Gly Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Ala Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Phe Pro Ile
          85           90           95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
          100          105

```

<210> SEQ ID NO 12
 <211> LENGTH: 115
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 12

```

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu
1           5           10           15
Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Phe Thr Phe Thr Ser Tyr
          20           25           30
Ala Met Ser Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val
          35           40           45
Ser Ile Ile Ser Gly Val Ala Phe Thr Thr Tyr Tyr Ala Asp Ser Val
          50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp His Ser Lys Asn Thr Leu Tyr
65           70           75           80
Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Val Lys Val Asp Gly Glu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr
          100          105          110
Val Ser Ser
          115

```

<210> SEQ ID NO 13
 <211> LENGTH: 108
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 13

-continued

Glu Ile Val Met Thr Gln Ser Pro Asp Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Ile Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ser Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Asn Trp Pro Pro
 85 90 95
 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 14
 <211> LENGTH: 117
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 14

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ile Thr Tyr
 20 25 30
 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Ser
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Gln Trp Glu Leu Phe Phe Phe Asp Phe Trp Gly Gln Gly Thr Pro
 100 105 110
 Val Thr Val Ser Ser
 115

<210> SEQ ID NO 15
 <211> LENGTH: 108
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 15

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Gln Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60

-continued

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 16
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 16

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Tyr Tyr
20 25 30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser His Ile Ser Ile Arg Ser Ser Thr Ile Tyr Phe Ala Asp Ser Ala
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Ser Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 17
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 17

Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Leu Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Leu Asn Ser Phe Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Asn
100 105

<210> SEQ ID NO 18

-continued

<211> LENGTH: 123
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 18

Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala
 20 25 30
 Arg Met Gly Val Thr Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Ser Thr Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Thr Gln Val
 65 70 75 80
 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ile Arg Asp Tyr Tyr Asp Ile Ser Ser Tyr Tyr Asp Tyr
 100 105 110
 Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ser
 115 120

<210> SEQ ID NO 19
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 19

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Phe Ser Phe Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> SEQ ID NO 20
 <211> LENGTH: 119
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 20

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

-continued

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Asn His
 20 25 30

Asn Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Ser Tyr Ile Ser Arg Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Asp His Ala Gln Trp Tyr Gly Met Asp Val Trp Gly Gln Gly
 100 105 110

Thr Thr Val Thr Val Ser Ser
 115

<210> SEQ ID NO 21
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 21

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
 20 25 30

Tyr Asn Asn Lys Asn Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45

Pro Pro Asn Leu Leu Ile Phe Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Tyr Tyr Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 22
 <211> LENGTH: 124
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 22

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Val Tyr
 65 70 75 80

-continued

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Val Asn Trp Gly Trp Arg Leu Tyr Trp His Phe Asp
100 105 110

Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 23

<211> LENGTH: 108

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 23

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95

Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 24

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 24

Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser His Ser Ser Ile Ser Arg Gly Asn Ile Tyr Phe Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Ser Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 25

<211> LENGTH: 112

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 25

Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
 1 5 10 15
 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly
 20 25 30
 Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys
 35 40 45
 Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg
 50 55 60
 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly
 65 70 75 80
 Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp
 85 90 95
 Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 26
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 26

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Asn Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Arg Gly Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Phe Ile Ser Gly Thr Trp Tyr Pro Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 27
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 27

Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
 1 5 10 15
 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly

-continued

20	25	30	
Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys			
35	40	45	
Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg			
50	55	60	
Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly			
65	70	75	80
Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Gly			
85	90	95	
Ser Leu Ser Ala Val Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu			
100	105	110	

<210> SEQ ID NO 28
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 28

1	5	10	15
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu			
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr			
20	25	30	
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met			
35	40	45	
Gly Ser Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe			
50	55	60	
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr			
65	70	75	80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys			
85	90	95	
Ala Ser Ser Thr Val Asp Tyr Pro Gly Tyr Ser Tyr Phe Asp Tyr Trp			
100	105	110	
Gly Gln Gly Thr Leu Val Thr Val Ser Ser			
115	120		

<210> SEQ ID NO 29
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 29

1	5	10	15
Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro			
Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly			
20	25	30	
Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys			
35	40	45	
Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg			
50	55	60	
Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly			
65	70	75	80
Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp			

-continued

85	90	95
Ser Leu Gly Ser Pro Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu		
100	105	110

<210> SEQ ID NO 30
 <211> LENGTH: 123
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 30

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu		
1	5	10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asn Tyr		
20	25	30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met		
35	40	45
Gly Ile Ile Tyr Pro Asp Gly Ser Asp Thr Arg Tyr Ser Pro Ser Phe		
50	55	60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr		
65	70	75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys		
85	90	95
Ala Arg Asp Ile Thr Ser Trp Tyr Tyr Gly Glu Pro Ala Phe Asp Ile		
100	105	110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser		
115	120	

<210> SEQ ID NO 31
 <211> LENGTH: 110
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 31

Glu Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser		
1	5	10 15
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser		
20	25	30
Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu		
35	40	45
Leu Ile Tyr Ala Ala Ser Ile Leu Gln Thr Gly Val Pro Ser Arg Phe		
50	55	60
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu		
65	70	75 80
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr		
85	90	95
Thr Met Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys		
100	105	110

<210> SEQ ID NO 32
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

polypeptide

<400> SEQUENCE: 32

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Ser
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Lys Gly Leu Ser Gln Ala Met Thr Gly Phe Gly Phe Asp Tyr Trp
 100 105 110
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 33

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 33

Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
 1 5 10 15
 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly
 20 25 30
 Ser Asn Tyr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys
 35 40 45
 Leu Leu Ile Tyr Gly Asp Tyr Gln Arg Pro Ser Gly Val Pro Asp Arg
 50 55 60
 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly
 65 70 75 80
 Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Arg Asp Asp
 85 90 95
 Ser Leu Ser Gly Ser Val Val Phe Gly Thr Gly Thr Lys Leu Thr Val
 100 105 110
 Leu

<210> SEQ ID NO 34

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 34

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Thr Ser Tyr
 20 25 30

-continued

Ala Arg Ala Ser Tyr Phe Asp Arg Gly Thr Gly Tyr Ser Ser Trp Trp
 100 105 110

Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 37
 <211> LENGTH: 110
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 37

Glu Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
 1 5 10 15

Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly
 20 25 30

Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Arg Gly Lys Ala Pro Lys Leu
 35 40 45

Leu Ile His Gly Ala Thr Ser Leu Ala Ser Gly Val Pro Ser Arg Phe
 50 55 60

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
 65 70 75 80

Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
 85 90 95

Thr Ser Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 38
 <211> LENGTH: 123
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 38

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gln Tyr
 20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Gly Gly Val Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Ser Asp Ile Ser Asp Ser Gly Gly Ser His Trp Tyr Phe Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 39
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 39

Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
 1 5 10 15
 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly
 20 25 30
 Arg Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys
 35 40 45
 Leu Leu Ile Tyr Arg Thr Asn Gln Arg Pro Ser Gly Val Pro Asp Arg
 50 55 60
 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly
 65 70 75 80
 Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp
 85 90 95
 Ser Leu Ser Gly Arg Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 40

<211> LENGTH: 121

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 40

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Gly Thr Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Val Arg Ala Gly Ile Asp Pro Thr Ala Ser Asp Val Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 41

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 41

Glu Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
 1 5 10 15
 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly
 20 25 30
 Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys

-continued

100 105 110

Leu

<210> SEQ ID NO 44
 <211> LENGTH: 119
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 44

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
 20 25 30
 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Glu Ile Ile Pro Ile Phe Gly Thr Ala Ser Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ala Gly Trp Asp Asp Ser Trp Phe Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 45
 <211> LENGTH: 110
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 45

Glu Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
 1 5 10 15
 Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp
 20 25 30
 Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
 35 40 45
 Leu Ile Tyr Ser Ala Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe
 50 55 60
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
 65 70 75 80
 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
 85 90 95
 Thr Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 46
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

-continued

<400> SEQUENCE: 46

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ala Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Val Ile Tyr Pro Gly Thr Ser Glu Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Lys Gly Leu Ser Ala Ser Ala Ser Gly Tyr Ser Phe Gln Tyr Trp
 100 105 110
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 47

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 47

Glu Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
 1 5 10 15
 Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly
 20 25 30
 Gln Ser Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
 35 40 45
 Leu Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe
 50 55 60
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
 65 70 75 80
 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
 85 90 95
 Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 48

<211> LENGTH: 124

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 48

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45

-continued

Gly Met Ile Ser Pro Gly Gly Ser Thr Thr Ile Tyr Arg Pro Ser Phe
 50 55 60

Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80

Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95

Ala Arg Glu Met Tyr Thr Gly Gly Tyr Gly Gly Ser Trp Tyr Phe Asp
 100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 49
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 49

Ser Tyr Gly Phe Ser
 1 5

<210> SEQ ID NO 50
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 50

Gly Gly Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 51
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 51

Gly Gly Thr Phe Ser Ser Tyr Gly Phe Ser
 1 5 10

<210> SEQ ID NO 52
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 52

Gly Ile Ile Pro Ile Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 53
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 53

Ile Pro Ile Phe Gly Ser
1 5

<210> SEQ ID NO 54

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 54

Gly Gly Ser Ser Ser Pro Phe Ala Tyr
1 5

<210> SEQ ID NO 55

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 55

Ser Tyr Gly Phe Ser
1 5

<210> SEQ ID NO 56

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 56

Gly Gly Thr Phe Ser Ser Tyr
1 5

<210> SEQ ID NO 57

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 57

Gly Gly Thr Phe Ser Ser Tyr Gly Phe Ser
1 5 10

<210> SEQ ID NO 58

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 58

Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15

Gly

-continued

<210> SEQ ID NO 59
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 59

Ile Pro Ile Phe Gly Thr
1 5

<210> SEQ ID NO 60
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 60

Gly Gly Ser Ser Ser Pro Phe Ala Tyr
1 5

<210> SEQ ID NO 61
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 61

Ser Tyr Tyr Trp Asn
1 5

<210> SEQ ID NO 62
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 62

Gly Gly Ser Ile Ser Ser Tyr
1 5

<210> SEQ ID NO 63
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 63

Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Asn
1 5 10

<210> SEQ ID NO 64
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 64

Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> SEQ ID NO 65

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 65

Tyr Tyr Ser Gly Ser
1 5

<210> SEQ ID NO 66

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 66

Asp Ile Arg Thr Trp
1 5

<210> SEQ ID NO 67

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 67

Asn Ser Trp Met Ser
1 5

<210> SEQ ID NO 68

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 68

Gly Phe Thr Phe Arg Asn Ser
1 5

<210> SEQ ID NO 69

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 69

Gly Phe Thr Phe Arg Asn Ser Trp Met Ser
1 5 10

<210> SEQ ID NO 70

<211> LENGTH: 17

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 70

Asn Ile Lys Arg Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 71
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 71

Lys Arg Asp Gly Ser Glu
 1 5

<210> SEQ ID NO 72
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 72

Asp Gln Thr Gly Ser Phe Asp Tyr
 1 5

<210> SEQ ID NO 73
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 73

Val Tyr Tyr Trp Ser
 1 5

<210> SEQ ID NO 74
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 74

Asp Asp Ser Ile Ser Val Tyr
 1 5

<210> SEQ ID NO 75
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 75

-continued

Asp Asp Ser Ile Ser Val Tyr Tyr Trp Ser
1 5 10

<210> SEQ ID NO 76
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 76

Val Tyr Ser Ser Gly Asn Ile Asn Tyr Asn Pro Ser Leu Glu Ser
1 5 10 15

<210> SEQ ID NO 77
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 77

Tyr Ser Ser Gly Asn
1 5

<210> SEQ ID NO 78
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 78

Gly Leu Asp Ala Phe Asp Ile
1 5

<210> SEQ ID NO 79
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 79

Ser Tyr Ala Met Ser
1 5

<210> SEQ ID NO 80
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 80

Gly Phe Thr Phe Thr Ser Tyr
1 5

<210> SEQ ID NO 81
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 81

Gly Phe Thr Phe Thr Ser Tyr Ala Met Ser
 1 5 10

<210> SEQ ID NO 82
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 82

Arg Val Tyr Ser Ser Gly Asn Ile Asn Tyr Asn Pro Ser Leu Glu Ser
 1 5 10 15

<210> SEQ ID NO 83
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 83

Tyr Ser Ser Gly Asn
 1 5

<210> SEQ ID NO 84
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 84

Gly Leu Asp Ala Phe Asp Ile
 1 5

<210> SEQ ID NO 85
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 85

Thr Tyr Ala Ile Ser
 1 5

<210> SEQ ID NO 86
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 86

Gly Gly Thr Phe Ile Thr Tyr
 1 5

-continued

<210> SEQ ID NO 87
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 87

Gly Gly Thr Phe Ile Thr Tyr Ala Ile Ser
 1 5 10

<210> SEQ ID NO 88
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 88

Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 89
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 89

Ile Pro Phe Phe Gly Thr
 1 5

<210> SEQ ID NO 90
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 90

Trp Glu Leu Phe Phe Phe Asp Phe
 1 5

<210> SEQ ID NO 91
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 91

Tyr Tyr Ser Met Asn
 1 5

<210> SEQ ID NO 92
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 92

Gly Phe Thr Phe Thr Tyr Tyr
 1 5

<210> SEQ ID NO 93

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 93

Gly Phe Thr Phe Thr Tyr Tyr Ser Met Asn
 1 5 10

<210> SEQ ID NO 94

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 94

His Ile Ser Ile Arg Ser Ser Thr Ile Tyr Phe Ala Asp Ser Ala Lys
 1 5 10 15

Gly

<210> SEQ ID NO 95

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 95

Ser Ile Arg Ser Ser Thr
 1 5

<210> SEQ ID NO 96

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 96

Gly Ser Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 97

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 97

Asn Ala Arg Met Gly Val Thr
 1 5

-continued

<210> SEQ ID NO 98
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 98

Gly Phe Ser Leu Ser Asn Ala Arg Met
 1 5

<210> SEQ ID NO 99
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 99

Gly Phe Ser Leu Ser Asn Ala Arg Met Gly Val Thr
 1 5 10

<210> SEQ ID NO 100
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 100

His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Ser Thr Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 101
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 101

Phe Ser Asn Asp Glu
 1 5

<210> SEQ ID NO 102
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 102

Ile Arg Asp Tyr Tyr Asp Ile Ser Ser Tyr Tyr Asp Tyr
 1 5 10

<210> SEQ ID NO 103
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 103

Asn His Asn Ile His
 1 5

<210> SEQ ID NO 104

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 104

Gly Phe Thr Phe Ser Asn His
 1 5

<210> SEQ ID NO 105

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 105

Gly Phe Thr Phe Ser Asn His Asn Ile His
 1 5 10

<210> SEQ ID NO 106

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 106

Tyr Ile Ser Arg Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 107

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 107

Ser Arg Ser Ser Ser Thr
 1 5

<210> SEQ ID NO 108

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 108

Asp His Ala Gln Trp Tyr Gly Met Asp Val
 1 5 10

<210> SEQ ID NO 109

-continued

<211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 109

Ser Tyr Trp Met Ser
 1 5

<210> SEQ ID NO 110
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 110

Gly Phe Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 111
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 111

Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
 1 5 10

<210> SEQ ID NO 112
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 112

Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 113
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 113

Lys Gln Asp Gly Ser Glu
 1 5

<210> SEQ ID NO 114
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 114

Glu Gly Val Asn Trp Gly Trp Arg Leu Tyr Trp His Phe Asp Leu
 1 5 10 15

<210> SEQ ID NO 115

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 115

Ser Tyr Ser Met Asn
 1 5

<210> SEQ ID NO 116

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 116

Gly Phe Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 117

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 117

Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn
 1 5 10

<210> SEQ ID NO 118

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 118

His Ser Ser Ile Ser Arg Gly Asn Ile Tyr Phe Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 119

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 119

Ser Ile Ser Arg Gly Asn
 1 5

<210> SEQ ID NO 120

-continued

<211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 120

Gly Ser Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 121
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 121

Asn Tyr Ala Met Ser
 1 5

<210> SEQ ID NO 122
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 122

Gly Phe Ala Phe Ser Asn Tyr
 1 5

<210> SEQ ID NO 123
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 123

Gly Phe Ala Phe Ser Asn Tyr Ala Met Ser
 1 5 10

<210> SEQ ID NO 124
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 124

Ala Ile Arg Gly Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 125
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 125

Arg Gly Gly Gly Gly Ser
 1 5

<210> SEQ ID NO 126

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 126

Asp Phe Ile Ser Gly Thr Trp Tyr Pro Asp Tyr
 1 5 10

<210> SEQ ID NO 127

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 127

Ser Tyr Trp Ile Gly
 1 5

<210> SEQ ID NO 128

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 128

Gly Tyr Arg Phe Thr Ser Tyr
 1 5

<210> SEQ ID NO 129

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 129

Gly Tyr Arg Phe Thr Ser Tyr Trp Ile Gly
 1 5 10

<210> SEQ ID NO 130

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 130

Ser Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 131

-continued

<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 131

Tyr Pro Asp Asp Ser Asp
1 5

<210> SEQ ID NO 132
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 132

Ser Thr Val Asp Tyr Pro Gly Tyr Ser Tyr Phe Asp Tyr
1 5 10

<210> SEQ ID NO 133
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 133

Asn Tyr Trp Ile Ala
1 5

<210> SEQ ID NO 134
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 134

Gly Tyr Thr Phe Thr Asn Tyr
1 5

<210> SEQ ID NO 135
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 135

Gly Tyr Thr Phe Thr Asn Tyr Trp Ile Ala
1 5 10

<210> SEQ ID NO 136
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 136

-continued

Ile Ile Tyr Pro Asp Gly Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15

Gly

<210> SEQ ID NO 137
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 <400> SEQUENCE: 137

Tyr Pro Asp Gly Ser Asp
1 5

<210> SEQ ID NO 138
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 <400> SEQUENCE: 138

Asp Ile Thr Ser Trp Tyr Tyr Gly Glu Pro Ala Phe Asp Ile
1 5 10

<210> SEQ ID NO 139
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 <400> SEQUENCE: 139

Ser Ser Trp Ile Gly
1 5

<210> SEQ ID NO 140
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 <400> SEQUENCE: 140

Gly Tyr Ser Phe Thr Ser Ser
1 5

<210> SEQ ID NO 141
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 <400> SEQUENCE: 141

Gly Tyr Ser Phe Thr Ser Ser Trp Ile Gly
1 5 10

<210> SEQ ID NO 142
 <211> LENGTH: 17
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 142

Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 143
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 143

Tyr Pro Gly Asp Ser Asp
 1 5

<210> SEQ ID NO 144
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 144

Gly Leu Ser Gln Ala Met Thr Gly Phe Gly Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 145
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 145

Ser Tyr Trp Ile Gly
 1 5

<210> SEQ ID NO 146
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 146

Gly Tyr Gly Phe Thr Ser Tyr
 1 5

<210> SEQ ID NO 147
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 147

-continued

Gly Tyr Gly Phe Thr Ser Tyr Trp Ile Gly
1 5 10

<210> SEQ ID NO 148
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 148

Ile Ile His Pro Asp Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe Gln
1 5 10 15

Gly

<210> SEQ ID NO 149
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 149

His Pro Asp Asp Ser Asp
1 5

<210> SEQ ID NO 150
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 150

Ser Tyr Leu Arg Gly Leu Trp Gly Gly Tyr Phe Asp Tyr
1 5 10

<210> SEQ ID NO 151
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 151

Ser Ser Trp Ile Gly
1 5

<210> SEQ ID NO 152
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 152

Gly Tyr Thr Phe Pro Ser Ser
1 5

<210> SEQ ID NO 153
<211> LENGTH: 10
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 153

Gly Tyr Thr Phe Pro Ser Ser Trp Ile Gly
 1 5 10

<210> SEQ ID NO 154
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 154

Ile Ile Tyr Pro Asp Thr Ser His Thr Arg Tyr Ser Pro Ser Phe Gln
 1 5 10 15

<210> SEQ ID NO 155
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 155

Tyr Pro Asp Thr Ser His
 1 5

<210> SEQ ID NO 156
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 156

Ala Ser Tyr Phe Asp Arg Gly Thr Gly Tyr Ser Ser Trp Trp Met Asp
 1 5 10 15

Val

<210> SEQ ID NO 157
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 157

Gln Tyr Ser Met Ser
 1 5

<210> SEQ ID NO 158
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 158

-continued

Gly Phe Thr Phe Ser Gln Tyr
1 5

<210> SEQ ID NO 159
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 159

Gly Phe Thr Phe Ser Gln Tyr Ser Met Ser
1 5 10

<210> SEQ ID NO 160
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 160

Ala Ile Ser Gly Gly Gly Val Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 161
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 161

Ser Gly Gly Gly Val Ser
1 5

<210> SEQ ID NO 162
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 162

Asp Ile Ser Asp Ser Gly Gly Ser His Trp Tyr Phe Asp Tyr
1 5 10

<210> SEQ ID NO 163
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 163

Ser Tyr Ala Met Ser
1 5

<210> SEQ ID NO 164
<211> LENGTH: 7
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 164

Gly Phe Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 165
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 165

Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
 1 5 10

<210> SEQ ID NO 166
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 166

Thr Ile Ser Gly Thr Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 167
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 167

Ser Gly Thr Gly Gly Thr
 1 5

<210> SEQ ID NO 168
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 168

Val Arg Ala Gly Ile Asp Pro Thr Ala Ser Asp Val
 1 5 10

<210> SEQ ID NO 169
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 169

-continued

Asn Phe Ala Met Ser
1 5

<210> SEQ ID NO 170
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 170

Gly Phe Thr Phe Asn Asn Phe
1 5

<210> SEQ ID NO 171
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 171

Gly Phe Thr Phe Asn Asn Phe Ala Met Ser
1 5 10

<210> SEQ ID NO 172
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 172

Gly Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 173
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 173

Ser Gly Ser Gly Asp Asn
1 5

<210> SEQ ID NO 174
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 174

Asp Arg Asp Ile Gly Leu Gly Trp Tyr Ser Tyr Tyr Leu Asp Val
1 5 10 15

<210> SEQ ID NO 175
<211> LENGTH: 5
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 175

Ser Tyr Ala Ile Ser
 1 5

<210> SEQ ID NO 176
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 176

Gly Gly Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 177
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 177

Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser
 1 5 10

<210> SEQ ID NO 178
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 178

Glu Ile Ile Pro Ile Phe Gly Thr Ala Ser Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 179
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 179

Ile Pro Ile Phe Gly Thr
 1 5

<210> SEQ ID NO 180
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 180

-continued

Ala Gly Trp Asp Asp Ser Trp Phe Asp Tyr
1 5 10

<210> SEQ ID NO 181
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 181

Ser Tyr Trp Ile Gly
1 5

<210> SEQ ID NO 182
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 182

Gly Tyr Ser Phe Ala Ser Tyr
1 5

<210> SEQ ID NO 183
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 183

Gly Tyr Ser Phe Ala Ser Tyr Trp Ile Gly
1 5 10

<210> SEQ ID NO 184
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 184

Val Ile Tyr Pro Gly Thr Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15

Gly

<210> SEQ ID NO 185
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 185

Tyr Pro Gly Thr Ser Glu
1 5

<210> SEQ ID NO 186
<211> LENGTH: 13
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 186

Gly Leu Ser Ala Ser Ala Ser Gly Tyr Ser Phe Gln Tyr
 1 5 10

<210> SEQ ID NO 187
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 187

Asp Tyr Trp Ile Gly
 1 5

<210> SEQ ID NO 188
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 188

Gly Tyr Ser Phe Thr Asp Tyr
 1 5

<210> SEQ ID NO 189
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 189

Gly Tyr Ser Phe Thr Asp Tyr Trp Ile Gly
 1 5 10

<210> SEQ ID NO 190
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 190

Met Ile Ser Pro Gly Gly Ser Thr Thr Ile Tyr Arg Pro Ser Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 191
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 191

-continued

Ser Pro Gly Gly Ser Thr
1 5

<210> SEQ ID NO 192
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 192

Met Tyr Thr Gly Gly Tyr Gly Gly Ser Trp Tyr Phe Asp Tyr
1 5 10

<210> SEQ ID NO 193
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 193

Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser
1 5 10 15

<210> SEQ ID NO 194
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 194

Lys Ile Ser Asn Arg Phe Ser
1 5

<210> SEQ ID NO 195
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 195

Met Gln Ala Thr Gln Phe Pro Leu Thr
1 5

<210> SEQ ID NO 196
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 196

Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser
1 5 10 15

<210> SEQ ID NO 197
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 197

Lys Ile Ser Asn Arg Phe Ser
1 5

<210> SEQ ID NO 198

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 198

Met Gln Ala Thr Gln Phe Pro Leu Thr
1 5

<210> SEQ ID NO 199

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 199

Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala
1 5 10

<210> SEQ ID NO 200

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 200

Ala Ala Ser Ser Leu Gln Ser
1 5

<210> SEQ ID NO 201

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 201

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr
1 5

<210> SEQ ID NO 202

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 202

Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Glu Asn Thr Tyr Leu Asn
1 5 10 15

-continued

<210> SEQ ID NO 203
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 203

Gln Val Ser Asn Arg Asp Ser
1 5

<210> SEQ ID NO 204
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 204

Met Gln Gly Thr Tyr Trp Pro Pro Thr
1 5

<210> SEQ ID NO 205
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 205

Arg Ala Ser Gln Ser Val Ser Ser Ser Leu Ala
1 5 10

<210> SEQ ID NO 206
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 206

Gly Ala Ser Thr Arg Ala Thr
1 5

<210> SEQ ID NO 207
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 207

Gln Gln Tyr Ile Asn Trp Pro His
1 5

<210> SEQ ID NO 208
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 208

-continued

Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> SEQ ID NO 209
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 209

Gly Ala Ser Asn Leu Glu Thr
1 5

<210> SEQ ID NO 210
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 210

Gln Gln Tyr Asp Asn Phe Pro Ile Thr
1 5

<210> SEQ ID NO 211
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 211

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10

<210> SEQ ID NO 212
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 212

Ser Ala Ser Thr Arg Ala Ser
1 5

<210> SEQ ID NO 213
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 213

Gln Gln Tyr Asp Asn Trp Pro Pro Leu Thr
1 5 10

<210> SEQ ID NO 214
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 214

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
 1 5 10

<210> SEQ ID NO 215
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 215

Gly Ala Ser Ser Arg Ala Thr
 1 5

<210> SEQ ID NO 216
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 216

Gln Gln Tyr Gly Ser Ser Pro Leu Thr
 1 5

<210> SEQ ID NO 217
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 217

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Ala
 1 5 10

<210> SEQ ID NO 218
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 218

Ala Ala Ser Ser Leu Gln Ser
 1 5

<210> SEQ ID NO 219
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 219

Leu Gln Leu Asn Ser Phe Pro Phe Thr
 1 5

-continued

<210> SEQ ID NO 220
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 220

Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
 1 5 10

<210> SEQ ID NO 221
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 221

Ala Ala Ser Ser Leu Gln Ser
 1 5

<210> SEQ ID NO 222
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 222

Gln Gln Ala Phe Ser Phe Pro Phe Thr
 1 5

<210> SEQ ID NO 223
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 223

Lys Ser Ser Gln Ser Val Leu Tyr Ser Tyr Asn Asn Lys Asn Tyr Val
 1 5 10 15

Ala

<210> SEQ ID NO 224
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 224

Trp Ala Ser Thr Arg Glu Ser
 1 5

<210> SEQ ID NO 225
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 225

Gln Gln Tyr Tyr Ser Thr Leu Thr
 1 5

<210> SEQ ID NO 226

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 226

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
 1 5 10

<210> SEQ ID NO 227

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 227

Asp Ala Ser Ser Arg Ala Thr
 1 5

<210> SEQ ID NO 228

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 228

Gln Gln Tyr Gly Ser Ser Pro Leu Thr
 1 5

<210> SEQ ID NO 229

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 229

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
 1 5 10

<210> SEQ ID NO 230

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 230

Arg Asn Asn Gln Arg Pro Ser
 1 5

<210> SEQ ID NO 231

-continued

<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 231

Ala Ala Trp Asp Asp Ser Leu Ser Gly Val Val
1 5 10

<210> SEQ ID NO 232
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 232

Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10

<210> SEQ ID NO 233
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 233

Arg Asn Asn Gln Arg Pro Ser
1 5

<210> SEQ ID NO 234
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 234

Ala Ser Trp Asp Gly Ser Leu Ser Ala Val Val
1 5 10

<210> SEQ ID NO 235
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 235

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10

<210> SEQ ID NO 236
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 236

-continued

Arg Asn Asn Gln Arg Pro Ser
1 5

<210> SEQ ID NO 237
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 237

Ala Thr Trp Asp Asp Ser Leu Gly Ser Pro Val
1 5 10

<210> SEQ ID NO 238
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 238

Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn
1 5 10

<210> SEQ ID NO 239
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 239

Ala Ala Ser Ile Leu Gln Thr
1 5

<210> SEQ ID NO 240
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 240

Gln Gln Ser Tyr Ser Thr Thr Met Trp Thr
1 5 10

<210> SEQ ID NO 241
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 241

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Asn
1 5 10

<210> SEQ ID NO 242
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 242

Gly Asp Tyr Gln Arg Pro Ser
1 5

<210> SEQ ID NO 243

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 243

Ala Thr Arg Asp Asp Ser Leu Ser Gly Ser Val Val
1 5 10

<210> SEQ ID NO 244

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 244

Arg Ala Ser Gln Ser Ile Tyr Asp Tyr Leu His
1 5 10

<210> SEQ ID NO 245

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 245

Asp Ala Ser Asn Leu Gln Ser
1 5

<210> SEQ ID NO 246

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 246

Gln Gln Ser Tyr Thr Thr Pro Leu Phe Thr
1 5 10

<210> SEQ ID NO 247

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 247

Arg Ala Ser Gln Tyr Ile Gly Arg Tyr Leu Asn
1 5 10

-continued

<210> SEQ ID NO 248
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 248

Gly Ala Thr Ser Leu Ala Ser
1 5

<210> SEQ ID NO 249
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 249

Gln Gln Ser Tyr Ser Thr Thr Ser Pro Thr
1 5 10

<210> SEQ ID NO 250
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 250

Ser Gly Ser Thr Ser Asn Ile Gly Arg Asn Tyr Val Tyr
1 5 10

<210> SEQ ID NO 251
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 251

Arg Thr Asn Gln Arg Pro Ser
1 5

<210> SEQ ID NO 252
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 252

Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val
1 5 10

<210> SEQ ID NO 253
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 253

-continued

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10

<210> SEQ ID NO 254
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 254

Met Asn Asn Gln Arg Pro Ser
1 5

<210> SEQ ID NO 255
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 255

Ala Ala Trp Asp Asp Ser Leu Ser Ala Val Val
1 5 10

<210> SEQ ID NO 256
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 256

Ser Gly Ser Asn Ser Asn Ile Gly Thr Asn Tyr Val Ser
1 5 10

<210> SEQ ID NO 257
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 257

Arg Ser Ser Arg Arg Pro Ser
1 5

<210> SEQ ID NO 258
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 258

Ala Ala Trp Asp Gly Ser Leu Ser Gly His Trp Val
1 5 10

<210> SEQ ID NO 259
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 259

Arg Ala Ser Gln Ser Ile Asp Thr Tyr Leu Asn
 1 5 10

<210> SEQ ID NO 260
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 260

Ser Ala Ser Ser Leu His Ser
 1 5

<210> SEQ ID NO 261
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 261

Gln Gln Ser Tyr Ser Thr Thr Ala Trp Thr
 1 5 10

<210> SEQ ID NO 262
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 262

Arg Ala Ser Gln Ser Ile Gly Gln Ser Leu Asn
 1 5 10

<210> SEQ ID NO 263
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 263

Gly Ala Ser Ser Leu Gln Ser
 1 5

<210> SEQ ID NO 264
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 264

Gln Gln Ser Tyr Ser Thr Pro Ile Thr
 1 5

-continued

<210> SEQ ID NO 265
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 265

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15
 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Phe Asn Val
 20 25 30
 Arg Ser Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45
 Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80
 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln
 85 90 95
 Ser Tyr Asp Leu Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> SEQ ID NO 266
 <211> LENGTH: 121
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 266

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30
 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Phe Ile Arg Asn Arg Ala Arg Gly Tyr Thr Ser Asp His Asn Pro
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Ala Arg Asp Arg Pro Ser Tyr Tyr Val Leu Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 267
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 267

Ser Asp Tyr Tyr Met Thr

-continued

1

5

<210> SEQ ID NO 268
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 268

Gly Phe Thr Phe Ser Asp Tyr
 1 5

<210> SEQ ID NO 269
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 269

Gly Phe Thr Phe Ser Asp Tyr Tyr Met Thr
 1 5 10

<210> SEQ ID NO 270
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 270

Arg Asn Arg Ala Arg Gly Tyr Thr
 1 5

<210> SEQ ID NO 271
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 271

Phe Ile Arg Asn Arg Ala Arg Gly Tyr Thr Ser Asp His Asn Pro Ser
 1 5 10 15

Val Lys Gly

<210> SEQ ID NO 272
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 272

Asp Arg Pro Ser Tyr Tyr Val Leu Asp Tyr
 1 5 10

<210> SEQ ID NO 273
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 273

Lys Ser Ser Gln Ser Leu Phe Asn Val Arg Ser Arg Lys Asn Tyr Leu
1 5 10 15

Ala

<210> SEQ ID NO 274

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 274

Trp Ala Ser Thr Arg Glu Ser
1 5

<210> SEQ ID NO 275

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 275

Lys Gln Ser Tyr Asp Leu Phe Thr
1 5

<210> SEQ ID NO 276

<211> LENGTH: 336

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 276

gacattgtga tgactcaatc ccccgactcc ctggctgtgt ccctcggcga acgcgcaact 60
atcaactgta aaagcagcca gtccctgttc aacgtccggt cgaggaagaa ctacctggcc 120
tggtatcagc agaaacctgg gcagccgccg aagcttctga tctcatgggc ctcaactcgg 180
gaaagcggag tgccagatag attctccgga tctggctccg gaaccgactt caccctgacg 240
atttcgagct tgcaagcggg ggatgtggcc gtgtactact gcaagcagtc ctacgacctc 300
ttcacctttg gttcgggcac caagctggag atcaaaa 336

<210> SEQ ID NO 277

<211> LENGTH: 363

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 277

gaagtccaac ttgtcgaatc gggaggaggg cttgtgcaac ccggtggatc cctgaggctg 60
tcatgcgcgg cctcgggctt caccttttcc gattactaca tgacctgggt cagacaggcc 120
cctggaaagg ggttggaatg ggtggcattc atccggaata gagcccgcgg atacacttcc 180

-continued

```

gaccacaacc ccagcgtgaa ggggcgggttc accattagcc gcgacaacgc caagaactcc 240
ctctacctcc aaatgaacag cctgcggggcg gaggataccg ctgtgtacta ctgcgcccgc 300
gaccggccgt cctactatgt gctggactac tggggccagg gtactacggt caccgtctcc 360
tca 363

```

```

<210> SEQ ID NO 278
<211> LENGTH: 193
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 278

```

```

Met Pro Glu Glu Gly Ser Gly Cys Ser Val Arg Arg Arg Pro Tyr Gly
1           5           10           15
Cys Val Leu Arg Ala Ala Leu Val Pro Leu Val Ala Gly Leu Val Ile
          20           25           30
Cys Leu Val Val Cys Ile Gln Arg Phe Ala Gln Ala Gln Gln Gln Leu
          35           40           45
Pro Leu Glu Ser Leu Gly Trp Asp Val Ala Glu Leu Gln Leu Asn His
          50           55           60
Thr Gly Pro Gln Gln Asp Pro Arg Leu Tyr Trp Gln Gly Gly Pro Ala
65           70           75           80
Leu Gly Arg Ser Phe Leu His Gly Pro Glu Leu Asp Lys Gly Gln Leu
          85           90           95
Arg Ile His Arg Asp Gly Ile Tyr Met Val His Ile Gln Val Thr Leu
          100          105          110
Ala Ile Cys Ser Ser Thr Thr Ala Ser Arg His His Pro Thr Thr Leu
          115          120          125
Ala Val Gly Ile Cys Ser Pro Ala Ser Arg Ser Ile Ser Leu Leu Arg
          130          135          140
Leu Ser Phe His Gln Gly Cys Thr Ile Ala Ser Gln Arg Leu Thr Pro
145          150          155          160
Leu Ala Arg Gly Asp Thr Leu Cys Thr Asn Leu Thr Gly Thr Leu Leu
          165          170          175
Pro Ser Arg Asn Thr Asp Glu Thr Phe Phe Gly Val Gln Trp Val Arg
          180          185          190
Pro

```

```

<210> SEQ ID NO 279
<211> LENGTH: 255
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 279

```

```

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1           5           10           15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
          20           25           30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
          35           40           45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
          50           55           60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
65           70           75           80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
          85           90           95

```

-continued

Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
 100 105 110

Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 130 135 140

Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
 145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
 165 170 175

Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
 180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
 210 215 220

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 245 250 255

<210> SEQ ID NO 280

<211> LENGTH: 255

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 280

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

-continued

20					25					30					
Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser
		35					40					45			
Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser
		50					55					60			
Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Asn	Phe	Gly	Thr	Gln	Thr
							70					75			80
Tyr	Thr	Cys	Asn	Val	Asp	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys
				85					90					95	
Thr	Val	Glu	Arg	Lys	Cys	Arg	Val	Arg	Cys	Pro	Arg	Cys	Pro	Ala	Pro
				100					105					110	
Pro	Val	Ala	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp
				115				120					125		
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Ala
				130				135				140			
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp	Gly
				145				150				155			160
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Phe	Asn
				165					170					175	
Ser	Thr	Phe	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Val	His	Gln	Asp	Trp
				180				185					190		
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Gly	Leu	Pro
			195				200					205			
Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Thr	Lys	Gly	Gln	Pro	Arg	Glu
				210				215				220			
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn
				225					230				235		240
Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile
				245					250					255	
Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr
				260				265					270		
Thr	Pro	Pro	Met	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Arg
				275				280					285		
Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys
				290				295				300			
Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu
				305								310			320
Ser	Leu	Ser	Pro	Gly	Lys										
				325											

<210> SEQ ID NO 283

<211> LENGTH: 255

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 283

gcctccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag 60

agcacagcgg ccctgggctg cctgggtcaag gactacttcc ccgaaccggt gacgggtgctg 120

tggaactcag gcgctctgac cagcggcgctg cacaccttcc cggtctgctc acagtctca 180

ggactctact ccctcagcag cgtagtgacc gtgccctcca gcaacttcgg caccagacc 240

tacacctgca acgta 255

-continued

<210> SEQ ID NO 284
 <211> LENGTH: 326
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 284

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15
 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30
 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
 65 70 75 80
 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Thr Val Glu Arg Lys Cys Glu Val Glu Cys Pro Glu Cys Pro Ala Pro
 100 105 110
 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 115 120 125
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Ala
 130 135 140
 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
 145 150 155 160
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
 165 170 175
 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
 180 185 190
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 195 200 205
 Ser Ser Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
 210 215 220
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 225 230 235 240
 Gln Val Ser Leu Thr Cys Glu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 245 250 255
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 260 265 270
 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 275 280 285
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 290 295 300
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 305 310 315 320
 Ser Leu Ser Pro Gly Lys
 325

<210> SEQ ID NO 285
 <211> LENGTH: 255
 <212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 285

```
gcctccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag      60
agcacagcgg ccctgggctg cctgggtcaag gactacttcc ccgaaccggt gacgggtgctg    120
tggaactcag gcgctctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca    180
ggactctact ccctcagcag cgtagtgacc gtgccctcca gcaacttcgg caccagacc      240
tacacctgca acgta                                                              255
```

<210> SEQ ID NO 286
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 286

```
Gly Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1          5          10          15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20          25          30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35          40          45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50          55          60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65          70          75          80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85          90          95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100         105
```

<210> SEQ ID NO 287
 <211> LENGTH: 255
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 287

```
ggaactgtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct      60
ggaactgcct ctgttgctg cctgctgaat aacttctatc ccagagaggc caaagtacag    120
tggaaggtgg ataacgcct ccaatcgggt aactcccagg agagtgtcac agagcaggac    180
agcaaggaca gcacctacag cctcagcagc acctgacgc tgagcaaagc agactacgag    240
aacacaaaag tctac                                                              255
```

<210> SEQ ID NO 288
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 288

```
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1          5          10          15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Trp
```


-continued

85	90	95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys		
100	105	

<210> SEQ ID NO 291
 <211> LENGTH: 113
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 291

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly		
1	5	10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn		
20	25	30
Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val		
35	40	45
Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys		
50	55	60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu		
65	70	75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala		
85	90	95
Arg Asn Trp Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser		
100	105	110

Ser

<210> SEQ ID NO 292
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 292

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly		
1	5	10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp		
20	25	30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile		
35	40	45
Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly		
50	55	60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro		
65	70	75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr		
85	90	95
Thr Phe Gly His Gly Thr Lys Leu Glu Ile Lys		
100	105	

<210> SEQ ID NO 293
 <211> LENGTH: 118
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

-continued

<400> SEQUENCE: 293

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asp Tyr Tyr
 20 25 30
 Phe Trp Asn Trp Phe Arg Gln Ser Pro Val Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly His Val Tyr Asp Ile Gly Asn Thr Lys Tyr Asn Pro Ser Leu Lys
 50 55 60
 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Glu Asn Gln Phe Ser Leu
 65 70 75 80
 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg Gly Glu Gly Ala Leu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr
 100 105 110
 Met Val Thr Val Ser Ser
 115

<210> SEQ ID NO 294

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 294

Asp Ile Gln Met Thr Gln Ser Pro Ser Ile Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
 35 40 45
 Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Thr Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Thr Tyr Ser His
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 295

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 295

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Asn Cys Thr Val Ser Gly Gly Ser Ile Ser Tyr Tyr
 20 25 30
 Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

-continued

Gly His Val Ile Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
 85 90 95

Arg Ala Glu Gly Ser Leu Asp Ala Phe Asp Leu Trp Gly Gln Gly Thr
 100 105 110

Met Val Thr Val Ser Ser
 115

<210> SEQ ID NO 296
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 296

Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30

Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Phe
 85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> SEQ ID NO 297
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 297

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Gly Ile His Trp Val Arg Gln Ala Pro Gly Met Gly Gln Glu Trp Val
 35 40 45

Ala Val Ile Trp Tyr Asp Gly Ser Ile Lys Lys Tyr Ser Asp Ser Val
 50 55 60

Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95

Ala Arg Asp Glu Val Gly Thr Phe Gly Ala Phe Asp Phe Trp Gly Gln
 100 105 110

-continued

Gly Thr Lys Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 298
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 298

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Ser Ile Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Thr Gly Lys Val Pro Lys Val Leu Ile
35 40 45
Tyr Ala Ala Ser Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn Ser Gly Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 299
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 299

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Leu Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp
20 25 30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Asn Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Met Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Thr Arg Asp Phe Gly Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115

<210> SEQ ID NO 300
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

-continued

<400> SEQUENCE: 300

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Thr Trp Tyr Gln Gln Lys Pro Gly Arg Val Pro Glu Val Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn Ser Ala Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 301

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 301

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Val Ser Ser Asp
 20 25 30
 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Ile Gly Tyr Ile Tyr Tyr Arg Arg Ile Thr Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Val Asn Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80
 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Asp Phe Gly Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr
 100 105 110
 Leu Val Ala Val Ser Ser
 115

<210> SEQ ID NO 302

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 302

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Val Leu Ile Leu Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

-continued

50	55	60																		
Asp	Arg	Val	Ser	Ala	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile					
65					70					75					80					
Ser	Arg	Met	Gln	Ala	Glu	Asp	Val	Gly	Ile	Tyr	Tyr	Cys	Met	Gln	Thr					
				85					90					95						
Leu	Gln	Thr	Pro	Phe	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys					
			100					105					110							

<210> SEQ ID NO 303
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 303

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala					
1				5					10					15						
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Gly	Tyr					
			20					25					30							
Tyr	Leu	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met					
		35					40					45								
Gly	Trp	Ile	Asn	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Tyr	Ala	Gln	Lys	Phe					
		50				55					60									
Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asp	Thr	Ser	Ile	Thr	Thr	Ala	Tyr					
65					70					75					80					
Met	Glu	Leu	Ser	Arg	Leu	Arg	Ile	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys					
				85					90					95						
Ala	Arg	Asp	Arg	Gly	Val	Thr	Met	Ile	Val	Asp	Gly	Met	Asp	Asp	Trp					
			100					105					110							
Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser											
		115					120													

<210> SEQ ID NO 304
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 304

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Phe	Leu	Ser	Ala	Ser	Val	Gly					
1				5					10					15						
Asp	Arg	Val	Ile	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Asn	Ser	His					
		20						25					30							
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile					
		35					40					45								
Tyr	Tyr	Ala	Ser	Thr	Leu	Pro	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly					
		50				55					60									
Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Val	Thr	Ser	Leu	Gln	Pro					
65					70					75				80						
Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Leu	Asn	His	Tyr	Pro	Ile					
			85						90				95							
Thr	Phe	Gly	Gln	Gly	Thr	Arg	Leu	Asp	Ile	Asn										
		100						105												

-continued

<210> SEQ ID NO 305
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 305

Glu Val Glu Leu Val Glu Ser Gly Gly Gly Met Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Met Gly Leu Glu Trp Val
 35 40 45
 Thr Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Glu Val Gly Phe Val Gly Ala Phe Asp Ile Trp Gly Gln
 100 105 110
 Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 306
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 306

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 307
 <211> LENGTH: 118
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 307

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15

-continued

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95

Cys Ala Arg Asp Phe Gly Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 310
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 310

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Ser Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Phe
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Val Leu Leu Ile
 35 40 45

Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu His Val Tyr Pro Ile
 85 90 95

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Arg
 100 105

<210> SEQ ID NO 311
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 311

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Gly Ile His Trp Val Arg Gln Ala Pro Gly Met Gly Gln Glu Trp Val
 35 40 45

Ala Val Ile Trp Tyr Asp Gly Ser Ile Lys Lys Tyr Ser Asp Ser Val
 50 55 60

Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95

Ala Arg Asp Glu Val Gly Thr Phe Gly Ala Phe Asp Phe Trp Gly Gln
 100 105 110

Gly Thr Lys Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 312

-continued

<211> LENGTH: 113
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 312

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
 20 25 30
 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45
 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 65 70 75 80
 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
 85 90 95
 Arg Ile Glu Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile
 100 105 110

Lys

<210> SEQ ID NO 313
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 313

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Ser Lys Thr Gly Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Ser Leu Ile Val Gly Ala Ile Ser Leu Phe Asp Tyr Trp
 100 105 110
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 314
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 314

Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Leu Ser Ala Ser Val Gly

-continued

1	5	10	15
Asp Arg Val Ala Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Thr Trp	20	25	30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile	35	40	45
Tyr Lys Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly	50	55	60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro	65	70	75
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Thr Phe Ser His	85	90	95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys	100	105	

<210> SEQ ID NO 315
 <211> LENGTH: 118
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 315

Gln Val Gln Leu Arg Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu	1	5	10	15
Thr Leu Ser Leu Thr Cys Thr Ile Ser Gly Gly Ser Ile Ser Tyr Tyr	20	25	30	
Phe Trp Thr Trp Ile Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile	35	40	45	
Gly Gln Ile Tyr Tyr Ser Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys	50	55	60	
Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu	65	70	75	80
Lys Leu Thr Ser Val Thr Val Ala Asp Thr Ala Val Tyr Tyr Cys Val	85	90	95	
Arg Ala Glu Gly Ser Leu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr	100	105	110	
Met Val Ala Val Ser Ser	115			

<210> SEQ ID NO 316
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 316

Asp Met Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly	1	5	10	15
Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr	20	25	30	
Leu Ala Trp Phe Gln Leu Lys Pro Gly Lys Val Pro Lys Leu Leu Ile	35	40	45	
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	50	55	60	
Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Ser Ser Leu Gln Pro				

-continued

65	70	75	80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Leu			
	85	90	95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys			
	100	105	

<210> SEQ ID NO 317
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 317

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly			
1	5	10	15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr			
	20	25	30
Ser Met Asn Trp Val Arg Gln Phe Pro Gly Lys Gly Leu Glu Trp Val			
	35	40	45
Ser Ser Ile Ser Thr Ser Ser Asn Tyr Ile His Tyr Ala Asp Ser Leu			
	50	55	60
Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr			
65	70	75	80
Leu Gln Met Ser Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys			
	85	90	95
Val Arg Asp Lys Gly Thr Thr Leu Thr Asn Trp Tyr Phe Asp Leu Trp			
	100	105	110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser			
	115	120	

<210> SEQ ID NO 318
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 318

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly			
1	5	10	15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Val His Ser			
	20	25	30
Asn Gly Tyr Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser			
	35	40	45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro			
	50	55	60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Lys Ile			
65	70	75	80
Ser Arg Met Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala			
	85	90	95
Ile Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Asn Val Glu Ile Lys			
	100	105	110

<210> SEQ ID NO 319
 <211> LENGTH: 121
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 319

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Gly Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Leu
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Gly Tyr Ser Gly Ser Ser Asp Ala Phe Asp Ile Trp Gly
 100 105 110
 Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 320
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 320

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
 35 40 45
 Tyr Lys Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Cys
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 321
 <211> LENGTH: 118
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 321

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Tyr Tyr
 20 25 30

-continued

Ala Arg Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
 100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Thr
 115 120

<210> SEQ ID NO 324
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 324

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Ile Leu Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asp Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Ala Asp Phe Thr Phe Thr Ile Ser Asn Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp His Leu Pro Ile
 85 90 95

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 325
 <211> LENGTH: 123
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 325

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Thr Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
 20 25 30

Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

Gln Asp Arg Val Thr Met Ala Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
 100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ala
 115 120

<210> SEQ ID NO 326
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 326

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Ile Leu Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asp Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Ala Asp Phe Thr Phe Thr Ile Ser Asn Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp His Leu Pro Ile
 85 90 95

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 327

<211> LENGTH: 123

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 327

Gln Val Gln Leu Val Gln Phe Gly Val Glu Val Arg Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Phe Thr Phe Thr Ser His
 20 25 30

Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Asp Arg Val Thr Met Ala Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ser Val Tyr Tyr Cys
 85 90 95

Val Lys Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
 100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 328

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 328

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

-continued

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 329
 <211> LENGTH: 119
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 329

Glu Val Gln Met Leu Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Lys Thr Ser Gly Phe Thr Leu Ser Ile Tyr
 20 25 30

Ala Ile His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val
 35 40 45

Ser Ser Phe Gly Gly Arg Gly Ser Ser Thr Tyr Phe Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Ala Ser Glu Asn Ser Leu Tyr
 65 70 75 80

Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Glu Lys Asp Trp Gly Arg Gly Phe Asp Tyr Trp Gly Gln Gly
 100 105 110

Thr Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 330
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 330

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser
 20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Phe Leu Asn Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Met Gln Ala
 85 90 95

-continued

Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> SEQ ID NO 331
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 331

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Ser Ser Thr Ile Tyr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Gly Trp Glu Val Phe Thr Leu Gly Phe Asp Tyr Trp
 100 105 110
 Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 332
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 332

Tyr Tyr Tyr Trp Thr
 1 5

<210> SEQ ID NO 333
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 333

Gly Gly Ser Ile Ser Tyr Tyr
 1 5

<210> SEQ ID NO 334
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 334

Gly Gly Ser Ile Ser Tyr Tyr Tyr Trp Thr
 1 5 10

-continued

<210> SEQ ID NO 335
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 335

His Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 336
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 336

Tyr Tyr Ser Gly Ser
 1 5

<210> SEQ ID NO 337
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 337

Ala Glu Gly Ser Leu Asp Ala Phe Asp Phe
 1 5 10

<210> SEQ ID NO 338
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 338

Ser Asn Tyr Met Thr
 1 5

<210> SEQ ID NO 339
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 339

Gly Phe Thr Val Ser Ser Asn
 1 5

<210> SEQ ID NO 340
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 340

Gly Phe Thr Val Ser Ser Asn Tyr Met Thr
1 5 10

<210> SEQ ID NO 341

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 341

Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15

<210> SEQ ID NO 342

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 342

Tyr Ser Gly Gly Ser
1 5

<210> SEQ ID NO 343

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 343

Asn Trp Gly Asp Tyr Trp
1 5

<210> SEQ ID NO 344

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 344

Tyr Tyr Phe Trp Asn
1 5

<210> SEQ ID NO 345

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 345

Gly Gly Ser Ile Asp Tyr Tyr
1 5

<210> SEQ ID NO 346

<211> LENGTH: 10

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 346

Gly Gly Ser Ile Asp Tyr Tyr Phe Trp Asn
 1 5 10

<210> SEQ ID NO 347
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 347

His Val Tyr Asp Ile Gly Asn Thr Lys Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 348
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 348

Tyr Asp Ile Gly Asn
 1 5

<210> SEQ ID NO 349
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 349

Gly Glu Gly Ala Leu Asp Ala Phe Asp Ile
 1 5 10

<210> SEQ ID NO 350
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 350

Tyr Tyr Tyr Trp Thr
 1 5

<210> SEQ ID NO 351
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 351

Gly Gly Ser Ile Ser Tyr Tyr

-continued

1

5

<210> SEQ ID NO 352
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 352

Gly Gly Ser Ile Ser Tyr Tyr Tyr Trp Thr
 1 5 10

<210> SEQ ID NO 353
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 353

His Val Ile Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 354
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 354

Ile Tyr Ser Gly Thr
 1 5

<210> SEQ ID NO 355
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 355

Ala Glu Gly Ser Leu Asp Ala Phe Asp Leu
 1 5 10

<210> SEQ ID NO 356
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 356

Asp Tyr Gly Ile His
 1 5

<210> SEQ ID NO 357
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 357

Gly Phe Thr Phe Ser Asp Tyr
 1 5

<210> SEQ ID NO 358

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 358

Gly Phe Thr Phe Ser Asp Tyr Gly Ile His
 1 5 10

<210> SEQ ID NO 359

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 359

Val Ile Trp Tyr Asp Gly Ser Ile Lys Lys Tyr Ser Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 360

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 360

Trp Tyr Asp Gly Ser Ile
 1 5

<210> SEQ ID NO 361

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 361

Asp Glu Val Gly Thr Phe Gly Ala Phe Asp Phe
 1 5 10

<210> SEQ ID NO 362

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 362

Ser Asp Gly Tyr Tyr Trp Ser
 1 5

-continued

<210> SEQ ID NO 363
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 363

Gly Gly Ser Ile Ser Ser Asp Gly Tyr
 1 5

<210> SEQ ID NO 364
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 364

Gly Gly Ser Ile Ser Ser Asp Gly Tyr Tyr Trp Ser
 1 5 10

<210> SEQ ID NO 365
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 365

Tyr Met Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 366
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 366

Tyr Tyr Ser Gly Ser
 1 5

<210> SEQ ID NO 367
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 367

Asp Phe Gly Trp Tyr Phe Asp Leu
 1 5

<210> SEQ ID NO 368
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 368

Ser Asp Gly Tyr Tyr Trp Ser
 1 5

<210> SEQ ID NO 369

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 369

Gly Gly Ser Val Ser Ser Asp Gly Tyr
 1 5

<210> SEQ ID NO 370

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 370

Gly Gly Ser Val Ser Ser Asp Gly Tyr Tyr Trp Ser
 1 5 10

<210> SEQ ID NO 371

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 371

Tyr Ile Tyr Tyr Arg Arg Ile Thr Asp Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 372

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 372

Tyr Tyr Arg Arg Ile
 1 5

<210> SEQ ID NO 373

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 373

Asp Phe Gly Trp Tyr Phe Asp Leu
 1 5

<210> SEQ ID NO 374

<211> LENGTH: 5

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 374

Gly Tyr Tyr Leu His
 1 5

<210> SEQ ID NO 375
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 375

Gly Tyr Thr Phe Thr Gly Tyr
 1 5

<210> SEQ ID NO 376
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 376

Gly Tyr Thr Phe Thr Gly Tyr Tyr Leu His
 1 5 10

<210> SEQ ID NO 377
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 377

Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 378
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 378

Asn Pro Asn Ser Gly Gly
 1 5

<210> SEQ ID NO 379
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 379

-continued

Asp Arg Gly Val Thr Met Ile Val Asp Gly Met Asp Asp
1 5 10

<210> SEQ ID NO 380
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 380

Asp Tyr Gly Met His
1 5

<210> SEQ ID NO 381
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 381

Gly Phe Thr Phe Ser Asp Tyr
1 5

<210> SEQ ID NO 382
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 382

Gly Phe Thr Phe Ser Asp Tyr Gly Met His
1 5 10

<210> SEQ ID NO 383
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 383

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 384
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 384

Trp Tyr Asp Gly Ser Asn
1 5

<210> SEQ ID NO 385
<211> LENGTH: 11
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 385

Asp Glu Val Gly Phe Val Gly Ala Phe Asp Ile
 1 5 10

<210> SEQ ID NO 386
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 386

Ser Asp Gly Tyr Tyr Trp Ser
 1 5

<210> SEQ ID NO 387
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 387

Gly Gly Ser Ile Ser Ser Asp Gly Tyr
 1 5

<210> SEQ ID NO 388
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 388

Gly Gly Ser Ile Ser Ser Asp Gly Tyr Tyr Trp Ser
 1 5 10

<210> SEQ ID NO 389
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 389

Tyr Met Tyr Tyr Ser Gly Ile Thr Tyr His Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 390
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 390

Tyr Tyr Ser Gly Ile
 1 5

-continued

<210> SEQ ID NO 391
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 391

Asp Phe Gly Trp Tyr Phe Asp Leu
1 5

<210> SEQ ID NO 392
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 392

Ser Asp Ala Tyr Tyr Trp Ser
1 5

<210> SEQ ID NO 393
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 393

Gly Gly Ser Ile Ser Ser Asp Ala Tyr
1 5

<210> SEQ ID NO 394
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 394

Gly Gly Ser Ile Ser Ser Asp Ala Tyr Tyr Trp Ser
1 5 10

<210> SEQ ID NO 395
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 395

Tyr Met Tyr Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> SEQ ID NO 396
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 396

Tyr Tyr Ser Gly Ile
1 5

<210> SEQ ID NO 397

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 397

Asp Phe Gly Trp Tyr Phe Asp Leu
1 5

<210> SEQ ID NO 398

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 398

Asp Tyr Gly Ile His
1 5

<210> SEQ ID NO 399

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 399

Gly Phe Thr Phe Ser Asp Tyr
1 5

<210> SEQ ID NO 400

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 400

Gly Phe Thr Phe Ser Asp Tyr Gly Ile His
1 5 10

<210> SEQ ID NO 401

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 401

Val Ile Trp Tyr Asp Gly Ser Ile Lys Lys Tyr Ser Asp Ser Val Lys
1 5 10 15

Gly

-continued

<210> SEQ ID NO 402
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 402

Trp Tyr Asp Gly Ser Ile
1 5

<210> SEQ ID NO 403
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 403

Asp Glu Val Gly Thr Phe Gly Ala Phe Asp Phe
1 5 10

<210> SEQ ID NO 404
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 404

Asn Ala Trp Met Ser
1 5

<210> SEQ ID NO 405
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 405

Gly Phe Thr Phe Ser Asn Ala
1 5

<210> SEQ ID NO 406
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 406

Gly Phe Thr Phe Ser Asn Ala Trp Met Ser
1 5 10

<210> SEQ ID NO 407
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 407

-continued

Arg Ile Lys Ser Lys Thr Gly Gly Gly Thr Thr Asp Tyr Ala Ala Pro
 1 5 10 15

Val Lys Gly

<210> SEQ ID NO 408
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 408

Lys Ser Lys Thr Gly Gly Gly Thr
 1 5

<210> SEQ ID NO 409
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 409

Leu Ile Val Gly Ala Ile Ser Leu Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 410
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 410

Tyr Tyr Phe Trp Thr
 1 5

<210> SEQ ID NO 411
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 411

Gly Gly Ser Ile Ser Tyr Tyr
 1 5

<210> SEQ ID NO 412
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 412

Gly Gly Ser Ile Ser Tyr Tyr Phe Trp Thr
 1 5 10

<210> SEQ ID NO 413
 <211> LENGTH: 16

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 413

Gln Ile Tyr Tyr Ser Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 414
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 414

Tyr Tyr Ser Gly Asn
 1 5

<210> SEQ ID NO 415
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 415

Ala Glu Gly Ser Leu Asp Ala Phe Asp Ile
 1 5 10

<210> SEQ ID NO 416
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 416

Ser Tyr Ser Met Asn
 1 5

<210> SEQ ID NO 417
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 417

Gly Phe Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 418
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 418

Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn

-continued

 1 5 10

<210> SEQ ID NO 419
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 419

Ser Ile Ser Thr Ser Ser Asn Tyr Ile His Tyr Ala Asp Ser Leu Gln
 1 5 10 15

Gly

<210> SEQ ID NO 420
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 420

Ser Thr Ser Ser Asn Tyr
 1 5

<210> SEQ ID NO 421
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 421

Asp Lys Gly Thr Thr Leu Thr Asn Trp Tyr Phe Asp Leu
 1 5 10

<210> SEQ ID NO 422
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 422

Ser Tyr Gly Met His
 1 5

<210> SEQ ID NO 423
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 423

Gly Phe Thr Phe Ser Ser Tyr
 1 5

<210> SEQ ID NO 424
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 424

Gly Phe Thr Phe Ser Ser Tyr Gly Met His
 1 5 10

<210> SEQ ID NO 425
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 425

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Leu Lys
 1 5 10 15

Gly

<210> SEQ ID NO 426
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 426

Trp Tyr Asp Gly Ser Asn
 1 5

<210> SEQ ID NO 427
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 427

Asp Gly Tyr Ser Gly Ser Ser Asp Ala Phe Asp Ile
 1 5 10

<210> SEQ ID NO 428
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 428

Tyr Tyr Tyr Trp Ser
 1 5

<210> SEQ ID NO 429
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 429

Gly Gly Ser Ile Ser Tyr Tyr

-continued

1

5

<210> SEQ ID NO 430
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 430

Gly Gly Ser Ile Ser Tyr Tyr Tyr Trp Ser
 1 5 10

<210> SEQ ID NO 431
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 431

Asn Ile Asn Tyr Met Gly Asn Thr Ile Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> SEQ ID NO 432
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 432

Asn Tyr Met Gly Asn
 1 5

<210> SEQ ID NO 433
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 433

Ala Glu Gly Ser Leu Asp Ala Phe Asp Phe
 1 5 10

<210> SEQ ID NO 434
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 434

Gly Tyr Tyr Ile Tyr
 1 5

<210> SEQ ID NO 435
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 435

Gly Tyr Ile Phe Thr Gly Tyr
 1 5

<210> SEQ ID NO 436

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 436

Gly Tyr Ile Phe Thr Gly Tyr Tyr Ile Tyr
 1 5 10

<210> SEQ ID NO 437

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 437

Trp Ile Asn Pro Ser Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

<210> SEQ ID NO 438

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 438

Asn Pro Ser Ser Gly Gly
 1 5

<210> SEQ ID NO 439

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 439

Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
 1 5 10

<210> SEQ ID NO 440

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 440

Ser His Tyr Ile Tyr
 1 5

-continued

<210> SEQ ID NO 441
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 441

Gly Tyr Thr Phe Thr Ser His
 1 5

<210> SEQ ID NO 442
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 442

Gly Tyr Thr Phe Thr Ser His Tyr Ile Tyr
 1 5 10

<210> SEQ ID NO 443
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 443

Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Asp

<210> SEQ ID NO 444
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 444

Asn Pro Asn Ser Gly Gly
 1 5

<210> SEQ ID NO 445
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 445

Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
 1 5 10

<210> SEQ ID NO 446
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 446

Ser His Tyr Ile Tyr
1 5

<210> SEQ ID NO 447
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 447

Gly Phe Thr Phe Thr Ser His
1 5

<210> SEQ ID NO 448
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 448

Gly Phe Thr Phe Thr Ser His Tyr Ile Tyr
1 5 10

<210> SEQ ID NO 449
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 449

Trp Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Ala Gln Lys Phe Gln
1 5 10 15

Asp

<210> SEQ ID NO 450
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 450

Asn Pro Asn Ser Gly Gly
1 5

<210> SEQ ID NO 451
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 451

Asp Arg Lys Arg Glu Tyr Tyr Tyr Asn Phe Gly Met Asp Val
1 5 10

-continued

<210> SEQ ID NO 452
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 452

Ile Tyr Ala Ile His
1 5

<210> SEQ ID NO 453
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 453

Gly Phe Thr Leu Ser Ile Tyr
1 5

<210> SEQ ID NO 454
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 454

Gly Phe Thr Leu Ser Ile Tyr Ala Ile His
1 5 10

<210> SEQ ID NO 455
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 455

Ser Phe Gly Gly Arg Gly Ser Ser Thr Tyr Phe Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 456
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 456

Gly Gly Arg Gly Ser Ser
1 5

<210> SEQ ID NO 457
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

peptide

<400> SEQUENCE: 457

Glu Lys Asp Trp Gly Arg Gly Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 458

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 458

Asn Tyr Ser Met Asn
 1 5

<210> SEQ ID NO 459

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 459

Gly Phe Thr Phe Ser Asn Tyr
 1 5

<210> SEQ ID NO 460

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 460

Gly Phe Thr Phe Ser Asn Tyr Ser Met Asn
 1 5 10

<210> SEQ ID NO 461

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 461

Ser Ile Ser Ser Ser Thr Ile Tyr Ile Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> SEQ ID NO 462

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 462

Ser Ser Ser Thr Ile Tyr
 1 5

-continued

<210> SEQ ID NO 463
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 463

Asp Ile Gly Trp Glu Val Phe Thr Leu Gly Phe Asp Tyr
1 5 10

<210> SEQ ID NO 464
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 464

Arg Ala Ser Gln Ser Ile Ser Thr Trp Leu Ala
1 5 10

<210> SEQ ID NO 465
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 465

Lys Ala Ser Ser Leu Glu Ser
1 5

<210> SEQ ID NO 466
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 466

Gln Gln Tyr Lys Ser Tyr Ser His Thr
1 5

<210> SEQ ID NO 467
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 467

Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala
1 5 10

<210> SEQ ID NO 468
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 468

Lys Ala Ser Ser Leu Glu Ser
1 5

<210> SEQ ID NO 469

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 469

Gln Gln Tyr Lys Ser Phe Ser Leu Thr
1 5

<210> SEQ ID NO 470

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 470

Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala
1 5 10

<210> SEQ ID NO 471

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 471

Lys Ala Ser Thr Leu Glu Ser
1 5

<210> SEQ ID NO 472

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 472

Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr
1 5

<210> SEQ ID NO 473

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 473

Arg Ala Ser Gln Ser Val Ser Ser Trp Leu Ala
1 5 10

<210> SEQ ID NO 474

<211> LENGTH: 7

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 474

Lys Ala Ser Ser Leu Glu Ser
 1 5

<210> SEQ ID NO 475
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 475

Gln Gln Tyr Asn Thr Tyr Ser His Thr
 1 5

<210> SEQ ID NO 476
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 476

Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly
 1 5 10

<210> SEQ ID NO 477
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 477

Ala Ala Ser Ser Leu Gln Ser
 1 5

<210> SEQ ID NO 478
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 478

Leu Gln Asp Tyr Asn Tyr Pro Phe Thr
 1 5

<210> SEQ ID NO 479
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 479

Arg Ala Ser Gln Asp Ile Asp Asn Tyr Leu Ala
 1 5 10

-continued

<210> SEQ ID NO 480
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 480

Ala Ala Ser Ala Leu Gln Ser
1 5

<210> SEQ ID NO 481
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 481

Gln Asn Tyr Asn Ser Gly Pro Arg Thr
1 5

<210> SEQ ID NO 482
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 482

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Thr
1 5 10

<210> SEQ ID NO 483
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 483

Ala Ala Ser Ala Leu Gln Ser
1 5

<210> SEQ ID NO 484
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 484

Gln Asn Tyr Asn Ser Ala Pro Arg Thr
1 5

<210> SEQ ID NO 485
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 485

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp
 1 5 10 15

<210> SEQ ID NO 486

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 486

Leu Gly Ser Asn Arg Ala Ser
 1 5

<210> SEQ ID NO 487

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 487

Met Gln Thr Leu Gln Thr Pro Phe Thr
 1 5

<210> SEQ ID NO 488

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 488

Arg Ala Ser Gln Gly Ile Asn Ser His Leu Ala
 1 5 10

<210> SEQ ID NO 489

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 489

Tyr Ala Ser Thr Leu Pro Ser
 1 5

<210> SEQ ID NO 490

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 490

Gln Gln Leu Asn His Tyr Pro Ile Thr
 1 5

<210> SEQ ID NO 491

<211> LENGTH: 11

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 491

Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala
 1 5 10

<210> SEQ ID NO 492
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 492

Ala Ala Ser Thr Leu His Ser
 1 5

<210> SEQ ID NO 493
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 493

Gln Lys Tyr Asn Ser Ala Pro Arg Thr
 1 5

<210> SEQ ID NO 494
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 494

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Ala
 1 5 10

<210> SEQ ID NO 495
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 495

Ala Ala Ser Thr Leu His Ser
 1 5

<210> SEQ ID NO 496
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 496

Gln Lys Tyr Asn Ser Ala Pro Arg Thr

-continued

1

5

<210> SEQ ID NO 497
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 497

Arg Ala Ser Gln Asp Ile Ser Ser Phe Leu Ala
 1 5 10

<210> SEQ ID NO 498
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 498

Val Ala Ser Thr Leu Gln Ser
 1 5

<210> SEQ ID NO 499
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 499

Gln Gln Leu His Val Tyr Pro Ile Thr
 1 5

<210> SEQ ID NO 500
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 500

Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu
 1 5 10 15

Asp

<210> SEQ ID NO 501
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 501

Thr Leu Ser Tyr Arg Ala Ser
 1 5

<210> SEQ ID NO 502
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 502

Met Gln Arg Ile Glu Phe Pro Phe Thr
1 5

<210> SEQ ID NO 503
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 503

Arg Ala Ser Gln Thr Ile Ser Thr Trp Leu Ala
1 5 10

<210> SEQ ID NO 504
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 504

Lys Ala Ser Asn Leu Glu Ser
1 5

<210> SEQ ID NO 505
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 505

Gln Gln Tyr Gln Thr Phe Ser His Thr
1 5

<210> SEQ ID NO 506
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 506

Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala
1 5 10

<210> SEQ ID NO 507
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 507

Ala Ala Ser Thr Leu Gln Ser
1 5

-continued

<210> SEQ ID NO 508
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 508

Gln Lys Tyr Asn Ser Ala Pro Leu Thr
 1 5

<210> SEQ ID NO 509
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 509

Arg Ser Ser Gln Thr Leu Val His Ser Asn Gly Tyr Asn Tyr Leu Asn
 1 5 10 15

<210> SEQ ID NO 510
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 510

Leu Gly Ser Asn Arg Ala Ser
 1 5

<210> SEQ ID NO 511
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 511

Met Gln Ala Ile Gln Thr Pro Tyr Thr
 1 5

<210> SEQ ID NO 512
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 512

Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala
 1 5 10

<210> SEQ ID NO 513
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

-continued

<400> SEQUENCE: 513

Lys Ala Ser Asn Leu Glu Ser
1 5

<210> SEQ ID NO 514

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 514

Gln Gln Tyr Asn Ser Tyr Ser Cys Thr
1 5

<210> SEQ ID NO 515

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 515

Gln Ala Ser Gln Asp Ile Asn Asn Tyr Leu His
1 5 10

<210> SEQ ID NO 516

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 516

Asp Ala Ser Asp Trp Glu Thr
1 5

<210> SEQ ID NO 517

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 517

Gln Gln Tyr Asp His Leu Pro Ile Thr
1 5

<210> SEQ ID NO 518

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 518

Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu His
1 5 10

<210> SEQ ID NO 519

<211> LENGTH: 7

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 519

Asp Ala Ser Asp Leu Glu Thr
 1 5

<210> SEQ ID NO 520
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 520

Gln Gln Tyr Asp His Leu Pro Ile Thr
 1 5

<210> SEQ ID NO 521
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 521

Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu His
 1 5 10

<210> SEQ ID NO 522
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 522

Asp Ala Ser Asp Leu Glu Thr
 1 5

<210> SEQ ID NO 523
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 523

Gln Gln Tyr Asp His Leu Pro Ile Thr
 1 5

<210> SEQ ID NO 524
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 524

Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
 1 5 10

-continued

<210> SEQ ID NO 525
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 525

Asp Ala Ser Asn Leu Glu Thr
1 5

<210> SEQ ID NO 526
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 526

Gln Gln Tyr Asp Asn Leu Pro Tyr Thr
1 5

<210> SEQ ID NO 527
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 527

Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn Tyr Leu Asp
1 5 10 15

<210> SEQ ID NO 528
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 528

Leu Asn Ser Asn Arg Ala Ser
1 5

<210> SEQ ID NO 529
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 529

Met Gln Ala Leu Gln Thr Pro Leu Thr
1 5

<210> SEQ ID NO 530
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 8xHis tag

-continued

<400> SEQUENCE: 530

His His His His His His His His
1 5

<210> SEQ ID NO 531

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
6xHis tag

<400> SEQUENCE: 531

His His His His His His
1 5

It is claimed:

1. An isolated antibody, which specifically binds to Cluster of Differentiation 70 (CD70), wherein the antibody comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein:

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 97,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; or

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 98,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 101,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; or

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 99,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; and

wherein

the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 217,

the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 218, and

the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 219.

2. The antibody of claim 1, wherein the VH region comprises the amino acid sequence of SEQ ID NO: 18 and the VL region comprises the amino acid sequence of SEQ ID NO: 17.

3. A bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antigen binding site of the bispecific antibody specifically binding to a target antigen, and comprising a second antigen binding site of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antigen binding site comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable (VL) region

20 comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH region comprises the amino acid sequence of SEQ ID NO: 18 and the VL region comprises the amino acid sequence of SEQ ID NO: 17.

25 4. A bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antigen binding site of the bispecific antibody specifically binding to CD70, and comprising a second antigen binding site of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antigen binding site comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 wherein:

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 97,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; or

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 98,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 101,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; or

the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 99,

the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100,

the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102; and

wherein

the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 217,

the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 218, and

the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 219.

5. The bispecific antibody of claim 4, wherein the second antigen binding site specifically binds to the effector antigen CD3.

6. The bispecific antibody of claim 5, wherein the second antigen binding site comprises

319

- a) a heavy chain variable (VH) region comprising (i) a VH complementary determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 267, 268, or 269; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 270 or 271; and (iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 272; and
- b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 273; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 274; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 275.
7. The bispecific antibody of claim 3, wherein both the first and the second antigen binding sites of the bispecific antibody comprise amino acid modifications at positions 223, 225, and 228 in the hinge region and at position 409 or 368, according to the EU numbering scheme, in the CH3 region of a human IgG2 comprising SEQ ID NO: 279.
8. The bispecific antibody of claim 7, further comprising an amino acid modification at one or more of positions 265, 330 and 331 of the human IgG2.
9. A nucleic acid encoding the antibody of claim 1.
10. A vector comprising the nucleic acid of claim 9.
11. A host cell comprising the nucleic acid of claim 9.
12. A method of treating a subject in need thereof comprising:
- a) providing the antibody of claim 1; and
- b) administering said antibody to said subject.
13. A pharmaceutical composition comprising the antibody of claim 1.
14. A method of treating a condition associated with malignant cells expressing CD70 in a subject comprising administering to a subject in need thereof an effective amount of the antibody of claim 1.
15. The method of claim 14, wherein the condition is a cancer.
16. The method of claim 15, wherein the cancer is an CD70 related cancer selected from the group consisting of Renal Cell Carcinoma, Glioblastoma, glioma such as low grade glioma, Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD), Waldenstrom's macroglobulinemia, Acute Myeloid Leukemia, Multiple Myeloma, diffuse large-cell lymphoma, follicular lymphoma or Non-Small Cell Lung Cancer.
17. A method of inhibiting tumor growth or progression in a subject who has malignant cells expressing CD70, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 13 to the subject.
18. A method of inhibiting metastasis of malignant cells expressing CD70 in a subject, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 13 to the subject.
19. A method of inducing tumor regression in a subject who has malignant cells expressing CD70, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 13 to the subject.

320

20. A method of producing an antibody, comprising culturing the host cell of claim 11 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture.
21. The antibody of claim 1, wherein:
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 97,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100, and
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102.
22. An isolated antibody, which specifically binds to Cluster of Differentiation 70 (CD70), wherein the antibody comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL region comprises the amino acid sequence of SEQ ID NO: 17 and the VH region comprises the amino acid sequence of SEQ ID NO: 18.
23. The bispecific antibody of claim 4, wherein:
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 97,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 100, and
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 102.
24. A pharmaceutical composition comprising the antibody of claim 2.
25. A pharmaceutical composition comprising the antibody of claim 3.
26. A pharmaceutical composition comprising the antibody of claim 4.
27. A pharmaceutical composition comprising the antibody of claim 5.
28. A pharmaceutical composition comprising the antibody of claim 6.
29. A pharmaceutical composition comprising the antibody of claim 7.
30. A pharmaceutical composition comprising the antibody of claim 8.
31. A pharmaceutical composition comprising the antibody of claim 21.
32. A pharmaceutical composition comprising the antibody of claim 22.
33. A pharmaceutical composition comprising the antibody of claim 23.
34. A host cell comprising the vector of claim 10.
35. A method of making the host cell of claim 11, comprising introducing the nucleic acid of claim 9 into a host cell.
36. A method of making the host cell of claim 34, comprising introducing the vector of claim 11 into a host cell.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 11,377,500 B2
APPLICATION NO. : 16/264485
DATED : July 5, 2022
INVENTOR(S) : Siler Panowski et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

In Claim 36, Line 55, delete "claim 11" and insert -- claim 10 --.

Signed and Sealed this
Seventh Day of January, 2025



Derrick Brent

Acting Director of the United States Patent and Trademark Office